{"PMC7120103": [["IntroductionThe proof of principle that antibodies could be efficiently expressed and targeted to different intracellular compartments in mammalian cells dates to 1990 (Biocca et al. 1990) and led to the concept of exploiting recombinant antibodies to block or modulate the function of target antigens for intercellular and intracellular immunization (Biocca and Cattaneo 1995; Cattaneo and Biocca 1997).", [["intracellular compartments", "ANATOMY", 108, 134], ["cells", "ANATOMY", 148, 153], ["intercellular", "ANATOMY", 306, 319], ["intracellular", "ANATOMY", 324, 337], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 108, 121], ["mammalian cells", "CELL", 138, 153], ["intercellular", "IMMATERIAL_ANATOMICAL_ENTITY", 306, 319], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 324, 337], ["antibodies", "PROTEIN", 40, 50], ["mammalian cells", "CELL_TYPE", 138, 153], ["recombinant antibodies", "PROTEIN", 226, 248], ["target antigens", "PROTEIN", 286, 301], ["principle that antibodies", "TREATMENT", 25, 50], ["exploiting recombinant antibodies to block", "PROBLEM", 215, 257], ["intercellular and intracellular immunization", "TREATMENT", 306, 350]]], ["Intrabodies have unique advantages comparing to other knockout gene techniques or RNA interference.", [["unique advantages", "TREATMENT", 17, 34], ["other knockout gene techniques", "TREATMENT", 48, 78], ["RNA interference", "PROBLEM", 82, 98]]], ["First, they can target the antigen in different intracellular compartments including extracellular milieu.", [["intracellular compartments", "ANATOMY", 48, 74], ["extracellular", "ANATOMY", 85, 98], ["intracellular compartments", "CELLULAR_COMPONENT", 48, 74], ["extracellular milieu", "CELLULAR_COMPONENT", 85, 105], ["extracellular milieu", "OBSERVATION", 85, 105]]], ["Secondly, they are highly specific reagents and are very stable in mammalian cells, especially when expressed in the secretory compartment.", [["cells", "ANATOMY", 77, 82], ["secretory compartment", "ANATOMY", 117, 138], ["mammalian cells", "CELL", 67, 82], ["secretory compartment", "MULTI-TISSUE_STRUCTURE", 117, 138], ["mammalian cells", "CELL_TYPE", 67, 82], ["stable", "OBSERVATION_MODIFIER", 57, 63], ["mammalian cells", "OBSERVATION", 67, 82], ["secretory compartment", "OBSERVATION", 117, 138]]], ["In addition, intrabodies can hit a variety of possible targets: (i) specific protein domains, (ii) specific protein-protein interaction sites, (iii) post-translational modifications, (iv) multiple conformational isoforms (oligomers, fibrils etc) and (v) even non protein antigens.IntroductionIn order to specifically target intrabodies to the physiological site of the antigen or to new intracellular localisations, dominant and autonomous targeting sequences should be grafted onto antibody chains.", [["intracellular", "ANATOMY", 387, 400], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 387, 400], ["protein domains", "PROTEIN", 77, 92], ["protein-protein interaction sites", "PROTEIN", 108, 141], ["conformational isoforms", "PROTEIN", 197, 220], ["fibrils etc", "PROTEIN", 233, 244], ["protein antigens", "PROTEIN", 263, 279], ["antibody chains", "PROTEIN", 483, 498], ["specific protein domains", "TEST", 68, 92], ["specific protein", "TEST", 99, 115], ["protein interaction sites", "PROBLEM", 116, 141], ["translational modifications", "TREATMENT", 154, 181], ["multiple conformational isoforms (oligomers", "TREATMENT", 188, 231], ["non protein antigens", "PROBLEM", 259, 279], ["new intracellular localisations", "TEST", 383, 414], ["dominant and autonomous targeting sequences", "PROBLEM", 416, 459]]], ["Recombinant antibody domains, in particular single-chain Fv (scFv) fragments have been expressed in the cytoplasm (Biocca et al. 1994), the nucleus (Duan et al. 1994; Mhashilkar et al. 1995) and the secretory pathway of mammalian cells (Marasco et al. 1993) and successfully used to inhibit the function of several intracellular antigens.", [["cytoplasm", "ANATOMY", 104, 113], ["nucleus", "ANATOMY", 140, 147], ["cells", "ANATOMY", 230, 235], ["intracellular", "ANATOMY", 315, 328], ["cytoplasm", "ORGANISM_SUBSTANCE", 104, 113], ["nucleus", "CELLULAR_COMPONENT", 140, 147], ["mammalian cells", "CELL", 220, 235], ["Marasco et al. 1993", "CELL", 237, 256], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 315, 328], ["Recombinant antibody domains", "PROTEIN", 0, 28], ["single-chain Fv (scFv) fragments", "PROTEIN", 44, 76], ["mammalian cells", "CELL_TYPE", 220, 235], ["intracellular antigens", "PROTEIN", 315, 337], ["Recombinant antibody domains", "PROBLEM", 0, 28], ["scFv) fragments", "PROBLEM", 61, 76], ["antibody domains", "OBSERVATION", 12, 28], ["chain Fv", "OBSERVATION_MODIFIER", 51, 59], ["scFv", "ANATOMY", 61, 65], ["cytoplasm", "OBSERVATION_MODIFIER", 104, 113], ["nucleus", "ANATOMY", 140, 147], ["mammalian cells", "OBSERVATION", 220, 235]]], ["New suitable antibody formats for their intracellular use are now available and functional intrabodies are employed as research tools to define the mechanisms of human pathologies at the molecular level and for a variety of therapeutic applications.", [["intracellular", "ANATOMY", 40, 53], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 40, 53], ["human", "ORGANISM", 162, 167], ["human", "SPECIES", 162, 167], ["human", "SPECIES", 162, 167], ["New suitable antibody formats", "TEST", 0, 29], ["research tools", "TEST", 119, 133], ["human pathologies", "PROBLEM", 162, 179], ["therapeutic applications", "TREATMENT", 224, 248], ["antibody", "OBSERVATION", 13, 21]]], ["For instance, intrabodies have been designed to inhibit single or simultaneously multiple signal transduction pathways (Lener et al. 2000; Tanaka et al. 2007; Jendreyko et al. 2005), inhibition of HIV viral proteins (Lo et al. 2008), inhibition of oncogene products (Williams and Zhu 2006; Griffin et al. 2006), misfolding-prone proteins (Cardinale and Biocca 2008a), receptors of the immune system (Kirschning et al. 2010) and also applied in post-transplantation surgery (Zdoroveac et al. 2008).Targeting Intrabodies to Different Intracellular LocationsAntibody fragments can be directed to specific target antigens present in the cytosol, nucleus, endoplasmic reticulum (ER), plasma membrane (PM), mitochondria, peroxisomes and trans-Golgi network (TGN) through in frame fusion with intracellular trafficking sequences (Cardinale et al. 2004).", [["Intracellular", "ANATOMY", 532, 545], ["cytosol", "ANATOMY", 633, 640], ["nucleus", "ANATOMY", 642, 649], ["endoplasmic reticulum", "ANATOMY", 651, 672], ["ER", "ANATOMY", 674, 676], ["plasma membrane", "ANATOMY", 679, 694], ["PM", "ANATOMY", 696, 698], ["mitochondria", "ANATOMY", 701, 713], ["peroxisomes", "ANATOMY", 715, 726], ["TGN", "ANATOMY", 752, 755], ["intracellular", "ANATOMY", 786, 799], ["HIV", "ORGANISM", 197, 200], ["cytosol", "CELLULAR_COMPONENT", 633, 640], ["nucleus", "CELLULAR_COMPONENT", 642, 649], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 651, 672], ["ER", "GENE_OR_GENE_PRODUCT", 674, 676], ["plasma membrane", "CELLULAR_COMPONENT", 679, 694], ["PM", "CELLULAR_COMPONENT", 696, 698], ["mitochondria", "CELLULAR_COMPONENT", 701, 713], ["peroxisomes", "CELLULAR_COMPONENT", 715, 726], ["Golgi network", "CELLULAR_COMPONENT", 737, 750], ["TGN", "CELLULAR_COMPONENT", 752, 755], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 786, 799], ["HIV viral proteins", "PROTEIN", 197, 215], ["oncogene products", "PROTEIN", 248, 265], ["misfolding-prone proteins", "PROTEIN", 312, 337], ["ER", "PROTEIN", 674, 676], ["trans-Golgi network", "PROTEIN", 731, 750], ["TGN", "PROTEIN", 752, 755], ["intracellular trafficking sequences", "PROTEIN", 786, 821], ["HIV", "SPECIES", 197, 200], ["HIV", "SPECIES", 197, 200], ["HIV viral proteins", "PROBLEM", 197, 215], ["inhibition of oncogene products", "TREATMENT", 234, 265], ["misfolding-prone proteins", "PROBLEM", 312, 337], ["Biocca", "TREATMENT", 353, 359], ["post-transplantation surgery", "TREATMENT", 444, 472], ["Intrabodies", "TREATMENT", 507, 518], ["Different Intracellular LocationsAntibody fragments", "PROBLEM", 522, 573], ["plasma membrane", "TEST", 679, 694], ["frame fusion", "TREATMENT", 768, 780], ["intracellular trafficking sequences", "TEST", 786, 821], ["Different", "OBSERVATION_MODIFIER", 522, 531], ["Intracellular", "OBSERVATION_MODIFIER", 532, 545], ["Locations", "OBSERVATION_MODIFIER", 546, 555], ["Antibody fragments", "OBSERVATION", 555, 573], ["cytosol", "ANATOMY", 633, 640], ["nucleus", "ANATOMY", 642, 649], ["endoplasmic reticulum", "ANATOMY", 651, 672]]], ["The following is a list of targeting signals successfully used for intracellular expression of antibodies.Targeting Intrabodies to Different Intracellular LocationsThe way to target intrabodies throughout the secretory pathway, as secreted proteins, is by exploiting the leader sequence for secretion of the immunoglobulin (Ig) at the N terminus.", [["intracellular", "ANATOMY", 67, 80], ["Intracellular", "ANATOMY", 141, 154], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 67, 80], ["intrabodies", "GENE_OR_GENE_PRODUCT", 182, 193], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 308, 322], ["Ig", "GENE_OR_GENE_PRODUCT", 324, 326], ["antibodies", "PROTEIN", 95, 105], ["secreted proteins", "PROTEIN", 231, 248], ["immunoglobulin", "PROTEIN", 308, 322], ["Ig", "PROTEIN", 324, 326], ["N terminus", "PROTEIN", 335, 345], ["intracellular expression of antibodies", "PROBLEM", 67, 105], ["Intrabodies", "TREATMENT", 116, 127], ["the immunoglobulin (Ig)", "TREATMENT", 304, 327], ["Different", "OBSERVATION_MODIFIER", 131, 140], ["Intracellular Locations", "OBSERVATION", 141, 164]]], ["ER-retained intrabodies are designed with a leader sequence at the N terminus and a retention peptide, KDEL, at the C terminus (Biocca et al. 1995).", [["N", "CHEMICAL", 67, 68], ["ER", "GENE_OR_GENE_PRODUCT", 0, 2], ["KDEL", "GENE_OR_GENE_PRODUCT", 103, 107], ["ER", "PROTEIN", 0, 2], ["intrabodies", "PROTEIN", 12, 23], ["N terminus", "PROTEIN", 67, 77], ["KDEL", "PROTEIN", 103, 107], ["C terminus", "PROTEIN", 116, 126], ["a leader sequence", "TEST", 42, 59], ["a retention peptide", "TREATMENT", 82, 101], ["retained intrabodies", "OBSERVATION", 3, 23], ["retention peptide", "OBSERVATION", 84, 101]]], ["Intrabodies in the ER behave as intracellular anchors and can be used either to prevent the appearance of receptor proteins on the plasma membrane or to inhibit the secretion of a protein.", [["ER", "ANATOMY", 19, 21], ["intracellular", "ANATOMY", 32, 45], ["plasma membrane", "ANATOMY", 131, 146], ["ER", "GENE_OR_GENE_PRODUCT", 19, 21], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 32, 45], ["plasma membrane", "CELLULAR_COMPONENT", 131, 146], ["ER", "PROTEIN", 19, 21], ["receptor proteins", "PROTEIN", 106, 123], ["intracellular anchors", "TREATMENT", 32, 53], ["receptor proteins", "PROBLEM", 106, 123], ["the plasma membrane", "TREATMENT", 127, 146]]], ["Similar protein retention in the trans-Golgi has been achieved with a trans-Golgi retention signal (Zhou et al. 1998).", [["Golgi", "ANATOMY", 39, 44], ["Golgi", "ANATOMY", 76, 81], ["Golgi", "CELLULAR_COMPONENT", 39, 44], ["Golgi", "CELLULAR_COMPONENT", 76, 81], ["Similar protein retention", "PROBLEM", 0, 25], ["protein retention", "OBSERVATION", 8, 25]]], ["Targeting to the plasma membrane has been obtained by fusing a scFv with a receptor transmembrane domain (Chesnut et al. 1996).Targeting Intrabodies to Different Intracellular LocationsRemoval of the leader sequence of variable heavy (VH) and variable light (VL) domains which target antibody fragments to the lumen of the endoplasmic reticulum allows the cytoplasmic expression of intrabodies (leader-less).", [["plasma membrane", "ANATOMY", 17, 32], ["Intracellular", "ANATOMY", 162, 175], ["fragments", "ANATOMY", 293, 302], ["lumen", "ANATOMY", 310, 315], ["endoplasmic reticulum", "ANATOMY", 323, 344], ["cytoplasmic", "ANATOMY", 356, 367], ["plasma membrane", "CELLULAR_COMPONENT", 17, 32], ["scFv", "GENE_OR_GENE_PRODUCT", 63, 67], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 310, 315], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 323, 344], ["cytoplasmic", "ORGANISM_SUBSTANCE", 356, 367], ["scFv", "PROTEIN", 63, 67], ["receptor transmembrane domain", "PROTEIN", 75, 104], ["leader sequence", "DNA", 200, 215], ["variable heavy (VH) and variable light (VL) domains", "PROTEIN", 219, 270], ["antibody fragments", "PROTEIN", 284, 302], ["intrabodies", "PROTEIN", 382, 393], ["a receptor transmembrane domain", "TREATMENT", 73, 104], ["Intrabodies", "TREATMENT", 137, 148], ["Removal", "TREATMENT", 185, 192], ["the leader sequence", "TEST", 196, 215], ["variable heavy (VH)", "PROBLEM", 219, 238], ["variable light (VL) domains", "PROBLEM", 243, 270], ["target antibody fragments", "PROBLEM", 277, 302], ["Different", "OBSERVATION_MODIFIER", 152, 161], ["Intracellular Locations", "OBSERVATION", 162, 185], ["variable", "OBSERVATION_MODIFIER", 219, 227], ["heavy", "OBSERVATION_MODIFIER", 228, 233], ["variable", "OBSERVATION_MODIFIER", 243, 251], ["light", "OBSERVATION_MODIFIER", 252, 257], ["antibody fragments", "OBSERVATION", 284, 302], ["lumen", "ANATOMY_MODIFIER", 310, 315], ["endoplasmic reticulum", "OBSERVATION", 323, 344], ["cytoplasmic expression", "OBSERVATION", 356, 378]]], ["Nuclear targeting can be achieved by adding one or more nuclear localisation sequences (NLS) to the leader-less antibody fragments, such as the PKKKRKV sequence of the large T antigen of SV40, either at the N- and C-terminus (Biocca et al. 1995).", [["Nuclear", "ANATOMY", 0, 7], ["nuclear", "ANATOMY", 56, 63], ["fragments", "ANATOMY", 121, 130], ["Nuclear", "CELLULAR_COMPONENT", 0, 7], ["PKKKRKV", "GENE_OR_GENE_PRODUCT", 144, 151], ["large T antigen", "GENE_OR_GENE_PRODUCT", 168, 183], ["SV40", "GENE_OR_GENE_PRODUCT", 187, 191], ["nuclear localisation sequences", "PROTEIN", 56, 86], ["NLS", "PROTEIN", 88, 91], ["leader-less antibody fragments", "DNA", 100, 130], ["PKKKRKV sequence", "DNA", 144, 160], ["T antigen", "PROTEIN", 174, 183], ["N- and C-terminus", "PROTEIN", 207, 224], ["less antibody fragments", "PROBLEM", 107, 130], ["the PKKKRKV sequence", "TEST", 140, 160], ["less", "OBSERVATION_MODIFIER", 107, 111], ["antibody fragments", "OBSERVATION", 112, 130], ["large", "OBSERVATION_MODIFIER", 168, 173]]], ["Intrabodies have been also targeted to mitochondria.", [["mitochondria", "ANATOMY", 39, 51], ["mitochondria", "CELLULAR_COMPONENT", 39, 51]]], ["N-terminal presequences are present in most of the nuclear-encoded mitochondrial proteins.", [["nuclear", "ANATOMY", 51, 58], ["mitochondrial", "ANATOMY", 67, 80], ["N", "CHEMICAL", 0, 1], ["nuclear", "CELLULAR_COMPONENT", 51, 58], ["mitochondrial", "CELLULAR_COMPONENT", 67, 80], ["N-terminal presequences", "PROTEIN", 0, 23], ["nuclear-encoded mitochondrial proteins", "PROTEIN", 51, 89], ["terminal", "OBSERVATION_MODIFIER", 2, 10], ["mitochondrial proteins", "OBSERVATION", 67, 89]]], ["These sequences are removed once the protein is translocated through the mitochondrial membrane.", [["mitochondrial membrane", "ANATOMY", 73, 95], ["mitochondrial membrane", "CELLULAR_COMPONENT", 73, 95], ["mitochondrial membrane", "OBSERVATION", 73, 95]]], ["The N-terminal presequence of the subunit VIII of human cytochrome oxidase (COX8.21), covering the cleavage junction, can be fused to the scFv fragment.", [["N", "CHEMICAL", 4, 5], ["human", "ORGANISM", 50, 55], ["cytochrome oxidase", "GENE_OR_GENE_PRODUCT", 56, 74], ["COX8.21", "GENE_OR_GENE_PRODUCT", 76, 83], ["N-terminal presequence", "PROTEIN", 4, 26], ["subunit VIII", "PROTEIN", 34, 46], ["human cytochrome oxidase", "PROTEIN", 50, 74], ["COX8.21", "PROTEIN", 76, 83], ["scFv fragment", "PROTEIN", 138, 151], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55], ["The N-terminal presequence", "TREATMENT", 0, 26], ["the subunit VIII of human cytochrome oxidase", "TREATMENT", 30, 74], ["the cleavage junction", "TREATMENT", 95, 116], ["cleavage junction", "OBSERVATION", 99, 116], ["scFv fragment", "OBSERVATION", 138, 151]]], ["The resulting molecule correctly localizes to mitochondria (Biocca et al. 1995).Targeting Intrabodies to Different Intracellular LocationsTo facilitate the expression of scFv fragments as secreted or intracellular proteins, a set of general vectors have been designed.", [["mitochondria", "ANATOMY", 46, 58], ["Intracellular", "ANATOMY", 115, 128], ["intracellular", "ANATOMY", 200, 213], ["mitochondria", "CELLULAR_COMPONENT", 46, 58], ["scFv", "GENE_OR_GENE_PRODUCT", 170, 174], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 200, 213], ["scFv fragments", "DNA", 170, 184], ["secreted or intracellular proteins", "PROTEIN", 188, 222], ["Intrabodies", "TREATMENT", 90, 101], ["scFv fragments", "PROBLEM", 170, 184], ["secreted or intracellular proteins", "PROBLEM", 188, 222], ["general vectors", "TREATMENT", 233, 248], ["Different", "OBSERVATION_MODIFIER", 105, 114], ["Intracellular Locations", "OBSERVATION", 115, 138], ["scFv fragments", "OBSERVATION", 170, 184]]], ["The integrated system of scFvexpress vectors (Persic et al. 1997a) derives from the VHexpress vector, a vector used to produce secretory immunoglobulin heavy chains from cloned IgH regions (Persic et al. 1997b).", [["immunoglobulin heavy chains", "GENE_OR_GENE_PRODUCT", 137, 164], ["IgH", "GENE_OR_GENE_PRODUCT", 177, 180], ["scFvexpress vectors", "DNA", 25, 44], ["VHexpress vector", "DNA", 84, 100], ["secretory immunoglobulin heavy chains", "PROTEIN", 127, 164], ["IgH regions", "DNA", 177, 188], ["scFvexpress vectors", "TREATMENT", 25, 44], ["the VHexpress vector", "TREATMENT", 80, 100], ["a vector", "TREATMENT", 102, 110], ["secretory immunoglobulin heavy chains", "TREATMENT", 127, 164]]], ["All the scFvexpress plasmids contain an N- or C-terminal localisation signal that allows the targeting of the antibody fragments to different compartments, including the endoplasmic reticulum (scFvex-ER), the cytoplasm (scFvex-cyt), the nucleus (scFvex-nuc) and the mitochondria (scFvex-mit).", [["plasmids", "ANATOMY", 20, 28], ["fragments", "ANATOMY", 119, 128], ["compartments", "ANATOMY", 142, 154], ["endoplasmic reticulum", "ANATOMY", 170, 191], ["scFvex-ER", "ANATOMY", 193, 202], ["cytoplasm", "ANATOMY", 209, 218], ["nucleus", "ANATOMY", 237, 244], ["mitochondria", "ANATOMY", 266, 278], ["N", "CHEMICAL", 40, 41], ["C", "CHEMICAL", 46, 47], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 170, 191], ["scFvex-ER", "GENE_OR_GENE_PRODUCT", 193, 202], ["cytoplasm", "ORGANISM_SUBSTANCE", 209, 218], ["scFvex-cyt", "GENE_OR_GENE_PRODUCT", 220, 230], ["nucleus", "CELLULAR_COMPONENT", 237, 244], ["scFvex-nuc", "GENE_OR_GENE_PRODUCT", 246, 256], ["mitochondria", "CELLULAR_COMPONENT", 266, 278], ["scFvexpress plasmids", "DNA", 8, 28], ["antibody fragments", "PROTEIN", 110, 128], ["scFvex", "PROTEIN", 193, 199], ["ER", "PROTEIN", 200, 202], ["scFvex", "PROTEIN", 220, 226], ["cyt", "PROTEIN", 227, 230], ["scFvex", "PROTEIN", 246, 252], ["nuc", "PROTEIN", 253, 256], ["scFvex", "PROTEIN", 280, 286], ["All the scFvexpress plasmids", "TEST", 0, 28], ["an N", "TEST", 37, 41], ["C-terminal localisation signal", "PROBLEM", 46, 76], ["the antibody fragments", "PROBLEM", 106, 128], ["the endoplasmic reticulum", "TEST", 166, 191], ["the cytoplasm", "TEST", 205, 218], ["antibody fragments", "OBSERVATION", 110, 128], ["endoplasmic reticulum", "ANATOMY", 170, 191], ["nucleus", "ANATOMY", 237, 244]]], ["The scFvexpress-cyt has no targeting signal (leader-less) and directs the expression of scFv in the cytoplasm, with an N-terminal methionine instead of the leader sequence for secretion.", [["cytoplasm", "ANATOMY", 100, 109], ["methionine", "CHEMICAL", 130, 140], ["N", "CHEMICAL", 119, 120], ["methionine", "CHEMICAL", 130, 140], ["scFvexpress-cyt", "GENE_OR_GENE_PRODUCT", 4, 19], ["scFv", "GENE_OR_GENE_PRODUCT", 88, 92], ["cytoplasm", "ORGANISM_SUBSTANCE", 100, 109], ["scFvexpress", "PROTEIN", 4, 15], ["cyt", "PROTEIN", 16, 19], ["scFv", "PROTEIN", 88, 92], ["The scFvexpress-cyt", "TEST", 0, 19], ["targeting signal", "PROBLEM", 27, 43], ["scFv in the cytoplasm", "PROBLEM", 88, 109], ["an N-terminal methionine", "TREATMENT", 116, 140], ["secretion", "PROBLEM", 176, 185], ["cyt", "ANATOMY", 16, 19], ["no", "UNCERTAINTY", 24, 26], ["scFv", "OBSERVATION", 88, 92]]], ["All other targeting vectors are derivatives of the scFvexpress-cyt and were obtained by the insertion of well characterized targeting signals (Biocca et al. 1995) either N- or C-terminal to the scFv, as appropriate.Targeting Intrabodies to Different Intracellular LocationsBesides the specific targeting signals, these vectors contain cassettes that encode for strong promoters and sequences for the resistance to selection antibiotics and a C-terminal myc-tag in frame with the scFv allowing its detection with the monoclonal antibody 9E10 (Persic et al. 1997a).Targeting Intrabodies to Different Intracellular LocationsThese vectors can be used for transient or stable transfection of mammalian cells.Intrabody FormatsInnovative DNA recombinant technologies have allowed the reformatting of antibody molecules in new smaller fragments with improved properties for their intracellular expression.", [["Intracellular", "ANATOMY", 250, 263], ["Intracellular", "ANATOMY", 598, 611], ["cells", "ANATOMY", 697, 702], ["fragments", "ANATOMY", 827, 836], ["intracellular", "ANATOMY", 872, 885], ["N", "CHEMICAL", 170, 171], ["C", "CHEMICAL", 176, 177], ["C", "CHEMICAL", 442, 443], ["scFvexpress-cyt", "GENE_OR_GENE_PRODUCT", 51, 66], ["scFv", "GENE_OR_GENE_PRODUCT", 194, 198], ["mammalian cells", "CELL", 687, 702], ["DNA", "CELLULAR_COMPONENT", 731, 734], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 872, 885], ["scFvexpress-cyt", "PROTEIN", 51, 66], ["scFv", "PROTEIN", 194, 198], ["promoters", "DNA", 368, 377], ["C-terminal myc-tag", "DNA", 442, 460], ["scFv", "PROTEIN", 479, 483], ["monoclonal antibody 9E10", "PROTEIN", 516, 540], ["mammalian cells", "CELL_TYPE", 687, 702], ["antibody molecules", "PROTEIN", 793, 811], ["the scFvexpress-cyt", "TEST", 47, 66], ["strong promoters", "TREATMENT", 361, 377], ["selection antibiotics", "TREATMENT", 414, 435], ["a C-terminal myc-tag", "PROBLEM", 440, 460], ["the scFv", "TREATMENT", 475, 483], ["the monoclonal antibody", "TEST", 512, 535], ["Intrabodies", "TREATMENT", 573, 584], ["These vectors", "TREATMENT", 621, 634], ["transient or stable transfection of mammalian cells", "PROBLEM", 651, 702], ["Intrabody FormatsInnovative DNA recombinant technologies", "TREATMENT", 703, 759], ["antibody molecules", "PROBLEM", 793, 811], ["new smaller fragments", "PROBLEM", 815, 836], ["Different", "OBSERVATION_MODIFIER", 240, 249], ["Intracellular Locations", "OBSERVATION", 250, 273], ["Different", "OBSERVATION_MODIFIER", 588, 597], ["Intracellular", "OBSERVATION_MODIFIER", 598, 611], ["stable", "OBSERVATION_MODIFIER", 664, 670], ["transfection", "OBSERVATION", 671, 683], ["mammalian cells", "OBSERVATION", 687, 702], ["new", "OBSERVATION_MODIFIER", 815, 818], ["smaller", "OBSERVATION_MODIFIER", 819, 826], ["fragments", "OBSERVATION", 827, 836], ["intracellular expression", "OBSERVATION", 872, 896]]], ["So far the single chain variable fragment (scFv) has been the recombinant antibody format more widely used for intrabodies.", [["single chain variable fragment", "PROTEIN", 11, 41], ["scFv", "PROTEIN", 43, 47], ["the single chain variable fragment (scFv", "TREATMENT", 7, 47], ["the recombinant antibody", "TREATMENT", 58, 82], ["intrabodies", "PROBLEM", 111, 122], ["single", "OBSERVATION_MODIFIER", 11, 17], ["chain", "OBSERVATION_MODIFIER", 18, 23], ["variable", "OBSERVATION_MODIFIER", 24, 32], ["fragment", "OBSERVATION", 33, 41]]], ["It contains the complete antigen binding site and it consists of the variable domains of the immunoglobulin heavy (VH) and light (VL) chains linked with a flexible polypeptide which prevents dissociation.", [["immunoglobulin", "GENE_OR_GENE_PRODUCT", 93, 107], ["antigen binding site", "PROTEIN", 25, 45], ["immunoglobulin heavy (VH) and light (VL) chains", "PROTEIN", 93, 140], ["the complete antigen binding site", "PROBLEM", 12, 45], ["light (VL) chains", "TREATMENT", 123, 140], ["a flexible polypeptide", "TREATMENT", 153, 175], ["dissociation", "PROBLEM", 191, 203], ["complete", "OBSERVATION_MODIFIER", 16, 24], ["antigen binding", "OBSERVATION", 25, 40]]], ["The resulting molecule is a monovalent antibody fragment, with a molecular weight of about 30 kDa compared to the 150 kDa of the full-length antibody.", [["monovalent antibody fragment", "PROTEIN", 28, 56], ["150 kDa", "PROTEIN", 114, 121], ["full-length antibody", "PROTEIN", 129, 149], ["a monovalent antibody fragment", "PROBLEM", 26, 56], ["a molecular weight", "TEST", 63, 81], ["molecule", "OBSERVATION_MODIFIER", 14, 22], ["monovalent", "OBSERVATION_MODIFIER", 28, 38], ["antibody fragment", "OBSERVATION", 39, 56]]], ["Other formats that have been successfully expressed inside cells are recombinant bispecific and tetravalent antibody fragments made of two scFvs linked through the second and third heavy chain constant domain, named intradiabodies.", [["cells", "ANATOMY", 59, 64], ["cells", "CELL", 59, 64], ["scFvs", "GENE_OR_GENE_PRODUCT", 139, 144], ["recombinant bispecific and tetravalent antibody fragments", "PROTEIN", 69, 126], ["scFvs", "PROTEIN", 139, 144], ["third heavy chain constant domain", "PROTEIN", 175, 208], ["intradiabodies", "PROTEIN", 216, 230], ["recombinant bispecific and tetravalent antibody fragments", "TREATMENT", 69, 126], ["two scFvs", "PROBLEM", 135, 144], ["antibody fragments", "OBSERVATION", 108, 126], ["scFvs", "OBSERVATION", 139, 144]]], ["These bispecific intrabodies have been designed for simultaneous trapping of two endothelial transmembrane receptors in the same compartment (Jendreyko et al. 2005).Intrabody FormatsScFv is not the minimal size for functional antibody fragments.", [["endothelial transmembrane", "ANATOMY", 81, 106], ["endothelial", "CELL", 81, 92], ["endothelial transmembrane receptors", "PROTEIN", 81, 116], ["FormatsScFv", "PROTEIN", 175, 186], ["functional antibody fragments", "DNA", 215, 244], ["two endothelial transmembrane receptors", "TREATMENT", 77, 116], ["functional antibody fragments", "PROBLEM", 215, 244], ["two", "ANATOMY_MODIFIER", 77, 80], ["endothelial", "ANATOMY_MODIFIER", 81, 92], ["transmembrane receptors", "OBSERVATION", 93, 116], ["minimal", "OBSERVATION_MODIFIER", 198, 205], ["size", "OBSERVATION_MODIFIER", 206, 210], ["functional", "OBSERVATION_MODIFIER", 215, 225], ["antibody fragments", "OBSERVATION", 226, 244]]], ["Other fragments made of one variable domain such the single VL and VH domains are the smallest functional fragments derived from immunoglobulin light and heavy chains.", [["fragments", "ANATOMY", 6, 15], ["fragments", "ANATOMY", 106, 115], ["immunoglobulin light", "GENE_OR_GENE_PRODUCT", 129, 149], ["VL and VH domains", "DNA", 60, 77], ["immunoglobulin light and heavy chains", "PROTEIN", 129, 166], ["Other fragments", "PROBLEM", 0, 15], ["one variable domain", "PROBLEM", 24, 43], ["the smallest functional fragments", "PROBLEM", 82, 115], ["fragments", "OBSERVATION", 6, 15], ["smallest", "OBSERVATION_MODIFIER", 86, 94], ["functional fragments", "OBSERVATION", 95, 115], ["immunoglobulin light", "OBSERVATION", 129, 149], ["heavy", "OBSERVATION_MODIFIER", 154, 159], ["chains", "OBSERVATION_MODIFIER", 160, 166]]], ["The so-called VHH single domain antibody fragments, derived from naturally occurring heavy-chain antibodies devoid of light chain present in the immune system of camelids, retain the antigen specificity of the whole antibody and have excellent properties of solubility, stability and expression in mammalian cells, aside from the absence of intra-domain disulfide bonds (Hamers-Casterman et al. 1993; Wesolowski et al. 2009).", [["immune system", "ANATOMY", 145, 158], ["camelids", "ANATOMY", 162, 170], ["cells", "ANATOMY", 308, 313], ["disulfide", "CHEMICAL", 354, 363], ["mammalian cells", "CELL", 298, 313], ["intra-domain disulfide bonds", "SIMPLE_CHEMICAL", 341, 369], ["VHH single domain antibody fragments", "PROTEIN", 14, 50], ["heavy-chain antibodies", "PROTEIN", 85, 107], ["light chain", "PROTEIN", 118, 129], ["whole antibody", "PROTEIN", 210, 224], ["mammalian cells", "CELL_TYPE", 298, 313], ["The so-called VHH single domain antibody fragments", "PROBLEM", 0, 50], ["light chain", "PROBLEM", 118, 129], ["the whole antibody", "TEST", 206, 224], ["expression in mammalian cells", "PROBLEM", 284, 313], ["intra-domain disulfide bonds", "PROBLEM", 341, 369], ["antibody fragments", "OBSERVATION", 32, 50], ["light chain", "OBSERVATION_MODIFIER", 118, 129], ["excellent properties", "OBSERVATION_MODIFIER", 234, 254], ["stability", "OBSERVATION_MODIFIER", 270, 279], ["mammalian cells", "OBSERVATION", 298, 313]]], ["They are easily produced as recombinant antibodies, much smaller in size and can be forged into new multispecific and multivalent reagents with enhanced therapeutic efficacy.", [["recombinant antibodies", "PROTEIN", 28, 50], ["recombinant antibodies", "PROBLEM", 28, 50], ["new multispecific and multivalent reagents", "TREATMENT", 96, 138], ["smaller", "OBSERVATION_MODIFIER", 57, 64], ["size", "OBSERVATION_MODIFIER", 68, 72]]], ["Due to their smaller size, they possess a great capacity to form long finger-like extensions that can potentially target cryptic epitopes that are difficult for intact antibodies or scFv fragments to reach.Selection Strategies to Improve Intrabody Stability and SolubilityAntibody fragments can be potentially targeted to any subcellular compartment, but their folding performance and stability can be limited by the micro-environmental intracellular conditions of the compartment where they are directed to.", [["fragments", "ANATOMY", 281, 290], ["subcellular compartment", "ANATOMY", 326, 349], ["intracellular", "ANATOMY", 437, 450], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 437, 450], ["cryptic epitopes", "PROTEIN", 121, 137], ["scFv fragments", "PROTEIN", 182, 196], ["a great capacity", "PROBLEM", 40, 56], ["long finger-like extensions", "PROBLEM", 65, 92], ["cryptic epitopes", "PROBLEM", 121, 137], ["intact antibodies", "PROBLEM", 161, 178], ["scFv fragments", "PROBLEM", 182, 196], ["Selection Strategies", "TREATMENT", 206, 226], ["Antibody fragments", "PROBLEM", 272, 290], ["smaller", "OBSERVATION_MODIFIER", 13, 20], ["size", "OBSERVATION_MODIFIER", 21, 25], ["great", "OBSERVATION_MODIFIER", 42, 47], ["capacity", "OBSERVATION", 48, 56], ["Intrabody Stability", "OBSERVATION", 238, 257], ["Solubility", "OBSERVATION_MODIFIER", 262, 272], ["fragments", "OBSERVATION", 281, 290], ["compartment", "ANATOMY_MODIFIER", 338, 349]]], ["Thus, a major issue raised in the initial phase of work on intrabodies was the limited half life of antibody and antibody domains and their tendency to aggregate when expressed in the cytoplasm of mammalian cells.", [["cytoplasm", "ANATOMY", 184, 193], ["cells", "ANATOMY", 207, 212], ["cytoplasm", "ORGANISM_SUBSTANCE", 184, 193], ["mammalian cells", "CELL", 197, 212], ["antibody and antibody domains", "PROTEIN", 100, 129], ["mammalian cells", "CELL_TYPE", 197, 212], ["antibody and antibody domains", "PROBLEM", 100, 129], ["mammalian cells", "OBSERVATION", 197, 212]]], ["Studies on targeting of scFv fragments showed, in fact, that the expression levels of the retargeted antibody domains may vary and the cytoplasm may be considered the worst case (Cattaneo and Biocca 1999).", [["cytoplasm", "ANATOMY", 135, 144], ["scFv", "GENE_OR_GENE_PRODUCT", 24, 28], ["cytoplasm", "ORGANISM_SUBSTANCE", 135, 144], ["scFv fragments", "DNA", 24, 38], ["retargeted antibody domains", "PROTEIN", 90, 117], ["scFv fragments", "PROBLEM", 24, 38], ["the retargeted antibody domains", "PROBLEM", 86, 117]]], ["In general, intrabodies expressed in the secretory compartment are more stable than those expressed in the cytoplasm.", [["secretory compartment", "ANATOMY", 41, 62], ["cytoplasm", "ANATOMY", 107, 116], ["intrabodies", "GENE_OR_GENE_PRODUCT", 12, 23], ["secretory compartment", "MULTI-TISSUE_STRUCTURE", 41, 62], ["cytoplasm", "ORGANISM_SUBSTANCE", 107, 116], ["intrabodies", "PROTEIN", 12, 23], ["more", "OBSERVATION_MODIFIER", 67, 71], ["stable", "OBSERVATION_MODIFIER", 72, 78]]], ["This is due to the fact that intradomain disulfide bonds, which contribute 4\u20136 Kcal mol\u20131 to the stability of the antibody domain, do not form in the reducing environment of the cytoplasm (Biocca et al. 1995).", [["cytoplasm", "ANATOMY", 178, 187], ["disulfide", "CHEMICAL", 41, 50], ["cytoplasm", "ORGANISM_SUBSTANCE", 178, 187], ["4\u20136 Kcal mol\u20131", "PROTEIN", 75, 89], ["antibody domain", "PROTEIN", 114, 129], ["intradomain disulfide bonds", "PROBLEM", 29, 56], ["the antibody domain", "TEST", 110, 129]]], ["As a consequence of the lower stability, some scFvs tend to misfold and aggregate as insoluble proteins.", [["scFvs", "GENE_OR_GENE_PRODUCT", 46, 51], ["scFvs", "PROTEIN", 46, 51], ["insoluble proteins", "PROTEIN", 85, 103], ["the lower stability", "PROBLEM", 20, 39], ["some scFvs", "PROBLEM", 41, 51], ["lower stability", "OBSERVATION_MODIFIER", 24, 39], ["scFvs", "OBSERVATION", 46, 51]]], ["Notwithstanding this fact, it is worth noting that in many cases cytoplasmic-targeted intrabodies bind the antigens and maintain their in vivo functional activity (Cardinale et al. 2001).Selection Strategies to Improve Intrabody Stability and SolubilityA recent comparative study between the cytoplasmic expression in mammalian cells of well characterized single-chain variable fragments and camelid VHHs, selected from antibody libraries based on similar scaffolds, have outlined the physico-chemical determinants that correlate with enhanced intracellular solubility.", [["cytoplasmic", "ANATOMY", 65, 76], ["cytoplasmic", "ANATOMY", 292, 303], ["cells", "ANATOMY", 328, 333], ["intracellular", "ANATOMY", 544, 557], ["cytoplasmic", "ORGANISM_SUBSTANCE", 65, 76], ["intrabodies", "SIMPLE_CHEMICAL", 86, 97], ["cytoplasmic", "ORGANISM_SUBSTANCE", 292, 303], ["mammalian cells", "CELL", 318, 333], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 544, 557], ["cytoplasmic-targeted intrabodies", "PROTEIN", 65, 97], ["antigens", "PROTEIN", 107, 115], ["mammalian cells", "CELL_TYPE", 318, 333], ["single-chain variable fragments", "DNA", 356, 387], ["camelid VHHs", "PROTEIN", 392, 404], ["Selection Strategies", "TREATMENT", 187, 207], ["A recent comparative study", "TEST", 253, 279], ["single-chain variable fragments", "PROBLEM", 356, 387], ["camelid VHHs", "PROBLEM", 392, 404], ["antibody libraries", "TREATMENT", 420, 438], ["similar scaffolds", "TREATMENT", 448, 465], ["Stability", "OBSERVATION_MODIFIER", 229, 238], ["mammalian cells", "OBSERVATION", 318, 333], ["chain variable", "OBSERVATION_MODIFIER", 363, 377], ["fragments", "OBSERVATION", 378, 387], ["intracellular solubility", "OBSERVATION", 544, 568]]], ["Soluble expression in the cytoplasm appears to be influenced by the complementary determining regions (CDRs) content and by the overall charge and hydropathicity of the intrabody sequence (Kvam et al. 2010).Selection Strategies to Improve Intrabody Stability and SolubilityThis issue is very important and during the last years many selection strategies have been developed to improve stability, solubility and functional properties of antibody fragments under conditions of intracellular expression.", [["cytoplasm", "ANATOMY", 26, 35], ["intracellular", "ANATOMY", 475, 488], ["cytoplasm", "ORGANISM_SUBSTANCE", 26, 35], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 475, 488], ["complementary determining regions", "PROTEIN", 68, 101], ["intrabody sequence", "DNA", 169, 187], ["antibody fragments", "PROTEIN", 436, 454], ["Soluble expression in the cytoplasm", "PROBLEM", 0, 35], ["the intrabody sequence", "TEST", 165, 187], ["Selection Strategies", "TREATMENT", 207, 227], ["selection strategies", "TREATMENT", 333, 353], ["antibody fragments", "PROBLEM", 436, 454], ["appears to be", "UNCERTAINTY", 36, 49], ["Intrabody Stability", "OBSERVATION", 239, 258], ["Solubility", "OBSERVATION_MODIFIER", 263, 273], ["antibody fragments", "OBSERVATION", 436, 454], ["intracellular expression", "OBSERVATION", 475, 499]]], ["The former relies on the introduction of educated mutations that stabilize pre-existing antibody fragments in order to obtain a \u201csuper-framework\u201d (Jung and Pl\u00fcckthun 1997; W\u00f6rn et al. 2000; Monsellier and Bedouelle 2006).", [["antibody fragments", "PROTEIN", 88, 106], ["educated mutations", "PROBLEM", 41, 59], ["pre-existing antibody fragments", "PROBLEM", 75, 106], ["antibody fragments", "OBSERVATION", 88, 106]]], ["The second approach exploits the availability of different antibody libraries for selection of the best functional molecules for intracellular expression (Hudson and Souriau 2003).", [["intracellular", "ANATOMY", 129, 142], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 129, 142], ["different antibody libraries", "TREATMENT", 49, 77]]], ["For the expression in the cytoplasm, new human phage antibody libraries have been generated based on single framework optimized for intracellular expression (Philibert et al. 2007).", [["cytoplasm", "ANATOMY", 26, 35], ["intracellular", "ANATOMY", 132, 145], ["cytoplasm", "ORGANISM_SUBSTANCE", 26, 35], ["human", "ORGANISM", 41, 46], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 132, 145], ["human phage antibody libraries", "DNA", 41, 71], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["the expression in the cytoplasm", "PROBLEM", 4, 35], ["new human phage antibody libraries", "TREATMENT", 37, 71]]], ["On the other hand, highly stable ribosome-display libraries, based on Escherichia coli SecM translation arrest mechanism, have been used for isolating scFvs that are stable under reducing conditions (Contreras-Mart\u0131\u00b4nez and DeLisa 2007).", [["Escherichia coli", "ORGANISM", 70, 86], ["scFvs", "GENE_OR_GENE_PRODUCT", 151, 156], ["scFvs", "PROTEIN", 151, 156], ["Escherichia coli", "SPECIES", 70, 86], ["Escherichia coli", "SPECIES", 70, 86], ["Escherichia coli SecM translation arrest mechanism", "PROBLEM", 70, 120], ["isolating scFvs", "TREATMENT", 141, 156], ["stable", "OBSERVATION", 26, 32], ["Escherichia coli", "OBSERVATION", 70, 86], ["stable", "OBSERVATION_MODIFIER", 166, 172]]], ["Moreover, antibody-antigen intracellular selection methods have been also developed for the isolation of intrabodies able to efficiently interact with the antigen in vivo.", [["intracellular", "ANATOMY", 27, 40], ["antibody-antigen", "GENE_OR_GENE_PRODUCT", 10, 26], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 27, 40], ["antibody", "TEST", 10, 18], ["the isolation of intrabodies", "PROBLEM", 88, 116], ["the antigen in vivo", "TREATMENT", 151, 170]]], ["To this aim an in vivo yeast two-hybrid system has been realized, described as intracellular antibody capture (IAC) technology (Visintin et al. 1999).", [["intracellular", "ANATOMY", 79, 92], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 79, 92], ["yeast", "SPECIES", 23, 28], ["yeast", "SPECIES", 23, 28]]], ["This approach combines a first round of in vitro selection of scFvs with a second round of in vivo screening of selected intrabodies and allows the isolation of antibody domains with no need to use purified antigens.", [["scFvs", "GENE_OR_GENE_PRODUCT", 62, 67], ["scFvs", "PROTEIN", 62, 67], ["antibody domains", "PROTEIN", 161, 177], ["purified antigens", "PROTEIN", 198, 215], ["vitro selection of scFvs", "TREATMENT", 43, 67], ["selected intrabodies", "PROBLEM", 112, 132], ["the isolation of antibody domains", "TREATMENT", 144, 177], ["purified antigens", "TREATMENT", 198, 215]]], ["IAC technology has recently allowed the direct in vivo intracellular selection of conformation-sensitive anti-oligomeric scFvs against the Alzheimer\u2019s amyloid \u03b2 peptide (Meli et al. 2009).", [["intracellular", "ANATOMY", 55, 68], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 55, 68], ["amyloid \u03b2 peptide", "GENE_OR_GENE_PRODUCT", 151, 168], ["anti-oligomeric scFvs", "PROTEIN", 105, 126], ["anti-oligomeric scFvs", "TREATMENT", 105, 126]]], ["Another procedure for direct in vivo selection of antigen-specific intrabodies, which utilises a single domain antibody format and is based on a predefined intrabody consensus framework has been described (IAC2) (Tanaka and Rabbitts 2003) and further developed (IAC3) (Tanaka and Rabbitts 2010).", [["Another procedure", "TREATMENT", 0, 17], ["a single domain antibody format", "TEST", 95, 126], ["a predefined intrabody consensus framework", "PROBLEM", 143, 185]]], ["This new protocol allows the isolation of functional VH and VL domains from different libraries in four steps, including confirmation of functional intrabodies in mammalian cells.Selection Strategies to Improve Intrabody Stability and SolubilityFor clinical applications of intrabodies, generation of humanized and/or human-derived antibody domains offers obvious potential advantages.", [["cells", "ANATOMY", 173, 178], ["VH", "GENE_OR_GENE_PRODUCT", 53, 55], ["mammalian cells", "CELL", 163, 178], ["human", "ORGANISM", 318, 323], ["VH and VL domains", "DNA", 53, 70], ["mammalian cells", "CELL_TYPE", 163, 178], ["humanized and/or human-derived antibody domains", "PROTEIN", 301, 348], ["human", "SPECIES", 318, 323], ["human", "SPECIES", 318, 323], ["This new protocol", "TREATMENT", 0, 17], ["functional VH and VL domains", "PROBLEM", 42, 70], ["functional intrabodies in mammalian cells", "PROBLEM", 137, 178], ["Selection Strategies", "TREATMENT", 179, 199], ["intrabodies", "TREATMENT", 274, 285], ["generation of humanized", "TREATMENT", 287, 310], ["human-derived antibody domains", "TREATMENT", 318, 348], ["functional VH", "OBSERVATION", 42, 55], ["different libraries", "OBSERVATION", 76, 95], ["functional intrabodies", "OBSERVATION", 137, 159], ["mammalian cells", "OBSERVATION", 163, 178], ["Intrabody Stability", "OBSERVATION", 211, 230], ["Solubility", "OBSERVATION_MODIFIER", 235, 245]]], ["Modern emerging strategies have improved in vitro selection of fully humanized recombinant antibodies directly from human antibody-display libraries, through the creation of large natural or synthetic repertoires of antibody fragments (Hudson and Souriau 2003; Hoogenboom 2005).", [["human", "ORGANISM", 116, 121], ["humanized recombinant antibodies", "PROTEIN", 69, 101], ["human antibody-display libraries", "DNA", 116, 148], ["antibody fragments", "PROTEIN", 216, 234], ["human", "SPECIES", 116, 121], ["human", "SPECIES", 116, 121], ["Modern emerging strategies", "TREATMENT", 0, 26], ["fully humanized recombinant antibodies", "TREATMENT", 63, 101], ["human antibody", "TEST", 116, 130], ["antibody fragments", "PROBLEM", 216, 234], ["improved", "OBSERVATION_MODIFIER", 32, 40], ["large", "OBSERVATION_MODIFIER", 174, 179], ["natural", "OBSERVATION_MODIFIER", 180, 187], ["antibody fragments", "OBSERVATION", 216, 234]]], ["A direct selection of human phage antibody libraries on tumor cells has been described (Goenaga et al. 2007).The Mode of Action of IntrabodiesIntrabodies can mediate their effect inside the cells by neutralizing the target protein through direct binding to the functional domain (Biocca et al. 1994; Cohen et al. 1998), blocking protein-protein interaction (Griffin et al. 2006; Tanaka et al. 2007; Van den Abbeele et al. 2010) or by relocating the antigen to a different intracellular location (Lener et al. 2000; Cardinale et al. 2005; B\u00f6ldicke 2007).", [["tumor cells", "ANATOMY", 56, 67], ["cells", "ANATOMY", 190, 195], ["intracellular", "ANATOMY", 472, 485], ["tumor", "DISEASE", 56, 61], ["human", "ORGANISM", 22, 27], ["tumor cells", "CELL", 56, 67], ["cells", "CELL", 190, 195], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 472, 485], ["human phage antibody libraries", "DNA", 22, 52], ["tumor cells", "CELL_TYPE", 56, 67], ["target protein", "PROTEIN", 216, 230], ["functional domain", "PROTEIN", 261, 278], ["human", "SPECIES", 22, 27], ["human", "SPECIES", 22, 27], ["A direct selection of human phage antibody libraries", "TREATMENT", 0, 52], ["tumor cells", "PROBLEM", 56, 67], ["IntrabodiesIntrabodies", "TREATMENT", 131, 153], ["tumor cells", "OBSERVATION", 56, 67]]], ["In this last case also non-neutralizing antibodies, according to in vitro biochemical criteria, can be effective when expressed in vivo.", [["non-neutralizing antibodies", "PROTEIN", 23, 50], ["non-neutralizing antibodies", "PROBLEM", 23, 50]]], ["This can be obtained by adding to the intrabody a specific targeting signal, as the ER retention signal KDEL, which confers to the antigen-antibody complex the retention in the endoplasmic reticulum.", [["ER", "ANATOMY", 84, 86], ["endoplasmic reticulum", "ANATOMY", 177, 198], ["ER", "GENE_OR_GENE_PRODUCT", 84, 86], ["KDEL", "GENE_OR_GENE_PRODUCT", 104, 108], ["antigen-antibody complex", "GENE_OR_GENE_PRODUCT", 131, 155], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 177, 198], ["ER", "PROTEIN", 84, 86], ["KDEL", "PROTEIN", 104, 108], ["antigen-antibody complex", "PROTEIN", 131, 155], ["the ER retention signal KDEL", "TEST", 80, 108], ["the antigen", "TEST", 127, 138], ["retention", "OBSERVATION_MODIFIER", 160, 169], ["endoplasmic reticulum", "OBSERVATION", 177, 198]]], ["In some described cases, intrabodies divert the antigen to the proteasome degradation pathway (Cardinale et al. 2003; Filesi et al. 2007).", [["intrabodies", "SIMPLE_CHEMICAL", 25, 36], ["proteasome", "PROTEIN", 63, 73]]], ["As mentioned before, intrabodies have different folding performance and stability particularly when they are expressed in the cytoplasm.", [["cytoplasm", "ANATOMY", 126, 135], ["cytoplasm", "ORGANISM_SUBSTANCE", 126, 135], ["different folding performance", "PROBLEM", 38, 67], ["different", "OBSERVATION_MODIFIER", 38, 47], ["folding", "OBSERVATION", 48, 55], ["stability", "OBSERVATION_MODIFIER", 72, 81]]], ["In this compartment, intradomain disulfide bonds do not form and intrabodies complexed to their corresponding antigen tend to misfold and aggregate.", [["disulfide", "CHEMICAL", 33, 42], ["intrabodies", "PROTEIN", 65, 76], ["intradomain disulfide bonds", "TREATMENT", 21, 48]]], ["This has been demonstrated for cytoplasmic, nuclear and secretory intrabodies.", [["cytoplasmic", "ANATOMY", 31, 42], ["nuclear", "ANATOMY", 44, 51], ["secretory intrabodies", "ANATOMY", 56, 77], ["cytoplasmic", "ORGANISM_SUBSTANCE", 31, 42], ["nuclear", "CELLULAR_COMPONENT", 44, 51], ["secretory intrabodies", "CELLULAR_COMPONENT", 56, 77], ["cytoplasmic, nuclear and secretory intrabodies", "PROTEIN", 31, 77], ["cytoplasmic, nuclear and secretory intrabodies", "PROBLEM", 31, 77], ["cytoplasmic", "OBSERVATION_MODIFIER", 31, 42], ["secretory intrabodies", "OBSERVATION", 56, 77]]], ["In the first case they aggregate and form aggresomes in a perinuclear location, whereas in the secretory compartments the antigen-antibody complexes are retrotranslocated from the ER, ubiquitinated and finally proteasome degraded (Filesi et al. 2007).The Mode of Action of IntrabodiesIn order to define the mode of action of new intrabodies, the solubility properties, the intracellular distribution and the resulting phenotypes should be routinely analysed with ad hoc assays.", [["perinuclear", "ANATOMY", 58, 69], ["secretory compartments", "ANATOMY", 95, 117], ["ER", "ANATOMY", 180, 182], ["intracellular", "ANATOMY", 373, 386], ["perinuclear", "CELLULAR_COMPONENT", 58, 69], ["secretory compartments", "CELLULAR_COMPONENT", 95, 117], ["antigen", "GENE_OR_GENE_PRODUCT", 122, 129], ["ER", "GENE_OR_GENE_PRODUCT", 180, 182], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 373, 386], ["antigen-antibody complexes", "PROTEIN", 122, 148], ["ER", "PROTEIN", 180, 182], ["proteasome", "PROTEIN", 210, 220], ["antibody complexes", "TEST", 130, 148], ["Intrabodies", "TREATMENT", 273, 284], ["new intrabodies", "PROBLEM", 325, 340], ["the solubility properties", "TREATMENT", 342, 367], ["the resulting phenotypes", "PROBLEM", 404, 428], ["new", "OBSERVATION_MODIFIER", 325, 328], ["intracellular distribution", "OBSERVATION", 373, 399]]], ["Protocols for studying the expression, solubility, stability properties, intracellular localisation and for the analysis of the antigen-intrabody complex in vivo have been described (Cardinale et al. 2004 and Cardinale and Biocca 2010).The Mode of Action of IntrabodiesIn summary, intrabodies can be used for preventing or treating human diseases by exploiting their ability to (a) divert the antigen from its functional location, (b) inhibit functional protein-protein interaction, (c) inhibit the functional site of the target antigen, (d) re-route the antigen to the degradation pathway and (e) inhibit different stages of the aggregation process.", [["intracellular", "ANATOMY", 73, 86], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 73, 86], ["antigen-intrabody complex", "GENE_OR_GENE_PRODUCT", 128, 153], ["human", "ORGANISM", 332, 337], ["antigen-intrabody complex", "PROTEIN", 128, 153], ["target antigen", "PROTEIN", 522, 536], ["human", "SPECIES", 332, 337], ["human", "SPECIES", 332, 337], ["intracellular localisation", "TEST", 73, 99], ["the analysis", "TEST", 108, 120], ["the antigen", "TEST", 124, 135], ["intrabodies", "TREATMENT", 281, 292], ["treating human diseases", "PROBLEM", 323, 346], ["functional protein-protein interaction", "PROBLEM", 443, 481], ["the aggregation process", "PROBLEM", 626, 649], ["aggregation process", "OBSERVATION", 630, 649]]], ["This latter mode of action can be achieved through stabilization of the native state isoform, inhibition of oligomerization, inhibition of fibril formation and disruption and clearance of preformed aggregates as demonstrated with scFv directed against misfolded prone proteins (Cardinale and Biocca 2008b).The Mode of Action of IntrabodiesFigure 9.1summarises the different modes of action of intrabodies observed in vivo.", [["fibril", "ANATOMY", 139, 145], ["fibril", "CELLULAR_COMPONENT", 139, 145], ["scFv directed against misfolded prone proteins", "GENE_OR_GENE_PRODUCT", 230, 276], ["native state isoform", "PROTEIN", 72, 92], ["scFv", "PROTEIN", 230, 234], ["misfolded prone proteins", "PROTEIN", 252, 276], ["Biocca 2008b", "PROTEIN", 292, 304], ["inhibition of oligomerization", "TREATMENT", 94, 123], ["fibril formation", "PROBLEM", 139, 155], ["disruption", "PROBLEM", 160, 170], ["clearance of preformed aggregates", "TREATMENT", 175, 208], ["scFv", "TREATMENT", 230, 234], ["misfolded prone proteins", "PROBLEM", 252, 276], ["IntrabodiesFigure", "TEST", 328, 345], ["action of intrabodies", "TREATMENT", 383, 404], ["fibril formation", "OBSERVATION", 139, 155]]], ["These activities have a great potential in medicine and represent a viable option for different pathologies, including neurodegenerative diseases, infectious diseases and cancer.", [["cancer", "ANATOMY", 171, 177], ["neurodegenerative diseases", "DISEASE", 119, 145], ["infectious diseases", "DISEASE", 147, 166], ["cancer", "DISEASE", 171, 177], ["cancer", "CANCER", 171, 177], ["different pathologies", "PROBLEM", 86, 107], ["neurodegenerative diseases", "PROBLEM", 119, 145], ["infectious diseases", "PROBLEM", 147, 166], ["cancer", "PROBLEM", 171, 177], ["neurodegenerative", "OBSERVATION_MODIFIER", 119, 136], ["diseases", "OBSERVATION", 137, 145], ["infectious", "OBSERVATION_MODIFIER", 147, 157], ["cancer", "OBSERVATION", 171, 177]]]], "e3b748c735f2ba33e17ce4d92cfac9293b1c4866": [["development of autoimmune disease, and B-cell-targeted therapies are effective in the treatment of human autoimmune diseases 5 .", [["B-cell", "ANATOMY", 39, 45], ["autoimmune disease", "DISEASE", 15, 33], ["autoimmune diseases", "DISEASE", 105, 124], ["B-cell", "CELL", 39, 45], ["human", "ORGANISM", 99, 104], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104], ["autoimmune disease", "PROBLEM", 15, 33], ["B-cell", "TREATMENT", 39, 45], ["targeted therapies", "TREATMENT", 46, 64], ["human autoimmune diseases", "PROBLEM", 99, 124], ["autoimmune disease", "OBSERVATION", 15, 33], ["B-cell", "OBSERVATION_MODIFIER", 39, 45], ["autoimmune diseases", "OBSERVATION", 105, 124]]]], "1ce4b4f580a5e4dcc098b2f935c60e817f2e2a6f": [["29In view of the absence of approved drugs or vaccines for COVID-19 (up to this day), Interventions (NPI) are the mechanisms that public health offices around the world are using in an 31 attempt to mitigate the impact of its epidemic (Lai et al., 2020; Ferguson et al., 2020) .", [["approved drugs", "TREATMENT", 28, 42], ["vaccines", "TREATMENT", 46, 54], ["COVID", "TEST", 59, 64]]], ["Similarly 32 to the actual spread of the disease, the dynamics of the contention patterns obtained as a result 33 of application of NPIs are complex and may depend not only on interactions (contacts) between Figure 1 .", [["NPIs", "GENE_OR_GENE_PRODUCT", 132, 136], ["the disease", "PROBLEM", 37, 48], ["application of NPIs", "TREATMENT", 117, 136], ["disease", "OBSERVATION", 41, 48]]], ["142 Accordingly, we designed three types of agents: a healthy agent associated to the S and R 143 states (the latter marked with an immunity condition), a sick agent associated to the I extended 144 state tagged with the CARDS conditions, and a dead agent associated to the E state.", [["I extended 144 state", "PROTEIN", 184, 204], ["agents", "TREATMENT", 44, 50], ["a healthy agent", "TREATMENT", 52, 67], ["a sick agent", "TREATMENT", 153, 165], ["a dead agent", "TREATMENT", 243, 255]]], ["In contrast to 145 population-dynamic simulation, instead of using transition rates between states, our model uses 150 Therefore, we consider the following transition events: is initially characterised as not confirmed, not tested, not severe, not deadly, not hospitalised 154 and not ICU-admitted.", [["dynamic simulation", "TEST", 30, 48]]], ["Besides, a recovery (or illness) period in days is assigned as a random 155 variate with a Gaussian distribution centered at the avg-duration model parameter.156\u2022 I + Confirmed.", [["a Gaussian distribution", "PROBLEM", 89, 112]]], ["This may happen in any 157 of the following moments: when the patient is tested for the virus and the test results positive; 158 when the agent has not been previously diagnosed as positive at the moment of admission to 159 hospital, or admission to ICU bed or death; or when the patient feels sufficiently symptomatic 160 so as to self-isolate.", [["death", "DISEASE", 261, 266], ["patient", "ORGANISM", 62, 69], ["patient", "ORGANISM", 280, 287], ["patient", "SPECIES", 62, 69], ["patient", "SPECIES", 280, 287], ["the virus", "PROBLEM", 84, 93], ["the test", "TEST", 98, 106], ["death", "PROBLEM", 261, 266], ["sufficiently symptomatic", "PROBLEM", 294, 318]]], ["On the other hand, if the Case Isolation NPI (see above) is lifted after 161 having been enforced during the course of the simulation, then the confirmed condition of 162 agents who have not been tested positive, is reversed (i.e those who self-isolated).163The distinction between confirmed and non-confirmed cases is used to identify individuals 164 that need to stay isolated so as to prevent his capability to spread the virus.", [["his capability", "PROBLEM", 396, 410], ["the virus", "PROBLEM", 421, 430]]], ["Besides, this 165 distinction is also useful to examine the discrepancy between \"official\" confirmed fatality rates CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)163The copyright holder for this preprint this version posted June 16, 2020 June 16, . . https://doi.org/10.1101 June 16, /2020 doi: medRxiv preprint a model parameter (%-asymptomatic).", [["CC", "CHEMICAL", 116, 118], ["https://doi.org/10.1101", "CHEMICAL", 407, 430], ["CC", "TEST", 116, 118], ["ND", "PROBLEM", 125, 127], ["The copyright holder", "TREATMENT", 321, 341], ["med", "ANATOMY", 221, 224]]], ["In the simulation tool, this condition is indicated with the colour of the agent (yellow for asymptomatic, red for symptomatic).172\u2022 I + Risky.", [["asymptomatic", "PROBLEM", 93, 105]]], ["Cur-173 rently the model does not consider neither risk stratification of co-morbidities nor age struc-174 ture of the population.", [["Cur-173", "CHEMICAL", 0, 7], ["Cur", "TEST", 0, 3]]], ["Therefore all these risk factors (obesity, diabetes, cardiovascular dis-175 ease or medium to old age) are encompassed in this single condition which is activated upon 176 acquiring the infection, with a probability defined as a model parameter (%-high risk).177\u2022 I + Severity.", [["cardiovascular", "ANATOMY", 53, 67], ["obesity", "DISEASE", 34, 41], ["diabetes", "DISEASE", 43, 51], ["infection", "DISEASE", 186, 195], ["obesity", "PROBLEM", 34, 41], ["diabetes", "PROBLEM", 43, 51], ["cardiovascular dis", "PROBLEM", 53, 71], ["the infection", "PROBLEM", 182, 195], ["a model parameter", "TEST", 227, 244], ["infection", "OBSERVATION", 186, 195]]], ["This condition indicates progression of the disease to a severe state, which in turn 178 represents a higher threat of death, as it is defined in the I E transition.", [["death", "DISEASE", 119, 124], ["the disease", "PROBLEM", 40, 51], ["a severe state", "PROBLEM", 55, 69], ["progression", "OBSERVATION_MODIFIER", 25, 36], ["disease", "OBSERVATION", 44, 51], ["severe", "OBSERVATION_MODIFIER", 57, 63]]], ["This event occurs 179 according to the following parameters (see Tuomisto et al. (2020) to hospital beds, on a daily basis but considering patients with a deadly condition instead.203Here, ICU beds are released when agents recover or die. .", [["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 16, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Since dead may occur in any day during the illness period, we modelled the chance of the day 208 of fatality as a triangular distribution with peak in the middle of such individual's particular 209 recovery period (half-recover-period).", [["fatality", "DISEASE", 100, 108], ["dead", "PROBLEM", 6, 10], ["triangular", "OBSERVATION_MODIFIER", 114, 124], ["distribution", "OBSERVATION_MODIFIER", 125, 137], ["peak", "OBSERVATION_MODIFIER", 143, 147], ["middle", "ANATOMY_MODIFIER", 155, 161]]], ["In other words, we assume:(which was not certified by peer review)where CDF stands for cumulative distributed function.", [["CDF", "PROTEIN", 72, 75]]], ["As a result, we compute the actual 211 probability of death in a given day as follows:(which was not certified by peer review)212 P(Extinct | day) = P(day) P(Extinct | Conditions).(which was not certified by peer review)\u2022 I R (recovery).", [["death", "DISEASE", 54, 59], ["I R", "GENE_OR_GENE_PRODUCT", 222, 225], ["death", "PROBLEM", 54, 59]]], ["An infected individual gets cured when he reaches the end of his recovery \u2022 lifestyle: simulates the daily routine of agents, which currently encompasses moving the agent ahead towards its current destination, or head it backwards home if he has reached 246 his range limit.", [["head", "ORGANISM_SUBDIVISION", 213, 217], ["agents", "TREATMENT", 118, 124], ["infected", "OBSERVATION", 3, 11]]], ["In any case, confirmed patients are not allowed to move around.247If zonal enforcement is on, the movement is restricted only within the periphery of the zone 248 where the agent is resident.", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["periphery", "ANATOMY_MODIFIER", 137, 146]]], ["In the simulation view, residents of different zones are identified 249 with different shapes and colours (the latter coincides with the colour of their zone's ground).250\u2022 epidemic: here the spread of the epidemic is simulated, with transmissions occurring in 251 proportion to proximity between infectious and susceptibles and probability of contagion. .", [["the simulation view", "TEST", 3, 22], ["different shapes", "OBSERVATION_MODIFIER", 77, 93], ["colours", "OBSERVATION_MODIFIER", 98, 105], ["infectious", "OBSERVATION", 297, 307]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 16, 2020. . https://doi.org/10.1101/2020.06.13.20130542 doi: medRxiv preprint NetLogo Web\" tab.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint NetLogo", "TREATMENT", 326, 350], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["NetLogo is a widely popular software platform for ABMs, which further to the 325 simulation language, also integrates a graphical view area and a test-bed for experimental design 326 (Wilensky and Rand, 2015) .", [["a test", "TEST", 144, 150]]], ["A snapshot of the simulation view area is shown in Figure 3 .", [["the simulation view area", "TEST", 14, 38]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 16, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Agents are identified by a different shape and colour per zone; additionally, the epidemic state of agents is indicated by red (sysmptomatic), yellow (asymptomatic) or white (recovered, immune); deaths are shown by black cross marks (\u00d7).", [["deaths", "DISEASE", 195, 201], ["Agents", "TREATMENT", 0, 6], ["agents", "TREATMENT", 100, 106], ["yellow (asymptomatic)", "PROBLEM", 143, 164], ["deaths", "PROBLEM", 195, 201], ["different", "OBSERVATION_MODIFIER", 27, 36], ["shape", "OBSERVATION_MODIFIER", 37, 42], ["zone", "OBSERVATION_MODIFIER", 58, 62]]], ["Besides, households and sentinels (ambulances) can also be seen.(which was not certified by peer review)agents are represented with different shapes according to the zone where they reside.", [["agents", "TREATMENT", 104, 110]]], ["The colour 330 of the agent also represents its extended state (healthy: same colour as zone ground; immune: 331 white; sick: red, or yellow if asymptomatic; dead: black \u00d7).", [["The colour", "TEST", 0, 10], ["red", "PROBLEM", 126, 129], ["yellow", "PROBLEM", 134, 140], ["asymptomatic", "PROBLEM", 144, 156]]], ["Special-purpose agents designed to im-332 plement some of the NPIs such as households for home-quarantine and ambulances for sentinel-333 testing can also be seen.334The control panel is organised in sections related to general, city and COVID-19 settings, mon-335 itors of epidemic indicators, parameters, action commands to execute the simulation, and a ded-341In this section we describe a number of scenarios conceived to illustrate how to perform a rapid 342 assessment of the effect of NPIs, or combination of NPIs, to contain the spread of the epidemics 343 in the population of agents.", [["sections", "ANATOMY", 200, 208], ["im-332", "CHEMICAL", 35, 41], ["Special-purpose agents", "TREATMENT", 0, 22], ["sentinel-333 testing", "TEST", 125, 145], ["The control panel", "TEST", 166, 183], ["COVID", "TEST", 238, 243], ["a rapid 342 assessment", "TEST", 452, 474], ["NPIs", "TREATMENT", 492, 496], ["NPIs", "TREATMENT", 516, 520], ["the epidemics", "PROBLEM", 547, 560]]], ["Then we simulate scenarios where the individual NPIs are applied.", [["NPIs", "GENE_OR_GENE_PRODUCT", 48, 52], ["the individual NPIs", "TREATMENT", 33, 52]]], ["Finally, we simulate 345 scenarios where these NPIs are combined with the zonal enforcement strategy in order to verify 346 its potential impact.", [["these NPIs", "TREATMENT", 41, 51], ["the zonal enforcement strategy", "TREATMENT", 70, 100]]], ["General, city and COVID-347 19 parameters used in all simulations are defined in Figure 2 .", [["COVID", "TEST", 18, 23]]], ["For each scenario, the epidemic is 348 assumed to begin with a \"patient zero\" seeded randomly in any zone of the city at 0d:12h after the 349 start of the simulation.", [["patient", "ORGANISM", 64, 71], ["patient", "SPECIES", 64, 71], ["the simulation", "TREATMENT", 151, 165]]], ["The application of the configured NPI policies begins at 04d:00h.", [["the configured NPI policies", "TREATMENT", 19, 46]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 16, 2020. . https://doi.org/10.1101/2020.06.13.20130542 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint", "TREATMENT", 326, 342], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 16, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Survivor, death and immune count in each scenario starting with a single infection.", [["death", "DISEASE", 10, 15], ["infection", "DISEASE", 73, 82], ["death", "PROBLEM", 10, 15], ["immune count", "TEST", 20, 32], ["a single infection", "PROBLEM", 64, 82], ["immune count", "OBSERVATION", 20, 32], ["infection", "OBSERVATION", 73, 82]]], ["Statistical significant differences in counts of survivors and deaths between the single NPI scenarios compared to their corresponding combined NPI+ZE scenarios, are marked as * (p<0.01) and ** (p<0.001).", [["deaths", "DISEASE", 63, 69], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["differences", "OBSERVATION_MODIFIER", 24, 35], ["marked", "OBSERVATION_MODIFIER", 166, 172]]], ["Epidemic indicators obtained in each scenario starting with an outbreak of 5% population.Scenario CFR (%) IFR (%)The latter increase is caused of course, by the larger amount of carriers at the beginning of the 424 simulation (20 individuals or 5%) yielding a higher burden on the hospital facilities at the peak of The main finding however, in our opinion, is that simultaneous application of the Zone Enforc- .", [["Epidemic indicators", "PROBLEM", 0, 19], ["Scenario CFR", "TEST", 89, 101], ["IFR", "TEST", 106, 109], ["increase", "OBSERVATION_MODIFIER", 124, 132], ["larger", "OBSERVATION_MODIFIER", 161, 167], ["amount", "OBSERVATION_MODIFIER", 168, 174], ["higher", "OBSERVATION_MODIFIER", 260, 266], ["burden", "OBSERVATION_MODIFIER", 267, 273], ["main", "OBSERVATION_MODIFIER", 320, 324]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 16, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["In addition, the proposed zonal enforcing NPI proved to be useful to boost the mitigation im-459 pact of combination of other individual NPIs.", [["other individual NPIs", "TREATMENT", 120, 141]]], ["Although this seems an appealing finding, practical 460 application of said zonal enforcing may require logistic, residential and economical adjustments, 461 since people usually reside and work in different districts of a city.", [["people", "ORGANISM", 164, 170], ["people", "SPECIES", 164, 170]]], ["Therefore the feasibility of 462 limiting mobility of people within districts will depend on the urban planning and development 463 of sufficient decentralised infrastructure, such as industrial, residential, technological, commercial 464 and financial hubs distributed in a way that motivate people to reside and work within the same 465 district.", [["people", "ORGANISM", 54, 60], ["people", "ORGANISM", 293, 299], ["people", "SPECIES", 54, 60], ["people", "SPECIES", 293, 299], ["the feasibility", "TEST", 10, 25]]], ["This may not be feasible to achieve for the current COVID-19 pandemic, particularly in 466 cities in Latin America where proper urban zonal planning is unsatisfactory, but it is an alluring 467 idea to start exploring as a preventive measure to counter new epidemics that may come in the 468 forthcoming future.469Finally, interesting gaps remain to be addressed in future work.", [["the current COVID", "TEST", 40, 57], ["pandemic", "PROBLEM", 61, 69], ["new epidemics", "PROBLEM", 253, 266]]], ["Some of the ideas we are con-470 sidering are: expanding the model to include more realistic attributes regarding patients and epi-471 demic dynamics, such as differentiated infectiousness taking into account symptomatic structures 472 associated with age and gender; also considering incubation periods, co-morbidity risk stratifica-473 tion with age windows, inclusion of conglomeration centres (that is, mass transportation, schools, 474 cinemas, hospitals), as well as the estimation of indicators of economic impacts and the study of 475 the importance of educational aspects in the habits of collective social intelligence that may be 476 beneficial for the mitigation power of NPIs.469Here we report plots of example executions of simulated scenarios with an outbreak infecting 5% 522 of the population.", [["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["co-morbidity risk stratifica", "PROBLEM", 305, 333], ["conglomeration centres", "PROBLEM", 374, 396], ["economic impacts", "PROBLEM", 505, 521], ["the study", "TEST", 526, 535], ["simulated scenarios", "PROBLEM", 738, 757]]], ["For each scenario in Table 1 , we include the individual NPIs outcome (left-hand 523 side) and the corresponding NPIs plus zonal enforcement outcome (right-hand side). .", [["left-hand", "ANATOMY", 71, 80], ["right-hand", "ANATOMY", 150, 160], ["NPIs", "CANCER", 57, 61], ["left", "ANATOMY_MODIFIER", 71, 75], ["right", "ANATOMY_MODIFIER", 150, 155]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)469The copyright holder for this preprint this version posted June 16, 2020. . https://doi.org/10.1101/2020.06.13.20130542 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 205, 225], ["medRxiv preprint", "TREATMENT", 330, 346], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)469The copyright holder for this preprint this version posted June 16, 2020. . https://doi.org/10.1101/2020.06.13.20130542 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 205, 225], ["medRxiv preprint", "TREATMENT", 330, 346], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)469The copyright holder for this preprint this version posted June 16, 2020. . https://doi.org/10.1101/2020.06.13.20130542 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 205, 225], ["medRxiv preprint", "TREATMENT", 330, 346], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)469The copyright holder for this preprint this version posted June 16, 2020. . https://doi.org/10.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 205, 225], ["med", "ANATOMY", 105, 108]]]], "05ab8bd6ff732bea31fa673b450d37b58da78c46": [["BackgroundThe key event in the pathogenesis of feline infectious peritonitis (FIP) is the switch in viral cell tropism, which originates from mutations of the feline coronavirus (FCoV) genome [1] .", [["cell", "ANATOMY", 106, 110], ["feline infectious peritonitis", "DISEASE", 47, 76], ["FIP", "DISEASE", 78, 81], ["feline", "ORGANISM", 47, 53], ["viral cell", "CELL", 100, 110], ["feline coronavirus", "ORGANISM", 159, 177], ["FCoV", "GENE_OR_GENE_PRODUCT", 179, 183], ["feline coronavirus (FCoV) genome", "DNA", 159, 191], ["feline", "SPECIES", 47, 53], ["feline coronavirus", "SPECIES", 159, 177], ["feline coronavirus", "SPECIES", 159, 177], ["FCoV", "SPECIES", 179, 183], ["feline infectious peritonitis", "PROBLEM", 47, 76], ["viral cell tropism", "PROBLEM", 100, 118], ["feline", "OBSERVATION_MODIFIER", 47, 53], ["infectious", "OBSERVATION_MODIFIER", 54, 64], ["peritonitis", "OBSERVATION", 65, 76], ["viral cell tropism", "OBSERVATION", 100, 118], ["feline coronavirus", "ANATOMY", 159, 177]]], ["According to the internal mutation hypothesis, feline infectious peritonitis virus (FIPV) emerges from feline enteric coronavirus (FECV) by spontaneous mutations within an infected cat [2, 3] .", [["infectious peritonitis", "DISEASE", 54, 76], ["feline enteric coronavirus", "DISEASE", 103, 129], ["feline infectious peritonitis virus", "ORGANISM", 47, 82], ["feline enteric coronavirus", "ORGANISM", 103, 129], ["FECV", "CANCER", 131, 135], ["cat", "ORGANISM", 181, 184], ["feline infectious peritonitis virus", "SPECIES", 47, 82], ["feline enteric coronavirus", "SPECIES", 103, 129], ["feline infectious peritonitis virus", "SPECIES", 47, 82], ["FIPV", "SPECIES", 84, 88], ["feline enteric coronavirus", "SPECIES", 103, 129], ["FECV", "SPECIES", 131, 135], ["the internal mutation hypothesis", "PROBLEM", 13, 45], ["feline infectious peritonitis virus", "PROBLEM", 47, 82], ["spontaneous mutations", "PROBLEM", 140, 161], ["infectious", "OBSERVATION_MODIFIER", 54, 64], ["peritonitis", "OBSERVATION", 65, 76], ["enteric coronavirus", "ANATOMY", 110, 129]]], ["While FECV causes asymptomatic infection or mild enteritis and is widespread among the cat population [4] [5] [6] and especially common in multi-cat environments [7] [8] [9] , FIPV causes FIP, a lethal immune-mediated disease [10, 11] .", [["FECV", "CHEMICAL", 6, 10], ["infection", "DISEASE", 31, 40], ["enteritis", "DISEASE", 49, 58], ["[4] [5] [6]", "CHEMICAL", 102, 113], ["[7] [8] [9", "CHEMICAL", 162, 172], ["FIPV", "CHEMICAL", 176, 180], ["FIP", "DISEASE", 188, 191], ["[7] [8] [9]", "SIMPLE_CHEMICAL", 162, 173], ["FIPV", "SIMPLE_CHEMICAL", 176, 180], ["asymptomatic infection", "PROBLEM", 18, 40], ["mild enteritis", "PROBLEM", 44, 58], ["FIPV", "PROBLEM", 176, 180], ["FIP", "PROBLEM", 188, 191], ["a lethal immune-mediated disease", "PROBLEM", 193, 225], ["asymptomatic", "OBSERVATION_MODIFIER", 18, 30], ["infection", "OBSERVATION", 31, 40], ["mild", "OBSERVATION_MODIFIER", 44, 48], ["enteritis", "OBSERVATION", 49, 58], ["widespread", "OBSERVATION_MODIFIER", 66, 76]]], ["FECV has a tropism for the small intestine apical villi epithelium [4, 12] , while FIPV can infect monocytes/macrophages and replicate sufficiently within these cells to allow systemic spread and macrophage activation [13] .BackgroundMutations in the FCoV spike gene and resulting amino acid substitutions in the spike protein are considered responsible for the acquisition of macrophage tropism due to the spike protein's role in receptor binding and cell entry [14] [15] [16] .", [["small intestine apical villi epithelium", "ANATOMY", 27, 66], ["monocytes", "ANATOMY", 99, 108], ["macrophages", "ANATOMY", 109, 120], ["cells", "ANATOMY", 161, 166], ["macrophage", "ANATOMY", 196, 206], ["macrophage", "ANATOMY", 377, 387], ["cell", "ANATOMY", 452, 456], ["FECV", "CHEMICAL", 0, 4], ["amino acid", "CHEMICAL", 281, 291], ["amino acid", "CHEMICAL", 281, 291], ["intestine", "ORGAN", 33, 42], ["apical villi epithelium", "TISSUE", 43, 66], ["FIPV", "GENE_OR_GENE_PRODUCT", 83, 87], ["monocytes", "CELL", 99, 108], ["macrophages", "CELL", 109, 120], ["cells", "CELL", 161, 166], ["macrophage", "CELL", 196, 206], ["FCoV", "GENE_OR_GENE_PRODUCT", 251, 255], ["amino acid", "AMINO_ACID", 281, 291], ["macrophage", "CELL", 377, 387], ["cell", "CELL", 452, 456], ["[14] [15] [16]", "SIMPLE_CHEMICAL", 463, 477], ["monocytes", "CELL_TYPE", 99, 108], ["macrophages", "CELL_TYPE", 109, 120], ["FCoV spike gene", "DNA", 251, 266], ["spike protein", "PROTEIN", 313, 326], ["spike protein", "PROTEIN", 407, 420], ["FECV", "SPECIES", 0, 4], ["FIPV", "SPECIES", 83, 87], ["the small intestine apical villi epithelium", "PROBLEM", 23, 66], ["FIPV", "PROBLEM", 83, 87], ["macrophages", "PROBLEM", 109, 120], ["systemic spread", "PROBLEM", 176, 191], ["BackgroundMutations", "PROBLEM", 224, 243], ["the FCoV spike gene", "PROBLEM", 247, 266], ["resulting amino acid substitutions", "PROBLEM", 271, 305], ["the spike protein", "PROBLEM", 309, 326], ["macrophage tropism", "PROBLEM", 377, 395], ["the spike protein", "PROBLEM", 403, 420], ["cell entry", "TEST", 452, 462], ["tropism", "OBSERVATION", 11, 18], ["small", "OBSERVATION_MODIFIER", 27, 32], ["intestine", "ANATOMY", 33, 42], ["apical", "ANATOMY_MODIFIER", 43, 49], ["villi", "ANATOMY_MODIFIER", 50, 55], ["epithelium", "ANATOMY_MODIFIER", 56, 66], ["FCoV spike", "OBSERVATION", 251, 261], ["acid substitutions", "OBSERVATION", 287, 305]]], ["Although amino acid substitutions M1058L and S1060A within the spike protein correlated with the FIP phenotype in >95% of cases in one study [15] , a subsequent study found them to be rather associated with systemic spread of FCoV in cats with and without FIP [14] .", [["amino acid", "CHEMICAL", 9, 19], ["FIP", "DISEASE", 256, 259], ["amino acid", "CHEMICAL", 9, 19], ["amino acid", "AMINO_ACID", 9, 19], ["S1060A", "AMINO_ACID", 45, 51], ["FCoV", "CANCER", 226, 230], ["cats", "ORGANISM", 234, 238], ["spike protein", "PROTEIN", 63, 76], ["cats", "SPECIES", 234, 238], ["amino acid substitutions", "TEST", 9, 33], ["the spike protein", "TEST", 59, 76], ["the FIP phenotype", "TEST", 93, 110], ["one study", "TEST", 131, 140], ["a subsequent study", "TEST", 148, 166], ["systemic spread of FCoV in cats", "PROBLEM", 207, 238], ["FIP", "PROBLEM", 256, 259], ["FCoV", "OBSERVATION", 226, 230]]], ["Focusing on a furin cleavage site in the region between receptor-binding and fusion domains of the spike gene, a recent study detected functionally relevant mutations strongly correlated with FIP and documented the emergence of one of these substitutions in a cat during the development of FIP [16] .BackgroundDefinitive ante-mortem diagnosis currently still requires invasive tissue sample collection for immunohistochemical demonstration of FCoV antigen in macrophages in tissue lesions [17] [18] [19] [20] .", [["tissue sample", "ANATOMY", 377, 390], ["macrophages", "ANATOMY", 459, 470], ["tissue lesions", "ANATOMY", 474, 488], ["FIP", "DISEASE", 192, 195], ["FIP", "DISEASE", 290, 293], ["furin", "GENE_OR_GENE_PRODUCT", 14, 19], ["cat", "ORGANISM", 260, 263], ["tissue", "TISSUE", 377, 383], ["FCoV antigen", "GENE_OR_GENE_PRODUCT", 443, 455], ["macrophages", "CELL", 459, 470], ["tissue", "TISSUE", 474, 480], ["furin cleavage site", "DNA", 14, 33], ["receptor-binding and fusion domains", "PROTEIN", 56, 91], ["spike gene", "DNA", 99, 109], ["FCoV antigen", "PROTEIN", 443, 455], ["macrophages", "CELL_TYPE", 459, 470], ["a furin cleavage site", "TREATMENT", 12, 33], ["receptor-binding and fusion domains", "TREATMENT", 56, 91], ["a recent study", "TEST", 111, 125], ["these substitutions", "PROBLEM", 235, 254], ["invasive tissue sample collection", "PROBLEM", 368, 401], ["immunohistochemical demonstration", "TEST", 406, 439], ["FCoV antigen", "TEST", 443, 455], ["macrophages in tissue lesions", "PROBLEM", 459, 488], ["FIP", "OBSERVATION", 290, 293], ["FCoV", "OBSERVATION", 443, 447]]], ["Reverse transcriptase polymerase chain reaction (RT-PCR) is frequently applied to detect FCoV RNA in diagnostic samples, and recent studies reported relatively satisfying results for real-time RT-PCR results using different materials [21] [22] [23] .", [["samples", "ANATOMY", 112, 119], ["FCoV", "GENE_OR_GENE_PRODUCT", 89, 93], ["FCoV RNA", "RNA", 89, 97], ["FCoV", "SPECIES", 89, 93], ["Reverse transcriptase polymerase chain reaction", "PROBLEM", 0, 47], ["RT-PCR", "TREATMENT", 49, 55], ["diagnostic samples", "TEST", 101, 119], ["recent studies", "TEST", 125, 139], ["RT-PCR", "TEST", 193, 199]]], ["Nevertheless, standard RT-PCR cannot distinguish FECV from FIPV and has been shown to detect FCoV RNA also in the blood of healthy cats that never developed FIP [24, 25] .BackgroundTherefore, it was the aim of this study to evaluate sensitivity and specificity of a real-time RT-PCR (FIP Virus RealPCR Test, IDEXX Laboratories) able to discriminate between FECV and FIPV in effusions and serum/plasma.", [["blood", "ANATOMY", 114, 119], ["effusions", "ANATOMY", 374, 383], ["serum", "ANATOMY", 388, 393], ["plasma", "ANATOMY", 394, 400], ["FIP", "DISEASE", 157, 160], ["effusions", "DISEASE", 374, 383], ["FECV", "CANCER", 49, 53], ["FIPV", "CANCER", 59, 63], ["FCoV", "GENE_OR_GENE_PRODUCT", 93, 97], ["blood", "ORGANISM_SUBSTANCE", 114, 119], ["cats", "ORGANISM", 131, 135], ["FECV", "CANCER", 357, 361], ["effusions", "CANCER", 374, 383], ["serum", "ORGANISM_SUBSTANCE", 388, 393], ["plasma", "ORGANISM_SUBSTANCE", 394, 400], ["FCoV RNA", "RNA", 93, 101], ["cats", "SPECIES", 131, 135], ["FECV", "SPECIES", 49, 53], ["FIPV", "SPECIES", 59, 63], ["FCoV", "SPECIES", 93, 97], ["FECV", "SPECIES", 357, 361], ["FIPV", "SPECIES", 366, 370], ["standard RT-PCR", "TEST", 14, 29], ["FIPV", "PROBLEM", 59, 63], ["FCoV RNA", "PROBLEM", 93, 101], ["this study", "TEST", 210, 220], ["sensitivity", "TEST", 233, 244], ["a real-time RT-PCR", "TEST", 264, 282], ["FIP Virus RealPCR Test", "TEST", 284, 306], ["FECV", "TEST", 357, 361], ["FIPV in effusions", "PROBLEM", 366, 383], ["serum/plasma", "TEST", 388, 400], ["FIPV", "OBSERVATION", 59, 63], ["FCoV", "OBSERVATION", 93, 97], ["FIPV", "OBSERVATION", 366, 370], ["effusions", "OBSERVATION", 374, 383]]], ["It was hypothesized that this discriminative PCR would correctly identify FIPV and thus, would be a noninvasive and reliable method to definitively diagnose FIP.AnimalsOverall, 63 cats with signs consistent with FIP were included in the study.", [["FIP", "DISEASE", 157, 160], ["FIP", "DISEASE", 212, 215], ["cats", "ORGANISM", 180, 184], ["cats", "SPECIES", 180, 184], ["FIPV", "SPECIES", 74, 78], ["this discriminative PCR", "TEST", 25, 48], ["FIPV", "PROBLEM", 74, 78], ["FIP", "PROBLEM", 212, 215], ["the study", "TEST", 233, 242], ["FIP", "OBSERVATION", 212, 215]]], ["All cats were presented either as sick feline patients (n = 48) or directly submitted for necropsy (n = 15).AnimalsFor 38 cats (FIP group, Table 1 ), a definitive diagnosis of FIP was established post-mortem either by histopathology (n = 10) (Fig. 1a-c) , or by histopathology and immunohistochemical (IHC) staining of FCoV antigen in tissue samples (Fig. 1d ) obtained at necropsy (n = 28).", [["tissue samples", "ANATOMY", 335, 349], ["FIP", "DISEASE", 176, 179], ["cats", "ORGANISM", 4, 8], ["feline", "ORGANISM", 39, 45], ["patients", "ORGANISM", 46, 54], ["cats", "ORGANISM", 122, 126], ["FIP", "ORGANISM", 176, 179], ["FCoV antigen", "GENE_OR_GENE_PRODUCT", 319, 331], ["tissue samples", "TISSUE", 335, 349], ["FCoV antigen", "PROTEIN", 319, 331], ["cats", "SPECIES", 4, 8], ["patients", "SPECIES", 46, 54], ["cats", "SPECIES", 122, 126], ["FIP", "PROBLEM", 176, 179], ["FCoV antigen", "TEST", 319, 331], ["tissue samples", "TEST", 335, 349], ["FIP", "OBSERVATION", 176, 179]]], ["In the cats with histopathological confirmation, a diagnosis of FIP was based on the occurrence of effusions (Fig. 1a) and/or yellow to white foci or nodules in different organs (Fig. 1b) plus presence of typical histological lesions, including plasma-cellular perivasculitis and/or accumulation of plasma cells accompanied by a necropurulent inflammation (Fig. 1c) .AnimalsCats in the control group (n = 25) were suspected of having FIP (Table 2 ) based on the existence of one or more of the following signs consistent with FIP: effusion (n = 24), fever with \u226420,000 white blood cells/\u03bcL and \u22641000 band neutrophils/\u03bcL (n = 1), icterus (n = 2), or neurological signs (n = 1).", [["effusions", "ANATOMY", 99, 108], ["white foci", "ANATOMY", 136, 146], ["nodules", "ANATOMY", 150, 157], ["organs", "ANATOMY", 171, 177], ["lesions", "ANATOMY", 226, 233], ["plasma", "ANATOMY", 245, 251], ["cellular", "ANATOMY", 252, 260], ["plasma cells", "ANATOMY", 299, 311], ["white blood cells", "ANATOMY", 569, 586], ["\u03bcL", "ANATOMY", 587, 589], ["neutrophils", "ANATOMY", 605, 616], ["\u03bcL", "ANATOMY", 617, 619], ["neurological", "ANATOMY", 649, 661], ["FIP", "DISEASE", 64, 67], ["effusions", "DISEASE", 99, 108], ["inflammation", "DISEASE", 343, 355], ["FIP", "DISEASE", 434, 437], ["FIP", "DISEASE", 526, 529], ["effusion", "DISEASE", 531, 539], ["fever", "DISEASE", 550, 555], ["icterus", "DISEASE", 629, 636], ["neurological signs", "DISEASE", 649, 667], ["cats", "ORGANISM", 7, 11], ["nodules", "CANCER", 150, 157], ["organs", "ORGAN", 171, 177], ["histological lesions", "CANCER", 213, 233], ["plasma", "ORGANISM_SUBSTANCE", 245, 251], ["cellular", "CELL", 252, 260], ["plasma cells", "CELL", 299, 311], ["blood cells", "CELL", 575, 586], ["\u03bcL", "CELL", 587, 589], ["plasma cells", "CELL_TYPE", 299, 311], ["histopathological confirmation", "TEST", 17, 47], ["FIP", "PROBLEM", 64, 67], ["effusions", "PROBLEM", 99, 108], ["yellow to white foci", "PROBLEM", 126, 146], ["nodules in different organs", "PROBLEM", 150, 177], ["typical histological lesions", "PROBLEM", 205, 233], ["plasma-cellular perivasculitis", "PROBLEM", 245, 275], ["accumulation of plasma cells", "PROBLEM", 283, 311], ["a necropurulent inflammation", "PROBLEM", 327, 355], ["effusion", "PROBLEM", 531, 539], ["fever", "PROBLEM", 550, 555], ["white blood cells", "TEST", 569, 586], ["\u03bcL", "TEST", 587, 589], ["\u2264", "TEST", 594, 595], ["band neutrophils", "TEST", 600, 616], ["\u03bcL", "TEST", 617, 619], ["icterus", "TEST", 629, 636], ["neurological signs", "TEST", 649, 667], ["FIP", "OBSERVATION", 64, 67], ["effusions", "OBSERVATION", 99, 108], ["white", "OBSERVATION_MODIFIER", 136, 141], ["foci", "OBSERVATION", 142, 146], ["nodules", "OBSERVATION", 150, 157], ["different", "ANATOMY_MODIFIER", 161, 170], ["organs", "ANATOMY", 171, 177], ["typical", "OBSERVATION_MODIFIER", 205, 212], ["histological", "OBSERVATION_MODIFIER", 213, 225], ["lesions", "OBSERVATION", 226, 233], ["cellular perivasculitis", "OBSERVATION", 252, 275], ["plasma cells", "OBSERVATION", 299, 311], ["necropurulent", "OBSERVATION_MODIFIER", 329, 342], ["inflammation", "OBSERVATION", 343, 355], ["consistent with", "UNCERTAINTY", 510, 525], ["FIP", "OBSERVATION", 526, 529], ["effusion", "OBSERVATION", 531, 539], ["icterus", "OBSERVATION", 629, 636]]], ["Some of the included cats showed several of these signs.", [["cats", "ORGANISM", 21, 25], ["cats", "SPECIES", 21, 25], ["these signs", "TEST", 44, 55]]], ["For all cats in the control group, a disease other than FIP was definitively diagnosed either at full post-mortem examination plus histopathology (n = 10), by histopathology of organ samples obtained post-mortem (n = 1), by bacterial culture and cytology diagnosing bacterial pleuritis (n = 2), by echocardiography diagnosing decompensated cardiac disease explaining pleural or abdominal effusion (n = 7), or by cytology diagnosing neoplasia (n = 5).SamplesIn total, 59 effusion samples and 17 serum/plasma samples were collected between 2009 and 2014.", [["organ samples", "ANATOMY", 177, 190], ["cardiac", "ANATOMY", 340, 347], ["pleural", "ANATOMY", 367, 374], ["abdominal effusion", "ANATOMY", 378, 396], ["neoplasia", "ANATOMY", 432, 441], ["effusion samples", "ANATOMY", 470, 486], ["serum", "ANATOMY", 494, 499], ["plasma samples", "ANATOMY", 500, 514], ["FIP", "DISEASE", 56, 59], ["bacterial pleuritis", "DISEASE", 266, 285], ["decompensated cardiac disease", "DISEASE", 326, 355], ["pleural or abdominal effusion", "DISEASE", 367, 396], ["neoplasia", "DISEASE", 432, 441], ["cats", "ORGANISM", 8, 12], ["organ samples", "TISSUE", 177, 190], ["cardiac", "ORGAN", 340, 347], ["pleural", "MULTI-TISSUE_STRUCTURE", 367, 374], ["abdominal", "ORGANISM_SUBDIVISION", 378, 387], ["neoplasia", "CANCER", 432, 441], ["effusion samples", "CANCER", 470, 486], ["serum", "ORGANISM_SUBSTANCE", 494, 499], ["plasma samples", "ORGANISM_SUBSTANCE", 500, 514], ["a disease other than FIP", "PROBLEM", 35, 59], ["full post-mortem examination", "TEST", 97, 125], ["histopathology", "TEST", 131, 145], ["organ samples", "TEST", 177, 190], ["bacterial culture", "TEST", 224, 241], ["cytology", "TEST", 246, 254], ["bacterial pleuritis", "PROBLEM", 266, 285], ["echocardiography", "TEST", 298, 314], ["decompensated cardiac disease", "PROBLEM", 326, 355], ["pleural or abdominal effusion", "PROBLEM", 367, 396], ["cytology diagnosing neoplasia", "PROBLEM", 412, 441], ["effusion samples", "TEST", 470, 486], ["serum/plasma samples", "TEST", 494, 514], ["organ", "ANATOMY", 177, 182], ["bacterial", "OBSERVATION_MODIFIER", 266, 275], ["pleuritis", "OBSERVATION", 276, 285], ["decompensated", "OBSERVATION_MODIFIER", 326, 339], ["cardiac", "ANATOMY", 340, 347], ["disease", "OBSERVATION", 348, 355], ["pleural", "ANATOMY", 367, 374], ["abdominal", "ANATOMY", 378, 387], ["effusion", "OBSERVATION", 388, 396], ["neoplasia", "OBSERVATION", 432, 441], ["effusion", "OBSERVATION", 470, 478]]], ["Effusion fluids (34 ascites, 25 pleural effusions) of 43 cats (25 with FIP, 18 controls) were stored at \u221280\u00b0C and effusion fluids of 16 cats (ten with FIP, six controls) were stored at \u221220\u00b0C. Of twelve of the cats (nine with FIP, three controls) for which blood was available, plasma was obtained and stored at \u221280\u00b0C in 2 mL low temperature freezer vials (VWR International GmbH) until assayed.", [["Effusion fluids", "ANATOMY", 0, 15], ["ascites", "ANATOMY", 20, 27], ["pleural effusions", "ANATOMY", 32, 49], ["effusion fluids", "ANATOMY", 114, 129], ["blood", "ANATOMY", 256, 261], ["plasma", "ANATOMY", 277, 283], ["ascites", "DISEASE", 20, 27], ["pleural effusions", "DISEASE", 32, 49], ["FIP", "DISEASE", 71, 74], ["FIP", "DISEASE", 151, 154], ["FIP", "DISEASE", 225, 228], ["ascites", "CANCER", 20, 27], ["pleural effusions", "CANCER", 32, 49], ["cats", "ORGANISM", 57, 61], ["C", "GENE_OR_GENE_PRODUCT", 108, 109], ["cats", "ORGANISM", 136, 140], ["cats", "ORGANISM", 209, 213], ["blood", "ORGANISM_SUBSTANCE", 256, 261], ["plasma", "ORGANISM_SUBSTANCE", 277, 283], ["cats", "SPECIES", 57, 61], ["cats", "SPECIES", 136, 140], ["cats", "SPECIES", 209, 213], ["Effusion fluids (34 ascites", "PROBLEM", 0, 27], ["25 pleural effusions", "PROBLEM", 29, 49], ["FIP", "TEST", 71, 74], ["effusion fluids of 16 cats", "TREATMENT", 114, 140], ["FIP", "TREATMENT", 151, 154], ["the cats", "TEST", 205, 213], ["fluids", "OBSERVATION", 9, 15], ["ascites", "OBSERVATION", 20, 27], ["pleural", "ANATOMY", 32, 39], ["effusions", "OBSERVATION", 40, 49], ["effusion", "OBSERVATION", 114, 122]]], ["Of the remaining five cats (all of them had FIP) for which blood was available, serum was obtained and stored at \u221220\u00b0C in 1.5 mL Eppendorf Safe-Lock microcentrifuge tubes (Eppendorf GmbH) until assayed.SamplesAll samples collected ante-mortem were originally obtained for diagnostic and, in the case of effusion, also for therapeutic purposes.Real-time RT-PCRReal-time RT-PCR was performed blinded with regard to the final diagnosis.Real-time RT-PCRTotal nucleic acid was extracted from effusion and serum/plasma samples by QIAamp DNA Blood BioRobot MDx Kit on an automated Qiagen platform (QIAGEN GmbH, Hilden, Germany) according to the manufacturer instructions with slight modifications.", [["blood", "ANATOMY", 59, 64], ["serum", "ANATOMY", 80, 85], ["Samples", "ANATOMY", 202, 209], ["samples", "ANATOMY", 213, 220], ["effusion", "ANATOMY", 487, 495], ["serum", "ANATOMY", 500, 505], ["plasma samples", "ANATOMY", 506, 520], ["Blood", "ANATOMY", 535, 540], ["FIP", "DISEASE", 44, 47], ["effusion", "DISEASE", 303, 311], ["nucleic acid", "CHEMICAL", 455, 467], ["cats", "ORGANISM", 22, 26], ["blood", "ORGANISM_SUBSTANCE", 59, 64], ["serum", "ORGANISM_SUBSTANCE", 80, 85], ["serum", "ORGANISM_SUBSTANCE", 500, 505], ["plasma samples", "ORGANISM_SUBSTANCE", 506, 520], ["Blood", "ORGANISM_SUBSTANCE", 535, 540], ["cats", "SPECIES", 22, 26], ["FIP", "PROBLEM", 44, 47], ["serum", "TEST", 80, 85], ["1.5 mL Eppendorf Safe-Lock microcentrifuge tubes", "TREATMENT", 122, 170], ["Samples", "TEST", 202, 209], ["All samples", "TEST", 209, 220], ["effusion", "PROBLEM", 303, 311], ["therapeutic purposes", "TEST", 322, 342], ["RT-PCR", "TEST", 369, 375], ["time RT-PCRTotal nucleic acid", "TEST", 438, 467], ["effusion", "PROBLEM", 487, 495], ["serum/plasma samples", "TEST", 500, 520], ["QIAamp DNA", "TEST", 524, 534], ["slight modifications", "TREATMENT", 669, 689], ["effusion", "OBSERVATION", 303, 311], ["effusion", "OBSERVATION", 487, 495], ["slight modifications", "OBSERVATION", 669, 689]]], ["In order to first detect FCoV and second to pathotype the FCoV strain, three real-time PCR assays were performed in parallel as singleplex reactions at a commercial reference laboratory (IDEXX Laboratories, Ludwigsburg, Germany): the first real-time PCR was based on the 7b gene [26] to quantify viral load, the other two real-time PCRs were targeting the M1058L and S1060A single nucleotide polymorphisms described before to correlate with the occurrence of the lethal FIPV genotype [15] .", [["FCoV", "GENE_OR_GENE_PRODUCT", 25, 29], ["M1058L", "GENE_OR_GENE_PRODUCT", 356, 362], ["FCoV", "PROTEIN", 25, 29], ["M1058L and S1060A single nucleotide polymorphisms", "DNA", 356, 405], ["FCoV", "PROBLEM", 25, 29], ["pathotype the FCoV strain", "PROBLEM", 44, 69], ["three real-time PCR assays", "TEST", 71, 97], ["PCR", "TEST", 250, 253], ["viral load", "TEST", 296, 306], ["single nucleotide polymorphisms", "PROBLEM", 374, 405], ["the lethal FIPV genotype", "PROBLEM", 459, 483], ["FCoV", "OBSERVATION", 58, 62]]], ["These two PCR tests allow typing of an FCoV strain based on the presence (FIPV) or absence (FECV) of one of two single nucleotide polymorphisms within the fusion peptide of the spike gene.", [["spike gene", "DNA", 177, 187], ["These two PCR tests", "TEST", 0, 19], ["an FCoV strain", "PROBLEM", 36, 50], ["two single nucleotide polymorphisms", "PROBLEM", 108, 143], ["the fusion peptide", "TREATMENT", 151, 169], ["FCoV", "OBSERVATION", 39, 43]]], ["Briefly, highly specific hydrolysis probes were designed to either detect the mutation at position 3174 or 3180 (corresponding to amino acid positions 1058 and 1060, M1058L and S1060A of reference sequence FJ938051 [15] , respectively) or wildtype sequences by using an allelic discrimination approach using real-time PCR.", [["amino acid", "CHEMICAL", 130, 140], ["amino acid", "CHEMICAL", 130, 140], ["amino acid", "AMINO_ACID", 130, 140], ["wildtype sequences", "DNA", 239, 257], ["highly specific hydrolysis probes", "PROBLEM", 9, 42], ["amino acid positions", "TEST", 130, 150], ["wildtype sequences", "TEST", 239, 257], ["an allelic discrimination approach", "TREATMENT", 267, 301]]], ["Fluorescence intensities were used to calculate ratios of the probes detecting the mutation or the wildtype sequences.", [["wildtype sequences", "DNA", 99, 117], ["Fluorescence intensities", "TEST", 0, 24], ["the probes", "TEST", 58, 68], ["the mutation", "PROBLEM", 79, 91], ["the wildtype sequences", "TEST", 95, 117]]], ["FIPV was assigned if the mutation probe exceeded a 2-fold higher fluorescence than the wildtype probe.", [["FIPV", "SIMPLE_CHEMICAL", 0, 4], ["FIPV", "DNA", 0, 4], ["wildtype probe", "DNA", 87, 101], ["FIPV", "SPECIES", 0, 4], ["FIPV", "TREATMENT", 0, 4], ["the mutation probe", "TEST", 21, 39], ["the wildtype probe", "TREATMENT", 83, 101]]], ["Real-time PCR was run with six quality controls ( Table 3) .Interpretation of real-time RT-PCR resultsAccording to the outcome of the typing assay, there were six possible results of the real-time RT-PCR.Statistical evaluationSensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and overall accuracyResultsThe FIPV pathotype was detected in 25/59 effusion samples.", [["effusion samples", "ANATOMY", 386, 402], ["effusion", "DISEASE", 386, 394], ["FIPV", "GENE_OR_GENE_PRODUCT", 349, 353], ["effusion samples", "CANCER", 386, 402], ["FIPV pathotype", "DNA", 349, 363], ["FIPV", "SPECIES", 349, 353], ["Real-time PCR", "TEST", 0, 13], ["the typing assay", "TEST", 130, 146], ["Statistical evaluationSensitivity", "TEST", 204, 237], ["PPV", "TEST", 279, 282], ["NPV", "TEST", 312, 315], ["The FIPV pathotype", "TEST", 345, 363], ["effusion samples", "PROBLEM", 386, 402], ["FIPV pathotype", "OBSERVATION", 349, 363], ["effusion", "OBSERVATION", 386, 394]]], ["Of these, 24 were from cats with FIP, but one effusion sample from a control cat was also positive for FIPV with mutation M1058L.", [["effusion sample", "ANATOMY", 46, 61], ["FIP", "DISEASE", 33, 36], ["effusion", "DISEASE", 46, 54], ["cats", "ORGANISM", 23, 27], ["cat", "ORGANISM", 77, 80], ["FIPV", "GENE_OR_GENE_PRODUCT", 103, 107], ["FIPV", "PROTEIN", 103, 107], ["FIP", "PROBLEM", 33, 36], ["one effusion sample", "PROBLEM", 42, 61], ["a control cat", "TEST", 67, 80], ["FIPV", "PROBLEM", 103, 107], ["effusion", "OBSERVATION", 46, 54]]], ["Mutation M1058L was found in 23/25 FIPV samples.", [["FIPV samples", "ANATOMY", 35, 47], ["FIPV samples", "CANCER", 35, 47], ["FIPV", "SPECIES", 35, 39], ["Mutation M1058L", "TEST", 0, 15]]], ["Mutation S1060A was found in none of the FIPV samples.", [["FIPV samples", "ANATOMY", 41, 53], ["S1060A", "GENE_OR_GENE_PRODUCT", 9, 15], ["Mutation S1060A", "PROBLEM", 0, 15]]], ["A mixed pathotype of FIPV and FECV was detected in 2/59 effusion samples (all from cats with FIP).", [["effusion samples", "ANATOMY", 56, 72], ["effusion", "DISEASE", 56, 64], ["FIP", "DISEASE", 93, 96], ["FIPV", "CANCER", 21, 25], ["FECV", "CANCER", 30, 34], ["effusion samples", "CANCER", 56, 72], ["cats", "ORGANISM", 83, 87], ["FIPV", "DNA", 21, 25], ["FIPV", "SPECIES", 21, 25], ["FECV", "SPECIES", 30, 34], ["A mixed pathotype of FIPV", "PROBLEM", 0, 25], ["FECV", "TEST", 30, 34], ["effusion samples", "PROBLEM", 56, 72], ["mixed", "OBSERVATION_MODIFIER", 2, 7], ["pathotype", "OBSERVATION_MODIFIER", 8, 17], ["FIPV", "OBSERVATION", 21, 25], ["effusion", "OBSERVATION", 56, 64]]], ["In 12/ 59 effusion samples, FCoV RNA was detected, but pathotyping was not possible (BLD or IND).", [["effusion samples", "ANATOMY", 10, 26], ["effusion samples", "CANCER", 10, 26], ["FCoV", "GENE_OR_GENE_PRODUCT", 28, 32], ["FCoV RNA", "RNA", 28, 36], ["FCoV", "SPECIES", 28, 32], ["effusion samples", "TEST", 10, 26], ["FCoV RNA", "PROBLEM", 28, 36], ["pathotyping", "PROBLEM", 55, 66], ["effusion", "OBSERVATION", 10, 18], ["FCoV RNA", "OBSERVATION", 28, 36]]], ["The remaining 22/59 effusion samples did not contain FCoV RNA (Tables 1, 2, 4, and 5).Real-time RT-PCR was negative in 15/17 serum/ plasma samples.", [["effusion samples", "ANATOMY", 20, 36], ["serum", "ANATOMY", 125, 130], ["plasma samples", "ANATOMY", 132, 146], ["effusion", "DISEASE", 20, 28], ["effusion samples", "CANCER", 20, 36], ["serum", "ORGANISM_SUBSTANCE", 125, 130], ["plasma samples", "ORGANISM_SUBSTANCE", 132, 146], ["FCoV RNA", "RNA", 53, 61], ["effusion samples", "TEST", 20, 36], ["FCoV RNA", "TEST", 53, 61], ["time RT-PCR", "TEST", 91, 102], ["serum/ plasma samples", "TEST", 125, 146], ["effusion", "OBSERVATION", 20, 28], ["FCoV RNA", "OBSERVATION", 53, 61]]], ["In the remaining two serum/plasma samples (all from cats with FIP), FCoV RNA could be detected, but only in low concentrations (BLD).", [["serum", "ANATOMY", 21, 26], ["plasma samples", "ANATOMY", 27, 41], ["serum", "ORGANISM_SUBSTANCE", 21, 26], ["plasma samples", "ORGANISM_SUBSTANCE", 27, 41], ["cats", "ORGANISM", 52, 56], ["FCoV", "GENE_OR_GENE_PRODUCT", 68, 72], ["FCoV RNA", "RNA", 68, 76], ["FCoV", "SPECIES", 68, 72], ["two serum/plasma samples", "TEST", 17, 41], ["FIP", "TEST", 62, 65], ["FCoV RNA", "PROBLEM", 68, 76], ["FCoV RNA", "OBSERVATION", 68, 76], ["low concentrations", "OBSERVATION_MODIFIER", 108, 126]]], ["None of the serum/plasma samples of control cats contained FCoV RNA (Tables 1, 2, 6, and 7) ., 4, and 5).Sensitivity, specificity, PPV, NPV, and overall accuracy are shown in Table 8 .DiscussionThis study evaluated the use of a new diagnostic test which is able to distinguish FIPV from FECV pathotypes in the diagnosis of FIP based on the presence of mutation M1058L or S1060A in the FCoV spike protein.DiscussionIn a lethal disease like FIP, specificity of a diagnostic test is more important than sensitivity, because it helps to prevent euthanasia of cats misdiagnosed with FIP.", [["serum", "ANATOMY", 12, 17], ["plasma samples", "ANATOMY", 18, 32], ["FIP", "DISEASE", 323, 326], ["FIP", "DISEASE", 439, 442], ["FIP", "DISEASE", 578, 581], ["serum", "ORGANISM_SUBSTANCE", 12, 17], ["plasma samples", "ORGANISM_SUBSTANCE", 18, 32], ["cats", "ORGANISM", 44, 48], ["FIPV", "GENE_OR_GENE_PRODUCT", 277, 281], ["FECV", "CANCER", 287, 291], ["S1060A", "AMINO_ACID", 371, 377], ["FCoV spike protein", "GENE_OR_GENE_PRODUCT", 385, 403], ["cats", "ORGANISM", 555, 559], ["FCoV RNA", "RNA", 59, 67], ["FCoV spike protein", "PROTEIN", 385, 403], ["FIPV", "SPECIES", 277, 281], ["FECV", "SPECIES", 287, 291], ["the serum/plasma samples", "TEST", 8, 32], ["FCoV RNA", "TEST", 59, 67], ["Sensitivity", "TEST", 105, 116], ["PPV", "TEST", 131, 134], ["NPV", "TEST", 136, 139], ["This study", "TEST", 194, 204], ["a new diagnostic test", "TEST", 226, 247], ["FIPV", "PROBLEM", 277, 281], ["FECV pathotypes", "PROBLEM", 287, 302], ["FIP", "PROBLEM", 323, 326], ["mutation M1058L", "PROBLEM", 352, 367], ["the FCoV spike protein", "TEST", 381, 403], ["a lethal disease like FIP", "PROBLEM", 417, 442], ["a diagnostic test", "TEST", 459, 476], ["euthanasia of cats", "PROBLEM", 541, 559], ["FIP", "PROBLEM", 578, 581], ["FCoV RNA", "OBSERVATION", 59, 67], ["FIP", "OBSERVATION", 323, 326], ["FIP", "OBSERVATION", 578, 581]]], ["Specificity of the real-time RT-PCR in effusion was 95.8%.", [["effusion", "DISEASE", 39, 47], ["Specificity", "TEST", 0, 11], ["PCR", "TEST", 32, 35], ["effusion", "PROBLEM", 39, 47], ["effusion", "OBSERVATION", 39, 47]]], ["The FIPV pathotype (M1058L) was found in an effusion sample from one control cat that had chronic kidney disease.", [["effusion sample", "ANATOMY", 44, 59], ["kidney", "ANATOMY", 98, 104], ["chronic kidney disease", "DISEASE", 90, 112], ["FIPV", "GENE_OR_GENE_PRODUCT", 4, 8], ["M1058L", "CANCER", 20, 26], ["cat", "ORGANISM", 77, 80], ["kidney", "ORGAN", 98, 104], ["FIPV pathotype", "DNA", 4, 18], ["The FIPV pathotype", "TEST", 0, 18], ["an effusion sample", "PROBLEM", 41, 59], ["chronic kidney disease", "PROBLEM", 90, 112], ["FIPV pathotype", "OBSERVATION", 4, 18], ["effusion", "OBSERVATION", 44, 52], ["chronic", "OBSERVATION_MODIFIER", 90, 97], ["kidney", "ANATOMY", 98, 104], ["disease", "OBSERVATION", 105, 112]]], ["There are several reasons that could explain this positive result.", [["this positive result", "PROBLEM", 45, 65]]], ["First, FCoV spike protein mutations M1058L and S1060A have previously been discussed as being a marker for the systemic spread of the virus rather than for the FIP phenotype, since they could also be found in tissue samples of healthy cats infected with FCoV [14] .", [["tissue samples", "ANATOMY", 209, 223], ["FCoV", "GENE_OR_GENE_PRODUCT", 7, 11], ["S1060A", "AMINO_ACID", 47, 53], ["tissue samples", "TISSUE", 209, 223], ["cats", "ORGANISM", 235, 239], ["FCoV spike protein", "PROTEIN", 7, 25], ["cats", "SPECIES", 235, 239], ["FCoV", "SPECIES", 254, 258], ["FCoV spike protein mutations", "TEST", 7, 35], ["the virus", "PROBLEM", 130, 139], ["the FIP phenotype", "PROBLEM", 156, 173]]], ["If this was correct, then it would be possible that the cat was infected with a \"benign\" FCoV that spread systemically and therefore exhibited mutation M1058L.", [["cat", "ORGANISM", 56, 59], ["FCoV", "CANCER", 89, 93], ["a \"benign\" FCoV", "PROBLEM", 78, 93], ["mutation M1058L", "PROBLEM", 143, 158], ["FCoV", "OBSERVATION", 89, 93]]], ["Second, full post-mortem examination including histopathology was performed in the cat and did not reveal any typical changes indicative of FIP.", [["FIP", "DISEASE", 140, 143], ["cat", "ORGANISM", 83, 86], ["full post-mortem examination", "TEST", 8, 36], ["histopathology", "TEST", 47, 61], ["FIP", "PROBLEM", 140, 143], ["FIP", "OBSERVATION", 140, 143]]], ["Nevertheless, it cannot be excluded that the cat suffered from early-stage FIP in addition to chronic kidney disease, but histopathological changes of FIP were still absent.", [["kidney", "ANATOMY", 102, 108], ["FIP", "DISEASE", 75, 78], ["chronic kidney disease", "DISEASE", 94, 116], ["FIP", "DISEASE", 151, 154], ["cat", "ORGANISM", 45, 48], ["kidney", "ORGAN", 102, 108], ["early-stage FIP", "PROBLEM", 63, 78], ["chronic kidney disease", "PROBLEM", 94, 116], ["histopathological changes of FIP", "PROBLEM", 122, 154], ["cannot be excluded", "UNCERTAINTY", 17, 35], ["early", "OBSERVATION_MODIFIER", 63, 68], ["-stage", "OBSERVATION_MODIFIER", 68, 74], ["FIP", "OBSERVATION", 75, 78], ["chronic", "OBSERVATION_MODIFIER", 94, 101], ["kidney", "ANATOMY", 102, 108], ["disease", "OBSERVATION", 109, 116], ["FIP", "OBSERVATION", 151, 154]]], ["Finally, it is possible that the result was a true false positive due to a methodological error.DiscussionThe effusion samples of two control cats contained FCoV RNA but the pathotype could not be determined due to a low virus load (BLD).", [["effusion samples", "ANATOMY", 110, 126], ["effusion samples", "CANCER", 110, 126], ["cats", "ORGANISM", 142, 146], ["FCoV", "GENE_OR_GENE_PRODUCT", 157, 161], ["FCoV RNA", "RNA", 157, 165], ["cats", "SPECIES", 142, 146], ["FCoV", "SPECIES", 157, 161], ["a true false positive", "PROBLEM", 44, 65], ["a methodological error", "PROBLEM", 73, 95], ["The effusion samples", "TEST", 106, 126], ["FCoV RNA", "PROBLEM", 157, 165], ["the pathotype", "PROBLEM", 170, 183], ["a low virus load", "PROBLEM", 215, 231], ["effusion", "OBSERVATION", 110, 118], ["FCoV RNA", "OBSERVATION", 157, 165]]], ["If a PCR had been used Defined as negative for statistical analysis that was not able to differentiate pathotypes, these cats would have falsely been diagnosed as having FIP.", [["FIP", "DISEASE", 170, 173], ["cats", "ORGANISM", 121, 125], ["a PCR", "TEST", 3, 8], ["statistical analysis", "TEST", 47, 67], ["pathotypes", "PROBLEM", 103, 113], ["FIP", "PROBLEM", 170, 173], ["FIP", "OBSERVATION", 170, 173]]], ["This fact emphasizes that the detection of any FCoV in effusion is not accurate enough to establish the diagnosis FIP.", [["effusion", "DISEASE", 55, 63], ["FIP", "DISEASE", 114, 117], ["FCoV", "GENE_OR_GENE_PRODUCT", 47, 51], ["any FCoV in effusion", "PROBLEM", 43, 63], ["FCoV", "OBSERVATION", 47, 51], ["effusion", "OBSERVATION", 55, 63]]], ["It has been shown previously that FECV can circulate systemically in blood monocytes during initial infection [12] .", [["blood monocytes", "ANATOMY", 69, 84], ["infection", "DISEASE", 100, 109], ["FECV", "GENE_OR_GENE_PRODUCT", 34, 38], ["blood monocytes", "ORGANISM_SUBSTANCE", 69, 84], ["FECV", "PROTEIN", 34, 38], ["blood monocytes", "CELL_TYPE", 69, 84], ["FECV", "SPECIES", 34, 38], ["blood monocytes", "TEST", 69, 84], ["initial infection", "PROBLEM", 92, 109], ["infection", "OBSERVATION", 100, 109]]], ["A moderate sensitivity of 68.6% was found in effusion in the present study.", [["effusion", "DISEASE", 45, 53], ["A moderate sensitivity", "TEST", 0, 22], ["effusion", "PROBLEM", 45, 53], ["the present study", "TEST", 57, 74], ["moderate", "OBSERVATION_MODIFIER", 2, 10], ["effusion", "OBSERVATION", 45, 53]]], ["This is comparable to or even lower than sensitivities reported in recent studies (65-89%) for different RT-PCR assays of effusions [22, 23, 27] .", [["effusions", "DISEASE", 122, 131], ["recent studies", "TEST", 67, 81], ["different RT-PCR assays", "TEST", 95, 118], ["effusions", "PROBLEM", 122, 131], ["effusions", "OBSERVATION", 122, 131]]], ["Most of these earlier studies determined the sensitivity of a RT-PCR that did not distinguish the two FCoV pathotypes [22, 23] .", [["these earlier studies", "TEST", 8, 29], ["a RT-PCR", "TEST", 60, 68], ["the two FCoV pathotypes", "PROBLEM", 94, 117]]], ["In contrast, the present study was designed to allow pathotyping of FCoV.", [["FCoV", "GENE_OR_GENE_PRODUCT", 68, 72], ["FCoV", "PROTEIN", 68, 72], ["the present study", "TEST", 13, 30], ["FCoV", "OBSERVATION", 68, 72]]], ["In order to prevent false positive real-time RT-PCR results arising from the detection of rare random spike gene mutations, the degree of fluorescence for the reported pathotype needed to exceed twice that of the other pathotype.", [["the detection", "TEST", 73, 86], ["rare random spike gene mutations", "PROBLEM", 90, 122], ["the reported pathotype", "PROBLEM", 155, 177]]], ["Therefore, even FCoVpositive samples were regarded as negative for the calculation of sensitivity if they did not allow definitive determination of either FIPV or FECV.", [["FCoVpositive samples", "ANATOMY", 16, 36], ["FCoVpositive samples", "CANCER", 16, 36], ["FIPV", "SPECIES", 155, 159], ["FECV", "SPECIES", 163, 167], ["FCoVpositive samples", "TEST", 16, 36], ["FIPV", "PROBLEM", 155, 159]]], ["Three of the effusion samples from cats with FIP typed as IND (high viral load but pathotyping was not possible) and therefore were considered negative for the calculation of sensitivity despite a high viral load.", [["effusion samples", "ANATOMY", 13, 29], ["FIP", "DISEASE", 45, 48], ["effusion samples", "CANCER", 13, 29], ["cats", "ORGANISM", 35, 39], ["cats", "SPECIES", 35, 39], ["the effusion samples", "PROBLEM", 9, 29], ["FIP", "PROBLEM", 45, 48], ["IND (high viral load", "PROBLEM", 58, 78], ["pathotyping", "PROBLEM", 83, 94], ["sensitivity", "PROBLEM", 175, 186], ["a high viral load", "PROBLEM", 195, 212], ["effusion", "OBSERVATION", 13, 21], ["viral load", "OBSERVATION", 202, 212]]], ["Additionally, in two of the serum/plasma and seven of the effusion samples from cats with FIP, FCoV RNA was detected, but the concentration was too low to allow pathotyping and therefore, these samples also were considered negative for the calculation of sensitivity.", [["serum", "ANATOMY", 28, 33], ["plasma", "ANATOMY", 34, 40], ["effusion samples", "ANATOMY", 58, 74], ["samples", "ANATOMY", 194, 201], ["FIP", "DISEASE", 90, 93], ["serum", "ORGANISM_SUBSTANCE", 28, 33], ["plasma", "ORGANISM_SUBSTANCE", 34, 40], ["effusion samples", "CANCER", 58, 74], ["cats", "ORGANISM", 80, 84], ["FCoV", "GENE_OR_GENE_PRODUCT", 95, 99], ["FCoV RNA", "RNA", 95, 103], ["cats", "SPECIES", 80, 84], ["FCoV", "SPECIES", 95, 99], ["the serum/plasma", "TEST", 24, 40], ["the effusion samples", "PROBLEM", 54, 74], ["FIP", "PROBLEM", 90, 93], ["FCoV RNA", "PROBLEM", 95, 103], ["these samples", "TEST", 188, 201], ["sensitivity", "PROBLEM", 255, 266], ["effusion", "OBSERVATION", 58, 66], ["FCoV RNA", "OBSERVATION", 95, 103]]], ["If sensitivity of the real-time RT-PCR had only been calculated for the detection of FCoV in general in the study population, then sensitivity would have been much better (97.1% for effusion and 14.3% for serum/plasma).DiscussionThe FIPV pathotype was detected in the majority (24/34, 71%) of FCoV-positive effusion samples from cats with FIP.", [["serum", "ANATOMY", 205, 210], ["plasma", "ANATOMY", 211, 217], ["effusion samples", "ANATOMY", 307, 323], ["effusion", "DISEASE", 182, 190], ["effusion", "DISEASE", 307, 315], ["FIP", "DISEASE", 339, 342], ["serum", "ORGANISM_SUBSTANCE", 205, 210], ["plasma", "ORGANISM_SUBSTANCE", 211, 217], ["FIPV", "GENE_OR_GENE_PRODUCT", 233, 237], ["FCoV", "GENE_OR_GENE_PRODUCT", 293, 297], ["effusion samples", "CANCER", 307, 323], ["cats", "ORGANISM", 329, 333], ["FIPV pathotype", "DNA", 233, 247], ["cats", "SPECIES", 329, 333], ["FCoV", "SPECIES", 85, 89], ["RT-PCR", "TEST", 32, 38], ["FCoV", "PROBLEM", 85, 89], ["effusion", "PROBLEM", 182, 190], ["serum/plasma", "TEST", 205, 217], ["The FIPV pathotype", "TEST", 229, 247], ["FCoV", "TEST", 293, 297], ["positive effusion samples", "PROBLEM", 298, 323], ["FIP", "PROBLEM", 339, 342], ["FCoV", "OBSERVATION", 85, 89], ["positive", "OBSERVATION_MODIFIER", 298, 306], ["effusion", "OBSERVATION", 307, 315]]], ["Substitution M1058L was found in 22/34 (65%), substitution S1060A in 0/34.", [["M1058L", "AMINO_ACID", 13, 19]]], ["These results are quite similar to a recent study detecting M1058L in 65% and S1060A in 6% of FCoV-positive effusions from cats with FIP [23] .", [["effusions", "ANATOMY", 108, 117], ["effusions", "DISEASE", 108, 117], ["FIP", "DISEASE", 133, 136], ["M1058L", "CANCER", 60, 66], ["FCoV", "GENE_OR_GENE_PRODUCT", 94, 98], ["cats", "ORGANISM", 123, 127], ["M1058L", "PROTEIN", 60, 66], ["a recent study", "TEST", 35, 49], ["M1058L", "TEST", 60, 66], ["FCoV", "TEST", 94, 98], ["positive effusions", "PROBLEM", 99, 117], ["positive", "OBSERVATION_MODIFIER", 99, 107], ["effusions", "OBSERVATION", 108, 117]]], ["Two of the effusion samples of cats with FIP were typed as mixed pathotype, meaning that populations of FECV and FIPV were present in the cat at the same time.", [["effusion samples", "ANATOMY", 11, 27], ["FIP", "DISEASE", 41, 44], ["effusion samples", "CANCER", 11, 27], ["cats", "ORGANISM", 31, 35], ["FECV", "GENE_OR_GENE_PRODUCT", 104, 108], ["FIPV", "GENE_OR_GENE_PRODUCT", 113, 117], ["cat", "ORGANISM", 138, 141], ["cats", "SPECIES", 31, 35], ["FECV", "SPECIES", 104, 108], ["FIPV", "SPECIES", 113, 117], ["the effusion samples of cats", "PROBLEM", 7, 35], ["FIP", "PROBLEM", 41, 44], ["mixed pathotype", "PROBLEM", 59, 74], ["FECV", "TREATMENT", 104, 108], ["FIPV", "PROBLEM", 113, 117], ["effusion", "OBSERVATION", 11, 19]]], ["It is likely that these cats were in an early stage during the transition of FECV to FIPV.", [["FIPV", "DISEASE", 85, 89], ["cats", "ORGANISM", 24, 28], ["FECV", "SPECIES", 77, 81], ["these cats", "PROBLEM", 18, 28], ["the transition of FECV to FIPV", "TREATMENT", 59, 89], ["is likely", "UNCERTAINTY", 3, 12], ["cats", "OBSERVATION", 24, 28]]], ["Additionally, it is conceivable that these cats with FIP were superinfected with an FECV, as described previously [28, 29] , and that their effusion samples were tested positive for both pathotypes due to leakage of FECV into the effusion.DiscussionAs stated before, three of the effusion samples of cats with FIP typed as IND (high virus load but pathotyping was not possible).", [["effusion samples", "ANATOMY", 140, 156], ["effusion", "ANATOMY", 230, 238], ["effusion samples", "ANATOMY", 280, 296], ["FIP", "DISEASE", 53, 56], ["effusion", "DISEASE", 140, 148], ["effusion", "DISEASE", 230, 238], ["FIP", "DISEASE", 310, 313], ["cats", "ORGANISM", 43, 47], ["effusion samples", "CANCER", 140, 156], ["effusion samples", "CANCER", 280, 296], ["cats", "ORGANISM", 300, 304], ["cats", "SPECIES", 43, 47], ["FECV", "SPECIES", 84, 88], ["FECV", "SPECIES", 216, 220], ["FIP", "PROBLEM", 53, 56], ["their effusion samples", "TEST", 134, 156], ["both pathotypes", "PROBLEM", 182, 197], ["leakage of FECV into the effusion", "PROBLEM", 205, 238], ["the effusion samples of cats", "PROBLEM", 276, 304], ["FIP", "PROBLEM", 310, 313], ["IND (high virus load", "PROBLEM", 323, 343], ["pathotyping", "PROBLEM", 348, 359], ["superinfected", "OBSERVATION_MODIFIER", 62, 75], ["effusion", "OBSERVATION", 140, 148], ["leakage", "OBSERVATION", 205, 212], ["effusion", "OBSERVATION", 230, 238], ["effusion", "OBSERVATION", 280, 288]]], ["The reason for this might be the existence of unknown spike gene sequence variations in the sample, which are not recognized by the current primer set.", [["sample", "ANATOMY", 92, 98], ["spike gene sequence", "DNA", 54, 73], ["unknown spike gene sequence variations in the sample", "PROBLEM", 46, 98]]], ["Since the spike gene assay is specific for serotype I FCoV, infection with a serotype II FCoV also could cause typing as IND.", [["infection", "DISEASE", 60, 69], ["serotype I FCoV", "GENE_OR_GENE_PRODUCT", 43, 58], ["serotype II FCoV", "ORGANISM", 77, 93], ["spike gene", "DNA", 10, 20], ["serotype II FCoV", "DNA", 77, 93], ["serotype I FCoV", "SPECIES", 43, 58], ["serotype II FCoV", "SPECIES", 77, 93], ["the spike gene assay", "TEST", 6, 26], ["serotype I FCoV", "PROBLEM", 43, 58], ["infection", "PROBLEM", 60, 69], ["a serotype II FCoV", "PROBLEM", 75, 93], ["infection", "OBSERVATION", 60, 69]]], ["Cats with FIP have been shown to exhibit higher viral loads than healthy FECV-infected cats [30] and therefore, if a sample is typed as IND, it is likely that the cat has FIP.", [["FIP", "DISEASE", 10, 13], ["FIP", "DISEASE", 171, 174], ["cats", "ORGANISM", 87, 91], ["cat", "ORGANISM", 163, 166], ["cats", "SPECIES", 87, 91], ["FIP", "PROBLEM", 10, 13], ["higher viral loads", "PROBLEM", 41, 59], ["FIP", "PROBLEM", 171, 174], ["is likely", "UNCERTAINTY", 144, 153], ["FIP", "OBSERVATION", 171, 174]]], ["Possibly, these cats exhibited alternative mutations in other parts of their genome that are characteristic for the development of the FIPV genotype.", [["cats", "ORGANISM", 16, 20], ["FIPV", "GENE_OR_GENE_PRODUCT", 135, 139], ["alternative mutations", "PROBLEM", 31, 52], ["the FIPV genotype", "PROBLEM", 131, 148], ["alternative mutations", "OBSERVATION", 31, 52], ["FIPV genotype", "OBSERVATION", 135, 148]]], ["The 3c gene and other regions in the S1 and S2 domains of the spike gene have been identified as other potential sites for mutation(s) involved in FIP pathogenesis [16, 28, 29, 31, 32] .", [["FIP", "DISEASE", 147, 150], ["S2", "GENE_OR_GENE_PRODUCT", 44, 46], ["3c gene", "DNA", 4, 11], ["S1 and S2 domains", "DNA", 37, 54], ["spike gene", "DNA", 62, 72], ["mutation", "PROBLEM", 123, 131], ["FIP pathogenesis", "PROBLEM", 147, 163], ["S1", "ANATOMY", 37, 39], ["S2", "ANATOMY", 44, 46]]], ["For example, variations in a furin cleavage site in the region between receptor-binding (S1) and fusion (S2) domains of the spike gene were detected when comparing FECV and FIPV sequences [16] .", [["furin", "GENE_OR_GENE_PRODUCT", 29, 34], ["receptor-binding (S1", "GENE_OR_GENE_PRODUCT", 71, 91], ["furin cleavage site", "PROTEIN", 29, 48], ["S1", "PROTEIN", 89, 91], ["fusion (S2) domains", "PROTEIN", 97, 116], ["spike gene", "DNA", 124, 134], ["FECV and FIPV sequences", "DNA", 164, 187], ["a furin cleavage site", "PROBLEM", 27, 48], ["fusion (S2)", "TREATMENT", 97, 108], ["the spike gene", "PROBLEM", 120, 134], ["FECV and FIPV sequences", "TEST", 164, 187], ["region", "ANATOMY_MODIFIER", 56, 62], ["S1", "ANATOMY", 89, 91]]], ["Another study compared FCoV from FIP lesions with FCoV from the feces of healthy cats and identified a consistent substitution of isoleucine with threonine at position 1108 of the spike protein in cats with FIP [32] .", [["FIP lesions", "ANATOMY", 33, 44], ["feces", "ANATOMY", 64, 69], ["FCoV", "CHEMICAL", 50, 54], ["isoleucine", "CHEMICAL", 130, 140], ["threonine", "CHEMICAL", 146, 155], ["FIP", "DISEASE", 207, 210], ["isoleucine", "CHEMICAL", 130, 140], ["threonine", "CHEMICAL", 146, 155], ["FCoV", "SIMPLE_CHEMICAL", 23, 27], ["FIP lesions", "CANCER", 33, 44], ["feces", "ORGANISM_SUBDIVISION", 64, 69], ["cats", "ORGANISM", 81, 85], ["isoleucine", "AMINO_ACID", 130, 140], ["threonine", "AMINO_ACID", 146, 155], ["position 1108", "AMINO_ACID", 159, 172], ["cats", "ORGANISM", 197, 201], ["position 1108", "PROTEIN", 159, 172], ["spike protein", "PROTEIN", 180, 193], ["cats", "SPECIES", 81, 85], ["Another study", "TEST", 0, 13], ["FCoV", "PROBLEM", 23, 27], ["FIP lesions", "PROBLEM", 33, 44], ["FCoV", "PROBLEM", 50, 54], ["a consistent substitution of isoleucine", "TREATMENT", 101, 140], ["threonine at position", "TREATMENT", 146, 167], ["the spike protein", "TEST", 176, 193], ["FCoV", "OBSERVATION", 50, 54]]], ["Additionally, mutations of the 3c gene might contribute to FIP pathogenesis.", [["FIP", "DISEASE", 59, 62], ["3c", "GENE_OR_GENE_PRODUCT", 31, 33], ["FIP", "PATHOLOGICAL_FORMATION", 59, 62], ["3c gene", "DNA", 31, 38], ["mutations of the 3c gene", "PROBLEM", 14, 38], ["FIP pathogenesis", "PROBLEM", 59, 75], ["might contribute to", "UNCERTAINTY", 39, 58], ["FIP", "OBSERVATION", 59, 62]]], ["Mutations in this gene were observed in the majority of FIPV, whereas an intact 3c gene [22, 34] .", [["FIPV", "GENE_OR_GENE_PRODUCT", 56, 60], ["FIPV", "DNA", 56, 60], ["intact 3c gene", "DNA", 73, 87], ["Mutations", "PROBLEM", 0, 9]]], ["A low concentration of FCoV RNA was detected in the serum/plasma of two cats with FIP, but the low virus load did not allow pathotype determination.", [["serum", "ANATOMY", 52, 57], ["plasma", "ANATOMY", 58, 64], ["FCoV", "CHEMICAL", 23, 27], ["FIP", "DISEASE", 82, 85], ["FCoV", "GENE_OR_GENE_PRODUCT", 23, 27], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["plasma", "ORGANISM_SUBSTANCE", 58, 64], ["cats", "ORGANISM", 72, 76], ["FCoV RNA", "RNA", 23, 31], ["cats", "SPECIES", 72, 76], ["A low concentration of FCoV RNA", "PROBLEM", 0, 31], ["the serum/plasma", "TEST", 48, 64], ["FIP", "PROBLEM", 82, 85], ["the low virus load", "PROBLEM", 91, 109], ["low concentration", "OBSERVATION_MODIFIER", 2, 19], ["FCoV RNA", "OBSERVATION", 23, 31], ["FIP", "OBSERVATION", 82, 85]]], ["Thus, sensitivity of the real-time RT-PCR in serum/plasma was 0%.", [["serum", "ANATOMY", 45, 50], ["plasma", "ANATOMY", 51, 57], ["serum", "ORGANISM_SUBSTANCE", 45, 50], ["plasma", "ORGANISM_SUBSTANCE", 51, 57], ["RT-PCR", "TEST", 35, 41], ["serum/plasma", "TEST", 45, 57]]], ["This is in contrast to results of previous studies evaluating different RT-PCR assays and reporting sensitivities of 53-87% using serum, plasma, or whole blood [24, 25, 35, 36] .", [["serum", "ANATOMY", 130, 135], ["plasma", "ANATOMY", 137, 143], ["whole blood", "ANATOMY", 148, 159], ["serum", "ORGANISM_SUBSTANCE", 130, 135], ["plasma", "ORGANISM_SUBSTANCE", 137, 143], ["blood", "ORGANISM_SUBSTANCE", 154, 159], ["previous studies", "TEST", 34, 50], ["different RT-PCR assays", "TEST", 62, 85], ["sensitivities", "TEST", 100, 113], ["serum", "TEST", 130, 135], ["plasma", "TEST", 137, 143], ["whole blood", "TEST", 148, 159]]], ["Nevertheless, in regard of the findings of a recent study, a low sensitivity in blood was expected, as FCoV RNA could not be detected in the whole blood, plasma, or white cell fraction of cats with experimentally induced FIP at any stage of disease.", [["blood", "ANATOMY", 80, 85], ["whole blood", "ANATOMY", 141, 152], ["plasma", "ANATOMY", 154, 160], ["white cell", "ANATOMY", 165, 175], ["FIP", "DISEASE", 221, 224], ["blood", "ORGANISM_SUBSTANCE", 80, 85], ["FCoV", "GENE_OR_GENE_PRODUCT", 103, 107], ["blood", "ORGANISM_SUBSTANCE", 147, 152], ["plasma", "ORGANISM_SUBSTANCE", 154, 160], ["white cell", "CELL", 165, 175], ["cats", "ORGANISM", 188, 192], ["FCoV RNA", "RNA", 103, 111], ["a recent study", "TEST", 43, 57], ["a low sensitivity in blood", "PROBLEM", 59, 85], ["FCoV RNA", "TEST", 103, 111], ["the whole blood", "TEST", 137, 152], ["plasma", "TEST", 154, 160], ["white cell fraction", "TEST", 165, 184], ["experimentally induced FIP", "PROBLEM", 198, 224], ["disease", "PROBLEM", 241, 248], ["FIP", "OBSERVATION", 221, 224], ["disease", "OBSERVATION", 241, 248]]], ["In the cats with FIP, viremia was either nonexistent, or virus load was below the detection limit [34] .", [["FIP", "DISEASE", 17, 20], ["viremia", "DISEASE", 22, 29], ["cats", "ORGANISM", 7, 11], ["cats", "SPECIES", 7, 11], ["FIP", "PROBLEM", 17, 20], ["viremia", "PROBLEM", 22, 29], ["virus load", "PROBLEM", 57, 67], ["FIP", "OBSERVATION", 17, 20], ["viremia", "OBSERVATION", 22, 29]]], ["It is also likely that in the present study the majority of cats with FIP either were not viremic or that FCoV RNA levels were below detection limit of the real-time RT-PCR.", [["FIP", "DISEASE", 70, 73], ["cats", "ORGANISM", 60, 64], ["FCoV", "GENE_OR_GENE_PRODUCT", 106, 110], ["FCoV RNA", "RNA", 106, 114], ["cats", "SPECIES", 60, 64], ["FCoV", "SPECIES", 106, 110], ["FIP", "PROBLEM", 70, 73], ["viremic", "PROBLEM", 90, 97], ["FCoV RNA levels", "TEST", 106, 121], ["also likely", "UNCERTAINTY", 6, 17]]], ["It could be argued that sensitivity would have been better when investigating whole blood, as FIPV replication is restricted to macrophages [34, 37, 38] .", [["whole blood", "ANATOMY", 78, 89], ["macrophages", "ANATOMY", 128, 139], ["blood", "ORGANISM_SUBSTANCE", 84, 89], ["FIPV", "GENE_OR_GENE_PRODUCT", 94, 98], ["macrophages", "CELL", 128, 139], ["macrophages", "CELL_TYPE", 128, 139], ["FIPV", "SPECIES", 94, 98], ["whole blood", "TEST", 78, 89], ["FIPV replication", "TREATMENT", 94, 110]]], ["However, real-time RT-PCR of serum and peripheral blood mononuclear cells (PBMC) has been compared and both showed rather low sensitivities, even though the sensitivity of PBMC (31.6%) was slightly better than that of serum (23.1%) [22] .", [["serum", "ANATOMY", 29, 34], ["peripheral blood mononuclear cells", "ANATOMY", 39, 73], ["PBMC", "ANATOMY", 75, 79], ["PBMC", "ANATOMY", 172, 176], ["serum", "ANATOMY", 218, 223], ["serum", "ORGANISM_SUBSTANCE", 29, 34], ["peripheral blood mononuclear cells", "CELL", 39, 73], ["PBMC", "CELL", 75, 79], ["PBMC", "CELL", 172, 176], ["serum", "ORGANISM_SUBSTANCE", 218, 223], ["peripheral blood mononuclear cells", "CELL_TYPE", 39, 73], ["PBMC", "CELL_TYPE", 75, 79], ["PBMC", "CELL_TYPE", 172, 176], ["real-time RT-PCR", "TEST", 9, 25], ["serum", "TEST", 29, 34], ["peripheral blood mononuclear cells", "TEST", 39, 73], ["PBMC", "TEST", 75, 79], ["rather low sensitivities", "PROBLEM", 115, 139], ["the sensitivity", "TEST", 153, 168], ["PBMC", "TEST", 172, 176], ["serum", "TEST", 218, 223], ["peripheral", "ANATOMY_MODIFIER", 39, 49], ["blood", "ANATOMY", 50, 55], ["mononuclear cells", "OBSERVATION", 56, 73], ["low sensitivities", "OBSERVATION_MODIFIER", 122, 139]]], ["In general, viral load in effusion is much higher than in blood [34] .DiscussionOne limitation of the present study was the inclusion criterion for some of the control cats.", [["blood", "ANATOMY", 58, 63], ["effusion", "DISEASE", 26, 34], ["blood", "ORGANISM_SUBSTANCE", 58, 63], ["cats", "ORGANISM", 168, 172], ["viral load in effusion", "PROBLEM", 12, 34], ["the present study", "TEST", 98, 115], ["viral load", "OBSERVATION", 12, 22], ["effusion", "OBSERVATION", 26, 34], ["higher", "OBSERVATION_MODIFIER", 43, 49]]], ["Histopathology could not be performed in all cats and confirmation of diagnosis was therefore achieved ante-mortem in 14 of the 25 control cats.", [["cats", "ORGANISM", 45, 49], ["cats", "ORGANISM", 139, 143], ["cats", "SPECIES", 139, 143], ["Histopathology", "TEST", 0, 14], ["ante-mortem", "TEST", 103, 114]]], ["Consequently, it cannot be totally excluded that some of these cats suffered from FIP in addition to their diagnosed diseases.", [["FIP", "DISEASE", 82, 85], ["cats", "ORGANISM", 63, 67], ["FIP", "PROBLEM", 82, 85], ["their diagnosed diseases", "PROBLEM", 101, 125], ["FIP", "OBSERVATION", 82, 85]]], ["Nevertheless, this seems rather unlikely, as real-time RT-PCR was false positive only in one of the control cats and in this specific cat, histopathology had been performed.", [["cats", "ORGANISM", 108, 112], ["cat", "ORGANISM", 134, 137], ["cats", "SPECIES", 108, 112], ["time RT-PCR", "TEST", 50, 61], ["false positive", "PROBLEM", 66, 80], ["seems rather unlikely", "UNCERTAINTY", 19, 40]]], ["A second limitation of the present study is the fact that in some of the cats, only one sample type (effusion or serum/ plasma) was available and overall, the number of available serum/plasma samples was rather low.ConclusionsThis study evaluated a discriminating real-time RT-PCR using effusion and/or serum/plasma in the diagnosis of FIP.", [["serum", "ANATOMY", 113, 118], ["plasma", "ANATOMY", 120, 126], ["serum", "ANATOMY", 179, 184], ["plasma samples", "ANATOMY", 185, 199], ["serum", "ANATOMY", 303, 308], ["plasma", "ANATOMY", 309, 315], ["effusion", "DISEASE", 101, 109], ["FIP", "DISEASE", 336, 339], ["cats", "ORGANISM", 73, 77], ["serum", "ORGANISM_SUBSTANCE", 113, 118], ["plasma", "ORGANISM_SUBSTANCE", 120, 126], ["serum", "ORGANISM_SUBSTANCE", 179, 184], ["plasma samples", "ORGANISM_SUBSTANCE", 185, 199], ["serum", "ORGANISM_SUBSTANCE", 303, 308], ["plasma", "ORGANISM_SUBSTANCE", 309, 315], ["cats", "SPECIES", 73, 77], ["the present study", "TEST", 23, 40], ["one sample type (effusion", "PROBLEM", 84, 109], ["serum/ plasma)", "TEST", 113, 127], ["serum/plasma samples", "TEST", 179, 199], ["This study", "TEST", 226, 236], ["effusion", "PROBLEM", 287, 295], ["serum/plasma", "TEST", 303, 315], ["FIP", "PROBLEM", 336, 339], ["effusion", "OBSERVATION", 101, 109], ["effusion", "OBSERVATION", 287, 295], ["FIP", "OBSERVATION", 336, 339]]], ["The results indicate that the detection of the FIPV pathotype with substitution M1058L is very specific for the FIP phenotype and can be a useful tool in the diagnosis of FIP.", [["FIP", "DISEASE", 171, 174], ["FIPV", "GENE_OR_GENE_PRODUCT", 47, 51], ["FIPV pathotype", "DNA", 47, 61], ["the FIPV pathotype", "PROBLEM", 43, 61], ["substitution M1058L", "TREATMENT", 67, 86], ["the FIP phenotype", "PROBLEM", 108, 125], ["FIP", "PROBLEM", 171, 174], ["FIPV pathotype", "OBSERVATION", 47, 61], ["FIP", "OBSERVATION", 171, 174]]], ["Nevertheless, substitution M1058L was also detected in one control cat without FIP.", [["FIP", "DISEASE", 79, 82], ["M1058L", "AMINO_ACID", 27, 33], ["cat", "ORGANISM", 67, 70], ["substitution M1058L", "TREATMENT", 14, 33], ["FIP", "OBSERVATION", 79, 82]]], ["As none of the FIPV-positive effusion samples contained substitution S1060A, it is considered a weak discriminatory factor for the diagnosis of FIP.", [["effusion samples", "ANATOMY", 29, 45], ["effusion", "DISEASE", 29, 37], ["FIP", "DISEASE", 144, 147], ["FIPV", "GENE_OR_GENE_PRODUCT", 15, 19], ["effusion samples", "CANCER", 29, 45], ["FIPV", "PROTEIN", 15, 19], ["the FIPV", "TEST", 11, 19], ["a weak discriminatory factor", "PROBLEM", 94, 122], ["FIP", "PROBLEM", 144, 147], ["positive", "OBSERVATION_MODIFIER", 20, 28], ["effusion", "OBSERVATION", 29, 37], ["FIP", "OBSERVATION", 144, 147]]], ["The fact that in two other control cats FCoV was detected, even though the pathotype could not be determined, shows that FCoV can cause viremia and therefore, traditional non-discriminating RT-PCR is not sufficient to definitively diagnose FIP.", [["FCoV", "CHEMICAL", 121, 125], ["viremia", "DISEASE", 136, 143], ["FIP", "DISEASE", 240, 243], ["cats", "ORGANISM", 35, 39], ["FCoV", "GENE_OR_GENE_PRODUCT", 40, 44], ["FCoV", "SIMPLE_CHEMICAL", 121, 125], ["the pathotype", "PROBLEM", 71, 84], ["FCoV", "PROBLEM", 121, 125], ["viremia", "PROBLEM", 136, 143], ["traditional non-discriminating RT-PCR", "TEST", 159, 196], ["FCoV", "OBSERVATION", 121, 125], ["viremia", "OBSERVATION", 136, 143]]], ["Discriminative RT-PCR should be performed in order to minimize the risk of euthanasia of cats suffering from different diseases.", [["cats", "ORGANISM", 89, 93], ["cats", "SPECIES", 89, 93], ["Discriminative RT-PCR", "TEST", 0, 21], ["euthanasia of cats", "PROBLEM", 75, 93], ["different diseases", "PROBLEM", 109, 127], ["euthanasia", "OBSERVATION", 75, 85], ["different", "OBSERVATION_MODIFIER", 109, 118], ["diseases", "OBSERVATION", 119, 127]]], ["The use of serum/plasma is not recommended owing to the low viral load in blood.", [["serum", "ANATOMY", 11, 16], ["plasma", "ANATOMY", 17, 23], ["blood", "ANATOMY", 74, 79], ["serum", "ORGANISM_SUBSTANCE", 11, 16], ["plasma", "ORGANISM_SUBSTANCE", 17, 23], ["blood", "ORGANISM_SUBSTANCE", 74, 79], ["serum/plasma", "TEST", 11, 23], ["the low viral load in blood", "PROBLEM", 52, 79]]], ["FIP feline infectious peritonitis a BLD (feline coronavirus present, but below limit of detection) and IND (feline coronavirus present, but indeterminate sequence variations) were defined as negative for statistical analysis, as the pathotype could not be determined.", [["infectious peritonitis", "DISEASE", 11, 33], ["BLD", "DISEASE", 36, 39], ["feline coronavirus", "DISEASE", 41, 59], ["feline coronavirus", "DISEASE", 108, 126], ["FIP feline", "ORGANISM", 0, 10], ["feline coronavirus", "ORGANISM", 41, 59], ["feline coronavirus", "ORGANISM", 108, 126], ["feline", "SPECIES", 4, 10], ["feline coronavirus", "SPECIES", 41, 59], ["feline coronavirus", "SPECIES", 108, 126], ["feline coronavirus", "SPECIES", 41, 59], ["feline coronavirus", "SPECIES", 108, 126], ["FIP feline infectious peritonitis", "PROBLEM", 0, 33], ["a BLD (feline coronavirus", "PROBLEM", 34, 59], ["IND (feline coronavirus", "PROBLEM", 103, 126], ["indeterminate sequence variations", "PROBLEM", 140, 173], ["statistical analysis", "TEST", 204, 224], ["the pathotype", "TEST", 229, 242], ["feline", "OBSERVATION_MODIFIER", 4, 10], ["infectious", "OBSERVATION_MODIFIER", 11, 21], ["peritonitis", "OBSERVATION", 22, 33]]], ["A mixed pathotype of feline infectious peritonitis virus and feline enteric coronavirus was defined as positive, as the mutated pathotype was detected", [["feline infectious peritonitis", "DISEASE", 21, 50], ["enteric coronavirus", "DISEASE", 68, 87], ["feline infectious peritonitis virus", "ORGANISM", 21, 56], ["feline enteric coronavirus", "ORGANISM", 61, 87], ["feline infectious peritonitis virus", "SPECIES", 21, 56], ["feline enteric coronavirus", "SPECIES", 61, 87], ["feline infectious peritonitis virus", "SPECIES", 21, 56], ["feline enteric coronavirus", "SPECIES", 61, 87], ["A mixed pathotype of feline infectious peritonitis virus", "PROBLEM", 0, 56], ["feline enteric coronavirus", "PROBLEM", 61, 87], ["the mutated pathotype", "PROBLEM", 116, 137], ["mixed", "OBSERVATION_MODIFIER", 2, 7], ["pathotype", "OBSERVATION_MODIFIER", 8, 17], ["feline", "OBSERVATION_MODIFIER", 21, 27], ["infectious", "OBSERVATION_MODIFIER", 28, 38], ["peritonitis", "OBSERVATION", 39, 50], ["enteric coronavirus", "OBSERVATION", 68, 87]]]], "PMC7239050": [["IntroductionThe COVID-19 pandemic, caused by SARS-CoV-2, has now spread to more than 100 countries on 6 continents.", [["SARS-CoV-2", "ORGANISM", 45, 55], ["SARS-CoV", "SPECIES", 45, 53], ["The COVID", "TEST", 12, 21], ["pandemic", "PROBLEM", 25, 33]]], ["SARS-CoV-2 is a new member of the subgenus Sarbecovirus, in the Orthocoronavirinae subfamily, and is distinct from MERS-CoV and SARS-CoV.1 The coronaviruses are single-strand RNA viruses, sharing properties with other single-stranded RNA viruses such as hepatitis C virus (HCV), West Nile virus, Marburg virus, HIV virus, Ebola virus, dengue virus, and rhinoviruses.", [["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 128, 132], ["hepatitis C", "DISEASE", 254, 265], ["HIV virus", "DISEASE", 311, 320], ["Ebola virus", "DISEASE", 322, 333], ["dengue", "DISEASE", 335, 341], ["rhinoviruses", "DISEASE", 353, 365], ["SARS-CoV-2", "ORGANISM", 0, 10], ["Sarbecovirus", "GENE_OR_GENE_PRODUCT", 43, 55], ["Orthocoronavirinae", "GENE_OR_GENE_PRODUCT", 64, 82], ["MERS-CoV", "ORGANISM", 115, 123], ["coronaviruses", "ORGANISM", 143, 156], ["hepatitis C virus", "ORGANISM", 254, 271], ["HCV", "ORGANISM", 273, 276], ["West Nile virus", "ORGANISM", 279, 294], ["Marburg virus", "ORGANISM", 296, 309], ["HIV virus", "ORGANISM", 311, 320], ["Ebola virus", "ORGANISM", 322, 333], ["dengue virus", "ORGANISM", 335, 347], ["rhinoviruses", "ORGANISM", 353, 365], ["Orthocoronavirinae subfamily", "PROTEIN", 64, 92], ["hepatitis C virus", "SPECIES", 254, 271], ["West Nile virus", "SPECIES", 279, 294], ["Marburg virus", "SPECIES", 296, 309], ["HIV virus", "SPECIES", 311, 320], ["Ebola virus", "SPECIES", 322, 333], ["dengue virus", "SPECIES", 335, 347], ["SARS-CoV", "SPECIES", 0, 8], ["MERS-CoV", "SPECIES", 115, 123], ["SARS-CoV.1", "SPECIES", 128, 138], ["hepatitis C virus", "SPECIES", 254, 271], ["HCV", "SPECIES", 273, 276], ["West Nile virus", "SPECIES", 279, 294], ["Marburg virus", "SPECIES", 296, 309], ["HIV virus", "SPECIES", 311, 320], ["Ebola virus", "SPECIES", 322, 333], ["dengue virus", "SPECIES", 335, 347], ["the subgenus Sarbecovirus", "PROBLEM", 30, 55], ["SARS", "PROBLEM", 128, 132], ["The coronaviruses", "PROBLEM", 139, 156], ["single-strand RNA viruses", "PROBLEM", 161, 186], ["other single-stranded RNA viruses", "PROBLEM", 212, 245], ["hepatitis C virus", "PROBLEM", 254, 271], ["HCV", "PROBLEM", 273, 276], ["West Nile virus", "PROBLEM", 279, 294], ["Marburg virus", "PROBLEM", 296, 309], ["HIV virus", "PROBLEM", 311, 320], ["Ebola virus", "PROBLEM", 322, 333], ["dengue virus", "PROBLEM", 335, 347], ["rhinoviruses", "PROBLEM", 353, 365], ["coronaviruses", "OBSERVATION", 143, 156], ["strand RNA viruses", "OBSERVATION", 168, 186], ["stranded RNA viruses", "OBSERVATION", 225, 245]]], ["Coronaviruses, like HCV and the flaviviruses, are positive-sense single-strand RNA viruses,2,3 and these viruses share a similar replication mechanism requiring a RNA-dependent RNA polymerase (RdRp).IntroductionPotential inhibitors have been designed to target nearly every stage of the viral replication cycle.2 However, despite decades of research, no effective drug is currently approved to treat serious coronavirus infections such as SARS, MERS, and now COVID-19.", [["coronavirus infections", "DISEASE", 408, 430], ["SARS", "DISEASE", 439, 443], ["MERS", "DISEASE", 445, 449], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["HCV", "ORGANISM", 20, 23], ["coronavirus", "ORGANISM", 408, 419], ["RNA-dependent RNA polymerase", "PROTEIN", 163, 191], ["RdRp", "PROTEIN", 193, 197], ["HCV", "SPECIES", 20, 23], ["Coronaviruses", "PROBLEM", 0, 13], ["HCV", "PROBLEM", 20, 23], ["the flaviviruses", "PROBLEM", 28, 44], ["sense single-strand RNA viruses", "PROBLEM", 59, 90], ["these viruses", "PROBLEM", 99, 112], ["a RNA-dependent RNA polymerase", "TREATMENT", 161, 191], ["IntroductionPotential inhibitors", "TREATMENT", 199, 231], ["the viral replication cycle.", "TREATMENT", 283, 311], ["serious coronavirus infections", "PROBLEM", 400, 430], ["SARS", "PROBLEM", 439, 443], ["COVID", "TEST", 459, 464], ["HCV", "OBSERVATION", 20, 23], ["flaviviruses", "OBSERVATION", 32, 44], ["similar replication", "OBSERVATION", 121, 140], ["viral replication", "OBSERVATION", 287, 304], ["no", "UNCERTAINTY", 351, 353]]], ["One of the most important druggable targets for coronaviruses is the RdRp.", [["coronaviruses", "ORGANISM", 48, 61], ["coronaviruses", "PROBLEM", 48, 61]]], ["This polymerase displays similar catalytic mechanisms and some key conserved amino acids in the active site among different positive sense RNA viruses, to which coronaviruses and HCV belong.4 Like RdRps in other viruses, the coronavirus enzyme is highly error-prone,5 which might increase its ability to accept modified nucleotide analogues as substrates.", [["amino acids", "CHEMICAL", 77, 88], ["nucleotide", "CHEMICAL", 320, 330], ["amino acids", "CHEMICAL", 77, 88], ["nucleotide", "CHEMICAL", 320, 330], ["amino acids", "AMINO_ACID", 77, 88], ["coronaviruses", "ORGANISM", 161, 174], ["HCV", "ORGANISM", 179, 182], ["RdRps", "GENE_OR_GENE_PRODUCT", 197, 202], ["coronavirus", "ORGANISM", 225, 236], ["RdRps", "PROTEIN", 197, 202], ["coronavirus enzyme", "PROTEIN", 225, 243], ["coronavirus", "SPECIES", 225, 236], ["HCV", "SPECIES", 179, 182], ["This polymerase", "TEST", 0, 15], ["similar catalytic mechanisms", "PROBLEM", 25, 53], ["some key conserved amino acids", "PROBLEM", 58, 88], ["the active site", "PROBLEM", 92, 107], ["different positive sense RNA viruses", "PROBLEM", 114, 150], ["HCV", "PROBLEM", 179, 182], ["the coronavirus enzyme", "TEST", 221, 243], ["modified nucleotide analogues", "TREATMENT", 311, 340], ["similar", "OBSERVATION_MODIFIER", 25, 32], ["catalytic mechanisms", "OBSERVATION", 33, 53], ["amino acids", "OBSERVATION", 77, 88], ["active", "OBSERVATION_MODIFIER", 96, 102], ["site", "OBSERVATION_MODIFIER", 103, 107], ["positive sense RNA viruses", "OBSERVATION", 124, 150], ["viruses", "OBSERVATION", 212, 219]]], ["Nucleotide and nucleoside analogues that inhibit polymerases are an important group of anti-viral agents.6\u20139IntroductionBased on our analysis of hepatitis C virus and coronavirus replication, and the molecular structures and activities of viral inhibitors, we previously demonstrated that three nucleotide analogues inhibit the SARS-CoV RNA-dependent RNA polymerase (RdRp).10 Using polymerase extension experiments, we demonstrated that the activated triphosphate form of Sofosbuvir was incorporated by SARS-CoV RdRp, and blocked further incorporation.", [["Nucleotide", "CHEMICAL", 0, 10], ["nucleoside", "CHEMICAL", 15, 25], ["hepatitis C", "DISEASE", 145, 156], ["nucleotide", "CHEMICAL", 295, 305], ["triphosphate", "CHEMICAL", 451, 463], ["Sofosbuvir", "CHEMICAL", 472, 482], ["Nucleotide", "CHEMICAL", 0, 10], ["nucleoside", "CHEMICAL", 15, 25], ["nucleotide", "CHEMICAL", 295, 305], ["triphosphate", "CHEMICAL", 451, 463], ["Sofosbuvir", "CHEMICAL", 472, 482], ["nucleoside analogues", "SIMPLE_CHEMICAL", 15, 35], ["hepatitis C virus", "ORGANISM", 145, 162], ["coronavirus", "ORGANISM", 167, 178], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 328, 336], ["triphosphate", "SIMPLE_CHEMICAL", 451, 463], ["Sofosbuvir", "SIMPLE_CHEMICAL", 472, 482], ["SARS-CoV RdRp", "ORGANISM", 503, 516], ["SARS-CoV RNA", "RNA", 328, 340], ["RNA polymerase", "PROTEIN", 351, 365], ["RdRp", "PROTEIN", 367, 371], ["SARS-CoV RdRp", "PROTEIN", 503, 516], ["hepatitis C virus", "SPECIES", 145, 162], ["coronavirus", "SPECIES", 167, 178], ["hepatitis C virus", "SPECIES", 145, 162], ["SARS-CoV", "SPECIES", 328, 336], ["SARS-CoV", "SPECIES", 503, 511], ["Nucleotide", "TREATMENT", 0, 10], ["nucleoside analogues", "TREATMENT", 15, 35], ["polymerases", "TREATMENT", 49, 60], ["anti-viral agents", "TREATMENT", 87, 104], ["our analysis", "TEST", 129, 141], ["hepatitis C virus", "PROBLEM", 145, 162], ["coronavirus replication", "TREATMENT", 167, 190], ["viral inhibitors", "TREATMENT", 239, 255], ["three nucleotide analogues", "PROBLEM", 289, 315], ["the SARS", "TEST", 324, 332], ["CoV RNA", "TEST", 333, 340], ["dependent RNA polymerase", "PROBLEM", 341, 365], ["polymerase extension experiments", "TEST", 382, 414], ["Sofosbuvir", "TREATMENT", 472, 482], ["CoV RdRp", "TREATMENT", 508, 516], ["blocked further incorporation", "TREATMENT", 522, 551], ["nucleoside analogues", "OBSERVATION", 15, 35], ["hepatitis", "OBSERVATION", 145, 154], ["coronavirus replication", "OBSERVATION", 167, 190], ["Sofosbuvir", "OBSERVATION", 472, 482]]], ["Using the same molecular insight, we selected two other anti-viral agents, Alovudine and AZT (the first FDA approved HIV/AIDS drug) for evaluation as inhibitors of SARS-CoV RdRp.", [["Alovudine", "CHEMICAL", 75, 84], ["AZT", "CHEMICAL", 89, 92], ["HIV/AIDS", "DISEASE", 117, 125], ["SARS", "DISEASE", 164, 168], ["Alovudine", "CHEMICAL", 75, 84], ["AZT", "CHEMICAL", 89, 92], ["Alovudine", "SIMPLE_CHEMICAL", 75, 84], ["AZT", "SIMPLE_CHEMICAL", 89, 92], ["HIV", "ORGANISM", 117, 120], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 164, 172], ["HIV", "SPECIES", 117, 120], ["SARS-CoV", "SPECIES", 164, 172], ["anti-viral agents", "TREATMENT", 56, 73], ["Alovudine", "TREATMENT", 75, 84], ["AZT", "TREATMENT", 89, 92], ["HIV/AIDS drug", "TREATMENT", 117, 130], ["evaluation", "TEST", 136, 146], ["SARS", "PROBLEM", 164, 168], ["CoV RdRp.", "TREATMENT", 169, 178]]], ["Alovudine and AZT share a similar backbone structure (base and ribose) to Sofosbuvir, but have fewer modification sites and less steric hindrance.", [["Alovudine", "CHEMICAL", 0, 9], ["AZT", "CHEMICAL", 14, 17], ["ribose", "CHEMICAL", 63, 69], ["Sofosbuvir", "CHEMICAL", 74, 84], ["Alovudine", "CHEMICAL", 0, 9], ["AZT", "CHEMICAL", 14, 17], ["ribose", "CHEMICAL", 63, 69], ["Sofosbuvir", "CHEMICAL", 74, 84], ["Alovudine", "SIMPLE_CHEMICAL", 0, 9], ["AZT", "SIMPLE_CHEMICAL", 14, 17], ["ribose", "SIMPLE_CHEMICAL", 63, 69], ["Sofosbuvir", "SIMPLE_CHEMICAL", 74, 84], ["Alovudine", "TREATMENT", 0, 9], ["AZT", "TREATMENT", 14, 17], ["a similar backbone structure (base and ribose)", "TREATMENT", 24, 70], ["Sofosbuvir", "TREATMENT", 74, 84], ["fewer modification sites", "PROBLEM", 95, 119], ["fewer", "OBSERVATION_MODIFIER", 95, 100], ["modification", "OBSERVATION", 101, 113], ["less", "OBSERVATION_MODIFIER", 124, 128], ["steric hindrance", "OBSERVATION", 129, 145]]], ["Furthermore, because these modifications on Alovudine and AZT are on the 3\u2019 carbon in place of the OH group, they directly prevent further incorporation of nucleotides leading to permanent termination of RNA synthesis and replication of the virus.", [["Alovudine", "CHEMICAL", 44, 53], ["AZT", "CHEMICAL", 58, 61], ["Alovudine", "CHEMICAL", 44, 53], ["AZT", "CHEMICAL", 58, 61], ["3\u2019 carbon", "CHEMICAL", 73, 82], ["OH", "CHEMICAL", 99, 101], ["nucleotides", "CHEMICAL", 156, 167], ["Alovudine", "SIMPLE_CHEMICAL", 44, 53], ["AZT", "SIMPLE_CHEMICAL", 58, 61], ["OH", "SIMPLE_CHEMICAL", 99, 101], ["Alovudine", "TREATMENT", 44, 53], ["AZT", "TREATMENT", 58, 61], ["the 3\u2019 carbon", "TREATMENT", 69, 82], ["further incorporation of nucleotides", "PROBLEM", 131, 167], ["RNA synthesis", "TREATMENT", 204, 217], ["the virus", "PROBLEM", 237, 246], ["RNA synthesis", "OBSERVATION", 204, 217]]], ["We also demonstrated the ability of two HIV reverse transcriptase inhibitors, 3\u2019-fluoro-3\u2019-deoxythymidine triphosphate and 3\u2019-azido-3\u2019-deoxythymidine triphosphate (the active triphosphate forms of Alovudine and AZT), to be incorporated by SARS-CoV RdRp where they also terminate further polymerase extension.10IntroductionIn this paper, we first constructed SARS-CoV-2 RdRp based on a similar procedure to that of SARS-CoV,11,12 and then demonstrated that the above three nucleotide analogues (Fig. 1 a, b, d) are inhibitors of SARS-CoV-2 RdRp.", [["3\u2019-fluoro-3\u2019-deoxythymidine triphosphate", "CHEMICAL", 78, 118], ["3\u2019-azido-3\u2019-deoxythymidine triphosphate", "CHEMICAL", 123, 162], ["triphosphate", "CHEMICAL", 175, 187], ["Alovudine", "CHEMICAL", 197, 206], ["AZT", "CHEMICAL", 211, 214], ["SARS", "DISEASE", 414, 418], ["nucleotide", "CHEMICAL", 472, 482], ["3\u2019-fluoro-3\u2019-deoxythymidine triphosphate", "CHEMICAL", 78, 118], ["3\u2019-azido-3\u2019-deoxythymidine triphosphate", "CHEMICAL", 123, 162], ["triphosphate", "CHEMICAL", 175, 187], ["Alovudine", "CHEMICAL", 197, 206], ["AZT", "CHEMICAL", 211, 214], ["nucleotide", "CHEMICAL", 472, 482], ["3\u2019-fluoro-3\u2019-deoxythymidine triphosphate", "SIMPLE_CHEMICAL", 78, 118], ["3\u2019-azido-3\u2019-deoxythymidine triphosphate", "SIMPLE_CHEMICAL", 123, 162], ["triphosphate", "SIMPLE_CHEMICAL", 175, 187], ["Alovudine", "SIMPLE_CHEMICAL", 197, 206], ["AZT", "SIMPLE_CHEMICAL", 211, 214], ["SARS-CoV RdRp", "ORGANISM", 239, 252], ["SARS-CoV", "ORGANISM", 414, 422], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 528, 538], ["RdRp", "ORGANISM", 539, 543], ["HIV reverse transcriptase", "PROTEIN", 40, 65], ["SARS-CoV RdRp", "PROTEIN", 239, 252], ["SARS-CoV-2 RdRp", "DNA", 358, 373], ["SARS-CoV-2 RdRp", "PROTEIN", 528, 543], ["HIV", "SPECIES", 40, 43], ["SARS-CoV", "SPECIES", 239, 247], ["SARS-CoV", "SPECIES", 414, 422], ["two HIV reverse transcriptase inhibitors", "TREATMENT", 36, 76], ["fluoro", "TREATMENT", 81, 87], ["deoxythymidine triphosphate", "TREATMENT", 91, 118], ["azido", "TREATMENT", 126, 131], ["deoxythymidine triphosphate", "TREATMENT", 135, 162], ["the active triphosphate forms", "TREATMENT", 164, 193], ["Alovudine and AZT)", "TREATMENT", 197, 215], ["CoV RdRp", "TREATMENT", 244, 252], ["a similar procedure", "TREATMENT", 383, 402], ["SARS", "PROBLEM", 414, 418], ["CoV", "TEST", 419, 422], ["nucleotide analogues", "TEST", 472, 492], ["SARS", "PROBLEM", 528, 532], ["CoV", "TEST", 533, 536]]], ["Using structure-activity based molecular insight, we selected the active triphosphate form of Tenofovir alafenamide (TAF, Vemlidy, an acyclic adenosine nucleotide) (Fig. 1 c), which is an FDA approved drug for HIV and hepatitis B virus (HBV) infection, for evaluation as a SARS-CoV-2 RdRp inhibitor.", [["triphosphate", "CHEMICAL", 73, 85], ["Tenofovir alafenamide", "CHEMICAL", 94, 115], ["Vemlidy", "CHEMICAL", 122, 129], ["adenosine", "CHEMICAL", 142, 151], ["nucleotide", "CHEMICAL", 152, 162], ["HIV and hepatitis B virus (HBV) infection", "DISEASE", 210, 251], ["triphosphate", "CHEMICAL", 73, 85], ["Tenofovir alafenamide", "CHEMICAL", 94, 115], ["TAF", "CHEMICAL", 117, 120], ["Vemlidy", "CHEMICAL", 122, 129], ["adenosine nucleotide", "CHEMICAL", 142, 162], ["triphosphate", "SIMPLE_CHEMICAL", 73, 85], ["Tenofovir alafenamide", "SIMPLE_CHEMICAL", 94, 115], ["TAF", "SIMPLE_CHEMICAL", 117, 120], ["Vemlidy", "SIMPLE_CHEMICAL", 122, 129], ["adenosine nucleotide", "SIMPLE_CHEMICAL", 142, 162], ["Fig. 1 c", "SIMPLE_CHEMICAL", 165, 173], ["HIV", "ORGANISM", 210, 213], ["hepatitis B virus", "ORGANISM", 218, 235], ["HBV", "ORGANISM", 237, 240], ["CoV-2", "ORGANISM", 278, 283], ["RdRp", "ORGANISM", 284, 288], ["HIV", "SPECIES", 210, 213], ["hepatitis B virus", "SPECIES", 218, 235], ["HIV", "SPECIES", 210, 213], ["hepatitis B virus", "SPECIES", 218, 235], ["HBV", "SPECIES", 237, 240], ["Tenofovir alafenamide", "TREATMENT", 94, 115], ["TAF", "TREATMENT", 117, 120], ["Vemlidy", "TREATMENT", 122, 129], ["an acyclic adenosine nucleotide)", "TREATMENT", 131, 163], ["an FDA", "TREATMENT", 185, 191], ["HIV", "PROBLEM", 210, 213], ["hepatitis B virus", "PROBLEM", 218, 235], ["HBV) infection", "PROBLEM", 237, 251], ["evaluation", "TEST", 257, 267], ["a SARS", "TEST", 271, 277], ["CoV", "TEST", 278, 281], ["2 RdRp inhibitor", "TREATMENT", 282, 298]]], ["The results indicated that the active triphosphate form of this molecule, tenofovir diphosphate (TFV-DP), also inhibited this polymerase.", [["triphosphate", "CHEMICAL", 38, 50], ["tenofovir diphosphate", "CHEMICAL", 74, 95], ["TFV-DP", "CHEMICAL", 97, 103], ["triphosphate", "CHEMICAL", 38, 50], ["tenofovir diphosphate", "CHEMICAL", 74, 95], ["TFV-DP", "CHEMICAL", 97, 103], ["triphosphate", "SIMPLE_CHEMICAL", 38, 50], ["tenofovir diphosphate", "SIMPLE_CHEMICAL", 74, 95], ["TFV-DP", "SIMPLE_CHEMICAL", 97, 103], ["this molecule", "TREATMENT", 59, 72], ["tenofovir diphosphate", "TREATMENT", 74, 95], ["this polymerase", "PROBLEM", 121, 136]]], ["TAF, a prodrug form of the nucleotide analogue viral polymerase inhibitor, shows potent activity for HIV and HBV, but only limited inhibition of host nuclear and mitochondrial polymerases.13,14 It is activated by a series of hydrolases to the deprotected monophosphate form, TFV, and then by two consecutive kinase reactions to TFV-DP.15 TFV-DP is an acyclic nucleotide and does not have a 3\u2019-OH group.", [["nuclear", "ANATOMY", 150, 157], ["mitochondrial", "ANATOMY", 162, 175], ["nucleotide", "CHEMICAL", 27, 37], ["monophosphate", "CHEMICAL", 255, 268], ["TFV", "CHEMICAL", 275, 278], ["TFV-DP.15 TFV-DP", "CHEMICAL", 328, 344], ["nucleotide", "CHEMICAL", 359, 369], ["nucleotide", "CHEMICAL", 27, 37], ["deprotected monophosphate", "CHEMICAL", 243, 268], ["TFV", "CHEMICAL", 275, 278], ["TFV-DP", "CHEMICAL", 338, 344], ["nucleotide", "CHEMICAL", 359, 369], ["3\u2019-OH", "CHEMICAL", 390, 395], ["TAF", "GENE_OR_GENE_PRODUCT", 0, 3], ["HIV", "ORGANISM", 101, 104], ["HBV", "ORGANISM", 109, 112], ["nuclear", "CELLULAR_COMPONENT", 150, 157], ["mitochondrial", "CELLULAR_COMPONENT", 162, 175], ["monophosphate", "SIMPLE_CHEMICAL", 255, 268], ["TFV", "SIMPLE_CHEMICAL", 275, 278], ["TFV", "SIMPLE_CHEMICAL", 328, 331], ["TFV-DP", "SIMPLE_CHEMICAL", 338, 344], ["3\u2019-OH", "SIMPLE_CHEMICAL", 390, 395], ["TAF", "PROTEIN", 0, 3], ["host nuclear and mitochondrial polymerases", "PROTEIN", 145, 187], ["HIV", "SPECIES", 101, 104], ["HIV", "SPECIES", 101, 104], ["HBV", "SPECIES", 109, 112], ["TAF", "TREATMENT", 0, 3], ["the nucleotide analogue viral polymerase inhibitor", "TREATMENT", 23, 73], ["HIV", "PROBLEM", 101, 104], ["HBV", "PROBLEM", 109, 112], ["host nuclear and mitochondrial polymerases", "PROBLEM", 145, 187], ["hydrolases", "TREATMENT", 225, 235], ["the deprotected monophosphate form", "TREATMENT", 239, 273], ["TFV", "TREATMENT", 275, 278], ["TFV", "TEST", 328, 331], ["an acyclic nucleotide", "TREATMENT", 348, 369], ["mitochondrial polymerases", "OBSERVATION", 162, 187]]], ["Remarkably, this molecule is incorporated by both HIV and HBV polymerases, terminating nucleic acid elongation and viral replication.13,15 In addition, resistance mutations were rarely seen in patients treated with regimens including TAF.16 In view of the fact that the active triphosphate form of TAF, Tenofovir diphosphate, is much smaller than natural nucleoside triphosphates, we expect that it can easily fit within the active site of SARS-CoV-2 RdRp.", [["nucleic acid", "CHEMICAL", 87, 99], ["triphosphate", "CHEMICAL", 277, 289], ["Tenofovir diphosphate", "CHEMICAL", 303, 324], ["nucleoside triphosphates", "CHEMICAL", 355, 379], ["triphosphate", "CHEMICAL", 277, 289], ["Tenofovir diphosphate", "CHEMICAL", 303, 324], ["nucleoside triphosphates", "CHEMICAL", 355, 379], ["HIV", "ORGANISM", 50, 53], ["HBV", "ORGANISM", 58, 61], ["patients", "ORGANISM", 193, 201], ["TAF", "GENE_OR_GENE_PRODUCT", 234, 237], ["triphosphate", "SIMPLE_CHEMICAL", 277, 289], ["TAF", "GENE_OR_GENE_PRODUCT", 298, 301], ["Tenofovir diphosphate", "SIMPLE_CHEMICAL", 303, 324], ["nucleoside triphosphates", "SIMPLE_CHEMICAL", 355, 379], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 440, 450], ["HBV polymerases", "PROTEIN", 58, 73], ["TAF", "PROTEIN", 234, 237], ["TAF", "PROTEIN", 298, 301], ["SARS-CoV-2 RdRp", "PROTEIN", 440, 455], ["patients", "SPECIES", 193, 201], ["HIV", "SPECIES", 50, 53], ["HBV", "SPECIES", 58, 61], ["both HIV and HBV polymerases", "PROBLEM", 45, 73], ["terminating nucleic acid elongation", "PROBLEM", 75, 110], ["viral replication", "TREATMENT", 115, 132], ["resistance mutations", "PROBLEM", 152, 172], ["regimens", "TREATMENT", 215, 223], ["TAF", "TREATMENT", 234, 237], ["TAF", "TREATMENT", 298, 301], ["Tenofovir diphosphate", "TREATMENT", 303, 324], ["natural nucleoside triphosphates", "TREATMENT", 347, 379], ["SARS", "PROBLEM", 440, 444], ["CoV", "TEST", 445, 448], ["both", "OBSERVATION_MODIFIER", 45, 49], ["HIV", "OBSERVATION", 50, 53], ["HBV polymerases", "OBSERVATION", 58, 73], ["acid", "OBSERVATION_MODIFIER", 95, 99], ["elongation", "OBSERVATION_MODIFIER", 100, 110], ["viral replication", "OBSERVATION", 115, 132], ["resistance mutations", "OBSERVATION", 152, 172], ["much smaller", "OBSERVATION_MODIFIER", 329, 341], ["active", "OBSERVATION_MODIFIER", 425, 431]]], ["As a noncyclic nucleotide, TFV-DP lacks a normal sugar ring configuration, and thus we reasoned that it is unlikely to be recognized by 3\u2019-exonucleases involved in SARS-CoV-2 proofreading processes, decreasing the likelihood of developing resistance to the drug.17Results and DiscussionGiven the 98% amino acid similarity of the SARS-CoV and SARS-CoV-2 RdRps,10 we reasoned that the four nucleotide analogues listed in Fig. 1 would also inhibit the SARS-CoV-2 polymerase.", [["nucleotide", "CHEMICAL", 15, 25], ["TFV-DP", "CHEMICAL", 27, 33], ["amino acid", "CHEMICAL", 300, 310], ["SARS", "DISEASE", 329, 333], ["nucleotide", "CHEMICAL", 388, 398], ["nucleotide", "CHEMICAL", 15, 25], ["sugar", "CHEMICAL", 49, 54], ["amino acid", "CHEMICAL", 300, 310], ["nucleotide", "CHEMICAL", 388, 398], ["TFV-DP", "GENE_OR_GENE_PRODUCT", 27, 33], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 164, 174], ["amino acid", "AMINO_ACID", 300, 310], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 449, 459], ["TFV", "PROTEIN", 27, 30], ["DP", "PROTEIN", 31, 33], ["3\u2019-exonucleases", "PROTEIN", 136, 151], ["SARS-CoV and SARS-CoV-2 RdRps", "DNA", 329, 358], ["SARS-CoV-2 polymerase", "PROTEIN", 449, 470], ["SARS-CoV", "SPECIES", 329, 337], ["a noncyclic nucleotide", "TEST", 3, 25], ["SARS", "PROBLEM", 164, 168], ["the drug", "TREATMENT", 253, 261], ["the SARS", "TEST", 325, 333], ["CoV", "TEST", 334, 337], ["SARS", "TEST", 342, 346], ["CoV", "TEST", 347, 350], ["the four nucleotide analogues", "TREATMENT", 379, 408], ["the SARS", "TEST", 445, 453], ["CoV", "TEST", 454, 457], ["normal", "OBSERVATION", 42, 48], ["sugar ring", "OBSERVATION_MODIFIER", 49, 59], ["configuration", "OBSERVATION_MODIFIER", 60, 73], ["resistance", "OBSERVATION", 239, 249], ["SARS", "OBSERVATION", 449, 453]]], ["We thus assessed the ability of 2\u2019-F,Me-UTP, 3\u2019-F-dTTP, TFV-DP, and 3\u2019-N3-dTTP (the active triphosphate forms of Sofosbuvir, Alovudine, TAF and AZT, respectively), to be incorporated by SARS-CoV-2 RdRp into an RNA primer and terminate the polymerase reaction.Results and DiscussionThe RdRp of SARS-CoV-2, referred to as nsp12, and its two protein cofactors, nsp7 and nsp8, whose homologs were shown to be required for the processive polymerase activity of nsp12 in SARS-CoV,11,12 were cloned and purified as described in the Methods.", [["UTP", "CHEMICAL", 40, 43], ["3\u2019-F-dTTP", "CHEMICAL", 45, 54], ["TFV-DP", "CHEMICAL", 56, 62], ["3\u2019-N3-dTTP", "CHEMICAL", 68, 78], ["triphosphate", "CHEMICAL", 91, 103], ["Sofosbuvir", "CHEMICAL", 113, 123], ["Alovudine", "CHEMICAL", 125, 134], ["AZT", "CHEMICAL", 144, 147], ["2\u2019-F", "CHEMICAL", 32, 36], ["Me-UTP", "CHEMICAL", 37, 43], ["3\u2019-F-dTTP", "CHEMICAL", 45, 54], ["TFV-DP", "CHEMICAL", 56, 62], ["3\u2019-N3-dTTP", "CHEMICAL", 68, 78], ["triphosphate", "CHEMICAL", 91, 103], ["Sofosbuvir", "CHEMICAL", 113, 123], ["Alovudine", "CHEMICAL", 125, 134], ["AZT", "CHEMICAL", 144, 147], ["2\u2019-F", "SIMPLE_CHEMICAL", 32, 36], ["Me-UTP", "SIMPLE_CHEMICAL", 37, 43], ["3\u2019-F-dTTP", "SIMPLE_CHEMICAL", 45, 54], ["TFV-DP", "SIMPLE_CHEMICAL", 56, 62], ["3\u2019-N3-dTTP", "SIMPLE_CHEMICAL", 68, 78], ["triphosphate", "SIMPLE_CHEMICAL", 91, 103], ["Sofosbuvir", "SIMPLE_CHEMICAL", 113, 123], ["Alovudine", "SIMPLE_CHEMICAL", 125, 134], ["TAF", "GENE_OR_GENE_PRODUCT", 136, 139], ["AZT", "SIMPLE_CHEMICAL", 144, 147], ["CoV-2 RdRp", "ORGANISM", 191, 201], ["SARS-CoV-2", "ORGANISM", 293, 303], ["nsp12", "GENE_OR_GENE_PRODUCT", 320, 325], ["nsp7", "GENE_OR_GENE_PRODUCT", 358, 362], ["nsp8", "GENE_OR_GENE_PRODUCT", 367, 371], ["nsp12", "GENE_OR_GENE_PRODUCT", 456, 461], ["SARS-CoV", "ORGANISM", 465, 473], ["SARS-CoV-2 RdRp", "PROTEIN", 186, 201], ["RNA primer", "DNA", 210, 220], ["RdRp", "PROTEIN", 285, 289], ["nsp12", "DNA", 320, 325], ["protein cofactors", "PROTEIN", 339, 356], ["nsp7", "PROTEIN", 358, 362], ["nsp8", "PROTEIN", 367, 371], ["nsp12", "PROTEIN", 456, 461], ["SARS-CoV", "SPECIES", 293, 301], ["SARS-CoV", "SPECIES", 465, 473], ["UTP", "TEST", 40, 43], ["dTTP", "TEST", 50, 54], ["TFV", "TEST", 56, 59], ["DP", "TEST", 60, 62], ["dTTP", "TREATMENT", 74, 78], ["Sofosbuvir", "TREATMENT", 113, 123], ["Alovudine", "TREATMENT", 125, 134], ["TAF", "TREATMENT", 136, 139], ["AZT", "TREATMENT", 144, 147], ["an RNA primer", "TREATMENT", 207, 220], ["the polymerase reaction", "PROBLEM", 235, 258], ["SARS", "PROBLEM", 293, 297], ["CoV", "TEST", 298, 301], ["nsp12", "TEST", 320, 325], ["nsp7", "TEST", 358, 362], ["the processive polymerase activity", "PROBLEM", 418, 452], ["DP", "ANATOMY", 60, 62]]], ["These three viral gene products in SARS-CoV-2 have high homology (e.g., 96% identity and 98% similarity for nsp12, with similar homology levels at the amino acid level for nsp7 and nsp8) to the equivalent gene products from SARS-CoV, the causative agent of SARS.10Results and DiscussionWe performed polymerase extension assays with 2\u2019-F,Me-UTP, 3\u2019-F-dTTP, 3\u2019-N3-dTTP or TFV-DP + UTP, following the addition of a pre-annealed RNA template and primer to a pre-assembled mixture of the SARS-CoV-2 RdRp (nsp12) and two cofactor proteins (nsp7 and nsp8).", [["amino acid", "CHEMICAL", 151, 161], ["SARS", "DISEASE", 224, 228], ["SARS", "DISEASE", 257, 261], ["UTP", "CHEMICAL", 340, 343], ["3\u2019-F-dTTP", "CHEMICAL", 345, 354], ["3\u2019-N3-dTTP", "CHEMICAL", 356, 366], ["TFV-DP", "CHEMICAL", 370, 376], ["UTP", "CHEMICAL", 379, 382], ["amino acid", "CHEMICAL", 151, 161], ["2\u2019-F", "CHEMICAL", 332, 336], ["UTP", "CHEMICAL", 340, 343], ["3\u2019-F-dTTP", "CHEMICAL", 345, 354], ["3\u2019-N3-dTTP", "CHEMICAL", 356, 366], ["TFV-DP", "CHEMICAL", 370, 376], ["UTP", "CHEMICAL", 379, 382], ["SARS-CoV-2", "ORGANISM", 35, 45], ["nsp12", "GENE_OR_GENE_PRODUCT", 108, 113], ["amino acid", "AMINO_ACID", 151, 161], ["nsp7", "GENE_OR_GENE_PRODUCT", 172, 176], ["nsp8", "GENE_OR_GENE_PRODUCT", 181, 185], ["SARS-CoV", "ORGANISM", 224, 232], ["2\u2019-F", "SIMPLE_CHEMICAL", 332, 336], ["Me-UTP", "SIMPLE_CHEMICAL", 337, 343], ["3\u2019-F-dTTP", "SIMPLE_CHEMICAL", 345, 354], ["3\u2019-N3-dTTP", "SIMPLE_CHEMICAL", 356, 366], ["TFV-DP + UTP", "SIMPLE_CHEMICAL", 370, 382], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 483, 493], ["nsp12", "GENE_OR_GENE_PRODUCT", 500, 505], ["nsp7", "GENE_OR_GENE_PRODUCT", 534, 538], ["nsp8", "GENE_OR_GENE_PRODUCT", 543, 547], ["viral gene products", "PROTEIN", 12, 31], ["nsp12", "PROTEIN", 108, 113], ["nsp7", "PROTEIN", 172, 176], ["nsp8", "PROTEIN", 181, 185], ["DP", "DNA", 374, 376], ["pre-annealed RNA template", "DNA", 412, 437], ["SARS-CoV-2 RdRp", "PROTEIN", 483, 498], ["nsp12", "PROTEIN", 500, 505], ["cofactor proteins", "PROTEIN", 515, 532], ["nsp7", "PROTEIN", 534, 538], ["nsp8", "PROTEIN", 543, 547], ["SARS-CoV", "SPECIES", 35, 43], ["SARS-CoV", "SPECIES", 224, 232], ["CoV", "TEST", 40, 43], ["nsp12", "TEST", 108, 113], ["similar homology levels", "PROBLEM", 120, 143], ["the amino acid level", "TEST", 147, 167], ["nsp7", "TREATMENT", 172, 176], ["SARS", "PROBLEM", 224, 228], ["SARS", "PROBLEM", 257, 261], ["polymerase extension assays", "TEST", 299, 326], ["UTP", "TEST", 340, 343], ["dTTP", "TEST", 350, 354], ["dTTP", "PROBLEM", 362, 366], ["TFV", "TEST", 370, 373], ["DP", "PROBLEM", 374, 376], ["UTP", "PROBLEM", 379, 382], ["a pre-annealed RNA template", "TREATMENT", 410, 437], ["the SARS", "PROBLEM", 479, 487], ["CoV", "TEST", 488, 491], ["two cofactor proteins", "TEST", 511, 532], ["viral gene", "OBSERVATION", 12, 22], ["TFV", "ANATOMY", 370, 373], ["DP", "ANATOMY_MODIFIER", 374, 376], ["+ UTP", "OBSERVATION", 377, 382], ["SARS", "OBSERVATION", 483, 487]]], ["The extended primer products from the reaction were subjected to MALDI-TOF-MS analysis.", [["The extended primer products", "TREATMENT", 0, 28], ["the reaction", "PROBLEM", 34, 46], ["MALDI", "TEST", 65, 70], ["MS analysis", "TEST", 75, 86]]], ["The RNA template and primer, corresponding to the 3\u2019 end of the SARS-CoV-2 genome, were used for the polymerase assay, and their sequences are indicated at the top of Fig. 2.", [["RNA template", "DNA", 4, 16], ["3\u2019 end", "DNA", 50, 56], ["SARS-CoV-2 genome", "DNA", 64, 81], ["SARS-CoV", "SPECIES", 64, 72], ["The RNA template and primer", "PROBLEM", 0, 27], ["the SARS", "TEST", 60, 68], ["CoV-2 genome", "TREATMENT", 69, 81], ["the polymerase assay", "TEST", 97, 117], ["their sequences", "TEST", 123, 138], ["RNA template", "OBSERVATION", 4, 16]]], ["Because there are two A\u2019s in a row in the next available positions of the template for RNA polymerase extension downstream of the priming site, if the 2\u2019-F,Me-UTP, 3\u2019-F-dTTP or 3\u2019-N3-dTTP are incorporated by the viral RdRp, a single nucleotide analogue will be added to the 3\u2019-end of the primer strand.", [["UTP", "CHEMICAL", 159, 162], ["dTTP", "CHEMICAL", 183, 187], ["nucleotide", "CHEMICAL", 233, 243], ["2\u2019-F", "CHEMICAL", 151, 155], ["UTP", "CHEMICAL", 159, 162], ["3\u2019-F", "CHEMICAL", 164, 168], ["3\u2019-N3-dTTP", "CHEMICAL", 177, 187], ["nucleotide", "CHEMICAL", 233, 243], ["Me-UTP", "GENE_OR_GENE_PRODUCT", 156, 162], ["3\u2019-F-dTTP", "GENE_OR_GENE_PRODUCT", 164, 173], ["3\u2019-N3-dTTP", "GENE_OR_GENE_PRODUCT", 177, 187], ["RNA polymerase", "PROTEIN", 87, 101], ["priming site", "DNA", 130, 142], ["2\u2019-F,Me-UTP, 3\u2019-F-dTTP or 3\u2019-N3-dTTP", "DNA", 151, 187], ["viral RdRp", "DNA", 212, 222], ["3\u2019-end", "DNA", 274, 280], ["primer strand", "DNA", 288, 301], ["the template", "TREATMENT", 70, 82], ["RNA polymerase extension", "PROBLEM", 87, 111], ["UTP", "TEST", 159, 162], ["-dTTP", "TEST", 168, 173], ["N3-dTTP", "TREATMENT", 180, 187], ["the viral RdRp", "PROBLEM", 208, 222], ["a single nucleotide analogue", "TREATMENT", 224, 252], ["the primer strand", "TREATMENT", 284, 301], ["viral RdRp", "OBSERVATION", 212, 222]]], ["If they are indeed inhibitors of the polymerase, the extension should stop after this incorporation; further 3\u2019-extension should be prevented.", [["the polymerase", "PROBLEM", 33, 47], ["this incorporation", "TREATMENT", 81, 99], ["further 3\u2019-extension", "TREATMENT", 101, 121]]], ["Because the two A\u2019s in the template are followed by 4 U\u2019s, in the case of the TFV-DP/UTP mixture, two UTP\u2019s should be incorporated prior to the incorporation and termination by TFV-DP, which has an adenosine base.", [["TFV-DP", "CHEMICAL", 78, 84], ["UTP", "CHEMICAL", 85, 88], ["UTP", "CHEMICAL", 102, 105], ["TFV-DP", "CHEMICAL", 177, 183], ["adenosine", "CHEMICAL", 198, 207], ["TFV-DP", "CHEMICAL", 78, 84], ["UTP", "CHEMICAL", 85, 88], ["UTP", "CHEMICAL", 102, 105], ["TFV-DP", "CHEMICAL", 177, 183], ["adenosine", "CHEMICAL", 198, 207], ["TFV", "SIMPLE_CHEMICAL", 78, 81], ["UTP", "SIMPLE_CHEMICAL", 85, 88], ["UTP", "SIMPLE_CHEMICAL", 102, 105], ["TFV-DP", "SIMPLE_CHEMICAL", 177, 183], ["adenosine", "SIMPLE_CHEMICAL", 198, 207], ["DP", "PROTEIN", 82, 84], ["DP/UTP mixture", "TREATMENT", 82, 96], ["two UTP\u2019s", "TREATMENT", 98, 107], ["an adenosine base", "TREATMENT", 195, 212], ["UTP mixture", "OBSERVATION", 85, 96], ["adenosine base", "OBSERVATION", 198, 212]]], ["In the MALDI-TOF MS trace in Fig. 2a, a peak indicative of the molecular weight of a single base primer extension product with one 2\u2019-F,Me-UTP was obtained (6644 Da observed, 6634 Da expected).", [["Fig", "OBSERVATION_MODIFIER", 29, 32]]], ["Similarly, in the trace in Fig. 2b, a single extension peak indicative of a single base extension by 3\u2019-F-dTTP is revealed (6623 Da observed, 6618 Da expected), with no further incorporation.", [["a single extension peak", "TEST", 36, 59], ["a single base extension", "PROBLEM", 74, 97], ["3\u2019-F-dTTP", "TEST", 101, 110], ["further incorporation", "PROBLEM", 169, 190], ["trace", "OBSERVATION_MODIFIER", 18, 23], ["no", "UNCERTAINTY", 166, 168], ["incorporation", "OBSERVATION", 177, 190]]], ["In the trace in Fig. 2d, a single extension peak indicative of a single-base extension by 3\u2019-N3-dTTP is seen (6633 Da observed, 6641 Da expected), with no evidence of further incorporation, though the incorporation efficiency was lower than for 2\u2019-F,Me-UTP and 3\u2019-F-dTTP, which may require further optimization.", [["3\u2019-N3-dTTP", "CHEMICAL", 90, 100], ["UTP", "CHEMICAL", 253, 256], ["3\u2019-N3-dTTP", "CHEMICAL", 90, 100], ["UTP", "CHEMICAL", 253, 256], ["3\u2019-F", "CHEMICAL", 261, 265], ["3\u2019-N3-dTTP", "SIMPLE_CHEMICAL", 90, 100], ["2\u2019-F", "SIMPLE_CHEMICAL", 245, 249], ["Me-UTP", "SIMPLE_CHEMICAL", 250, 256], ["3\u2019-F-dTTP", "SIMPLE_CHEMICAL", 261, 270], ["a single extension peak", "TEST", 25, 48], ["a single-base extension", "PROBLEM", 63, 86], ["further incorporation", "PROBLEM", 167, 188], ["the incorporation efficiency", "PROBLEM", 197, 225], ["UTP", "TEST", 253, 256], ["3\u2019-F-dTTP", "PROBLEM", 261, 270], ["further optimization", "TREATMENT", 290, 310], ["trace", "OBSERVATION_MODIFIER", 7, 12], ["base", "ANATOMY_MODIFIER", 72, 76], ["no evidence of", "UNCERTAINTY", 152, 166], ["incorporation", "OBSERVATION", 175, 188]]], ["Finally, in the trace in Fig. 2c, a peak indicative of the molecular weight of a primer extension product formed by incorporating 2 U\u2019s and 1 TFV is found (7198 Da observed, 7193 Da expected), in addition to other peaks representing partial incorporation (1 U, 6623 Da observed, 6618 Da expected) or misincorporation (3 U\u2019s, 7235 Da observed, 7230 Da expected).", [["trace", "OBSERVATION_MODIFIER", 16, 21], ["partial", "OBSERVATION_MODIFIER", 233, 240], ["incorporation", "OBSERVATION", 241, 254]]], ["Importantly, once the TFV-DP was incorporated, there was no further extension, indicating it was a permanent terminator.Results and DiscussionIn summary, these results demonstrate that the nucleotide analogues 2\u2019-F,Me-UTP, 3\u2019-F-dTTP, 3\u2019-N3-dTTP, and TFV-DP are permanent terminators for the SARS-CoV-2 RdRp.", [["TFV-DP", "CHEMICAL", 22, 28], ["nucleotide", "CHEMICAL", 189, 199], ["2\u2019-F,Me-UTP, 3\u2019-F-dTTP", "CHEMICAL", 210, 232], ["nucleotide", "CHEMICAL", 189, 199], ["2\u2019-F", "CHEMICAL", 210, 214], ["UTP", "CHEMICAL", 218, 221], ["3\u2019-F-dTTP", "CHEMICAL", 223, 232], ["3\u2019-N3-dTTP", "CHEMICAL", 234, 244], ["TFV-DP", "CHEMICAL", 250, 256], ["TFV-DP", "GENE_OR_GENE_PRODUCT", 22, 28], ["2\u2019-F", "SIMPLE_CHEMICAL", 210, 214], ["Me-UTP", "SIMPLE_CHEMICAL", 215, 221], ["3\u2019-F-dTTP", "SIMPLE_CHEMICAL", 223, 232], ["3\u2019-N3-dTTP", "SIMPLE_CHEMICAL", 234, 244], ["TFV-DP", "SIMPLE_CHEMICAL", 250, 256], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 291, 301], ["TFV", "PROTEIN", 22, 25], ["DP", "PROTEIN", 26, 28], ["F-dTTP, 3\u2019-N3-dTTP, and TFV-DP", "DNA", 226, 256], ["SARS-CoV-2 RdRp", "DNA", 291, 306], ["further extension", "PROBLEM", 60, 77], ["a permanent terminator", "TREATMENT", 97, 119], ["the nucleotide analogues", "TEST", 185, 209], ["Me", "TEST", 215, 217], ["UTP", "TEST", 218, 221], ["dTTP", "TEST", 228, 232], ["N3", "TEST", 237, 239], ["TTP", "TEST", 241, 244], ["TFV", "TEST", 250, 253], ["permanent terminators", "TREATMENT", 261, 282], ["the SARS", "TEST", 287, 295], ["CoV", "TEST", 296, 299], ["no", "UNCERTAINTY", 57, 59], ["permanent", "OBSERVATION", 261, 270]]], ["Their prodrug versions (Sofosbuvir, 3\u2019- F-5\u2019-O-phosphoramidate dT nucleoside, 3\u2019-N3-5\u2019-O-phosphoramidate dT nucleoside, and TAF) are available or can be readily synthesized using the ProTide prodrug approach,18 as shown in Fig. 1 a\u2013d, and can be developed as therapeutics for COVID-19.", [["Sofosbuvir", "CHEMICAL", 24, 34], ["3\u2019- F-5\u2019-O-phosphoramidate dT nucleoside, 3\u2019-N3-5\u2019-O-phosphoramidate dT nucleoside", "CHEMICAL", 36, 118], ["Sofosbuvir", "CHEMICAL", 24, 34], ["3\u2019- F-5\u2019-O-phosphoramidate dT nucleoside", "CHEMICAL", 36, 76], ["3\u2019-N3-5\u2019-O-phosphoramidate", "CHEMICAL", 78, 104], ["nucleoside", "CHEMICAL", 108, 118], ["ProTide", "CHEMICAL", 183, 190], ["COVID-19", "CHEMICAL", 276, 284], ["Sofosbuvir", "SIMPLE_CHEMICAL", 24, 34], ["3\u2019- F-5\u2019-O-phosphoramidate dT nucleoside, 3\u2019-N3-5\u2019-O-phosphoramidate dT nucleoside", "SIMPLE_CHEMICAL", 36, 118], ["TAF", "SIMPLE_CHEMICAL", 124, 127], ["ProTide", "SIMPLE_CHEMICAL", 183, 190], ["TAF", "PROTEIN", 124, 127], ["Their prodrug versions", "TREATMENT", 0, 22], ["Sofosbuvir", "TREATMENT", 24, 34], ["phosphoramidate dT nucleoside", "TREATMENT", 47, 76], ["N3", "TREATMENT", 81, 83], ["phosphoramidate dT nucleoside", "TREATMENT", 89, 118], ["TAF", "TREATMENT", 124, 127], ["the ProTide prodrug approach", "TREATMENT", 179, 207], ["COVID", "TEST", 276, 281]]], ["Importantly, since Sofosbuvir, Tenofovir and AZT are widely available FDA approved drugs, they can be evaluated quickly in laboratory and clinical settings for COVID-19 treatment.SARS-CoV-2 nsp12: ::: Recombinant Protein Expression of RdRp (nsp12) and cofactors (nsp7 and nsp8) from SARS-CoV-2. ::: MethodsThe SARS-CoV-2 sp12 gene was codon optimized and cloned into pFastBac with C-terminal additions of a TEV site and strep tag (Genscript).", [["Sofosbuvir", "CHEMICAL", 19, 29], ["Tenofovir", "CHEMICAL", 31, 40], ["AZT", "CHEMICAL", 45, 48], ["COVID-19", "CHEMICAL", 160, 168], ["Sofosbuvir", "CHEMICAL", 19, 29], ["Tenofovir", "CHEMICAL", 31, 40], ["AZT", "CHEMICAL", 45, 48], ["COVID-19", "CHEMICAL", 160, 168], ["C", "CHEMICAL", 381, 382], ["Sofosbuvir", "SIMPLE_CHEMICAL", 19, 29], ["Tenofovir", "SIMPLE_CHEMICAL", 31, 40], ["AZT", "SIMPLE_CHEMICAL", 45, 48], ["RdRp", "GENE_OR_GENE_PRODUCT", 235, 239], ["nsp12", "GENE_OR_GENE_PRODUCT", 241, 246], ["nsp7", "GENE_OR_GENE_PRODUCT", 263, 267], ["nsp8", "GENE_OR_GENE_PRODUCT", 272, 276], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 310, 320], ["sp12", "GENE_OR_GENE_PRODUCT", 321, 325], ["pFastBac", "GENE_OR_GENE_PRODUCT", 367, 375], ["SARS-CoV-2 nsp12", "DNA", 179, 195], ["RdRp", "PROTEIN", 235, 239], ["nsp12", "PROTEIN", 241, 246], ["cofactors", "PROTEIN", 252, 261], ["nsp7", "PROTEIN", 263, 267], ["nsp8", "PROTEIN", 272, 276], ["SARS-CoV-2 sp12 gene", "DNA", 310, 330], ["C-terminal additions", "DNA", 381, 401], ["TEV site", "DNA", 407, 415], ["strep tag", "DNA", 420, 429], ["SARS-CoV", "SPECIES", 283, 291], ["SARS-CoV", "SPECIES", 310, 318], ["Sofosbuvir", "TREATMENT", 19, 29], ["Tenofovir", "TREATMENT", 31, 40], ["AZT", "TREATMENT", 45, 48], ["drugs", "TREATMENT", 83, 88], ["COVID-19 treatment", "TREATMENT", 160, 178], ["SARS", "TEST", 179, 183], ["CoV", "TEST", 184, 187], ["RdRp", "TEST", 235, 239], ["cofactors (nsp7 and nsp8)", "PROBLEM", 252, 277], ["SARS", "PROBLEM", 283, 287], ["Methods", "TEST", 299, 306], ["The SARS", "TEST", 306, 314], ["CoV", "TEST", 315, 318], ["codon optimized", "TREATMENT", 335, 350], ["a TEV site", "TREATMENT", 405, 415], ["strep tag", "TEST", 420, 429]]], ["The pFastBac plasmid and DH10Bac E. coli (Life Technologies) were used to create recombinant bacmids.", [["pFastBac", "GENE_OR_GENE_PRODUCT", 4, 12], ["DH10Bac E. coli", "ORGANISM", 25, 40], ["pFastBac plasmid", "DNA", 4, 20], ["recombinant bacmids", "PROTEIN", 81, 100], ["E. coli", "SPECIES", 33, 40], ["E. coli", "SPECIES", 33, 40], ["The pFastBac plasmid", "TREATMENT", 0, 20], ["DH10Bac E. coli (Life Technologies", "TREATMENT", 25, 59], ["recombinant bacmids", "TREATMENT", 81, 100], ["E. coli", "OBSERVATION", 33, 40]]], ["The bacmid was transfected into Sf9 cells (Expression Systems) with Cellfectin II (Life Technologies) to generate recombinant baculovirus.", [["Sf9 cells", "ANATOMY", 32, 41], ["Cellfectin II", "CHEMICAL", 68, 81], ["Sf9 cells", "CELL", 32, 41], ["Cellfectin II", "GENE_OR_GENE_PRODUCT", 68, 81], ["baculovirus", "ORGANISM", 126, 137], ["Sf9 cells", "CELL_LINE", 32, 41], ["Cellfectin II", "PROTEIN", 68, 81], ["recombinant baculovirus", "PROTEIN", 114, 137], ["Sf9", "SPECIES", 32, 35], ["baculovirus", "SPECIES", 126, 137], ["The bacmid", "TREATMENT", 0, 10], ["Cellfectin II (Life Technologies", "TREATMENT", 68, 100], ["recombinant baculovirus", "TREATMENT", 114, 137]]], ["The baculovirus was amplified through two passages in Sf9 cells, and then used to infect 1 L of Sf21 cells (Expression Systems) and incubated for 48 hrs at 27\u00b0C. Cells were harvested by centrifugation, resuspended in wash buffer (25 mM HEPES pH 7.4, 300 mM NaCl, 1 mM MgCl2, 5 mM DTT) with 143 \u03bcL of BioLock per liter of culture.", [["Sf9 cells", "ANATOMY", 54, 63], ["Sf21 cells", "ANATOMY", 96, 106], ["Cells", "ANATOMY", 162, 167], ["NaCl", "CHEMICAL", 257, 261], ["NaCl", "CHEMICAL", 257, 261], ["MgCl2", "CHEMICAL", 268, 273], ["DTT", "CHEMICAL", 280, 283], ["baculovirus", "ORGANISM", 4, 15], ["Sf9 cells", "CELL", 54, 63], ["Sf21 cells", "CELL", 96, 106], ["Cells", "CELL", 162, 167], ["Sf9 cells", "CELL_LINE", 54, 63], ["Sf21 cells", "CELL_LINE", 96, 106], ["baculovirus", "SPECIES", 4, 15], ["Sf9", "SPECIES", 54, 57], ["The baculovirus", "TREATMENT", 0, 15], ["two passages in Sf9 cells", "TREATMENT", 38, 63], ["HEPES pH", "TEST", 236, 244], ["NaCl", "TEST", 257, 261], ["MgCl2", "TEST", 268, 273], ["DTT", "TEST", 280, 283], ["BioLock", "TREATMENT", 300, 307], ["culture", "TEST", 321, 328], ["Sf9 cells", "OBSERVATION", 54, 63]]], ["Cells were lysed via microfluidization (Microfluidics).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5]]], ["Lysates were cleared by centrifugation and filtration.", [["Lysates", "ANATOMY", 0, 7], ["Lysates", "ORGANISM_SUBSTANCE", 0, 7], ["Lysates", "TEST", 0, 7]]], ["The protein was purified using Strep Tactin superflow agarose (IBA).", [["agarose", "SIMPLE_CHEMICAL", 54, 61], ["IBA", "SIMPLE_CHEMICAL", 63, 66], ["The protein", "TEST", 0, 11], ["Strep Tactin superflow agarose", "TREATMENT", 31, 61]]], ["Strep Tactin eluted protein was further purified by size exclusion chromatography using a Superdex 200 Increase 10/300 column (GE Life Sciences) in 25 mM HEPES, 300 mM NaCl, 100 \u03bcM MgCl2, 2 mM TCEP, at pH 7.4.", [["NaCl", "CHEMICAL", 168, 172], ["MgCl2", "CHEMICAL", 181, 186], ["HEPES", "CHEMICAL", 154, 159], ["NaCl", "CHEMICAL", 168, 172], ["MgCl2", "CHEMICAL", 181, 186], ["TCEP", "CHEMICAL", 193, 197], ["TCEP", "SIMPLE_CHEMICAL", 193, 197], ["Strep Tactin eluted protein", "PROTEIN", 0, 27], ["Strep Tactin eluted protein", "PROBLEM", 0, 27], ["a Superdex", "TREATMENT", 88, 98], ["25 mM HEPES", "TREATMENT", 148, 159], ["300 mM NaCl", "TREATMENT", 161, 172], ["2 mM TCEP", "TREATMENT", 188, 197], ["pH", "TEST", 202, 204]]], ["Pure protein was concentrated by ultrafiltration prior to flash freezing in liquid nitrogen.SARS-CoV-2 nsp7 and nsp8: ::: Recombinant Protein Expression of RdRp (nsp12) and cofactors (nsp7 and nsp8) from SARS-CoV-2. ::: MethodsThe SARS-CoV-2 nsp7 and nsp8 genes were codon optimized and cloned into pET46 (Novagen) with an N-terminal 6x histidine tag, an enterokinase site, and a TEV protease site.", [["SARS", "DISEASE", 92, 96], ["nitrogen", "CHEMICAL", 83, 91], ["N", "CHEMICAL", 323, 324], ["histidine", "CHEMICAL", 337, 346], ["SARS-CoV-2 nsp7", "GENE_OR_GENE_PRODUCT", 92, 107], ["nsp8", "GENE_OR_GENE_PRODUCT", 112, 116], ["RdRp", "GENE_OR_GENE_PRODUCT", 156, 160], ["nsp12", "GENE_OR_GENE_PRODUCT", 162, 167], ["nsp7", "GENE_OR_GENE_PRODUCT", 184, 188], ["nsp8", "GENE_OR_GENE_PRODUCT", 193, 197], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 231, 241], ["nsp7", "GENE_OR_GENE_PRODUCT", 242, 246], ["nsp8", "GENE_OR_GENE_PRODUCT", 251, 255], ["pET46", "GENE_OR_GENE_PRODUCT", 299, 304], ["Novagen", "GENE_OR_GENE_PRODUCT", 306, 313], ["enterokinase", "GENE_OR_GENE_PRODUCT", 355, 367], ["SARS-CoV-2 nsp7", "DNA", 92, 107], ["nsp8", "DNA", 112, 116], ["RdRp", "PROTEIN", 156, 160], ["nsp12", "PROTEIN", 162, 167], ["cofactors", "PROTEIN", 173, 182], ["nsp7", "PROTEIN", 184, 188], ["nsp8", "PROTEIN", 193, 197], ["SARS-CoV-2 nsp7 and nsp8 genes", "DNA", 231, 261], ["pET46", "DNA", 299, 304], ["Novagen", "DNA", 306, 313], ["N-terminal 6x histidine tag", "DNA", 323, 350], ["enterokinase site", "DNA", 355, 372], ["TEV protease site", "DNA", 380, 397], ["SARS-CoV", "SPECIES", 204, 212], ["SARS-CoV", "SPECIES", 231, 239], ["ultrafiltration", "TREATMENT", 33, 48], ["flash freezing in liquid nitrogen", "TREATMENT", 58, 91], ["SARS", "TEST", 92, 96], ["CoV", "TEST", 97, 100], ["RdRp (nsp12", "TEST", 156, 167], ["cofactors", "TEST", 173, 182], ["nsp7", "TEST", 184, 188], ["SARS", "PROBLEM", 204, 208], ["Methods", "TEST", 220, 227], ["The SARS", "TEST", 227, 235], ["CoV", "TEST", 236, 239], ["nsp8 genes", "TREATMENT", 251, 261], ["codon", "TREATMENT", 267, 272], ["an N-terminal 6x histidine tag", "TREATMENT", 320, 350], ["an enterokinase site", "TREATMENT", 352, 372], ["a TEV protease site", "TREATMENT", 378, 397], ["liquid nitrogen", "OBSERVATION", 76, 91]]], ["Rosetta2 pLys E. coli cells (Novagen) were used for bacterial expression.", [["cells", "ANATOMY", 22, 27], ["E. coli cells", "CELL", 14, 27], ["Novagen", "GENE_OR_GENE_PRODUCT", 29, 36], ["Rosetta2 pLys E. coli cells", "CELL_LINE", 0, 27], ["Novagen", "PROTEIN", 29, 36], ["E. coli", "SPECIES", 14, 21], ["E. coli", "SPECIES", 14, 21], ["E. coli cells (Novagen)", "TREATMENT", 14, 37], ["bacterial expression", "PROBLEM", 52, 72], ["coli cells", "OBSERVATION", 17, 27]]], ["After induction with isopropyl \u03b2-D-1-thiogalactopyranoside (IPTG), cultures were grown at 16\u00b0C for 16 hrs.", [["isopropyl \u03b2-D-1-thiogalactopyranoside", "CHEMICAL", 21, 58], ["IPTG", "CHEMICAL", 60, 64], ["isopropyl \u03b2-D-1-thiogalactopyranoside", "CHEMICAL", 21, 58], ["IPTG", "CHEMICAL", 60, 64], ["isopropyl \u03b2-D-1-thiogalactopyranoside", "SIMPLE_CHEMICAL", 21, 58], ["IPTG", "SIMPLE_CHEMICAL", 60, 64], ["isopropyl", "TREATMENT", 21, 30], ["thiogalactopyranoside (IPTG", "TREATMENT", 37, 64], ["cultures", "TEST", 67, 75]]], ["Cells were harvested by centrifugation and pellets were resuspended in wash buffer (10mM Tris pH 8.0, 300 mM NaCl, 30 mM imidazole, 2 mM DTT).", [["Cells", "ANATOMY", 0, 5], ["NaCl", "CHEMICAL", 109, 113], ["imidazole", "CHEMICAL", 121, 130], ["NaCl", "CHEMICAL", 109, 113], ["imidazole", "CHEMICAL", 121, 130], ["DTT", "CHEMICAL", 137, 140], ["Cells", "CELL", 0, 5], ["pellets", "TREATMENT", 43, 50], ["Tris pH", "TEST", 89, 96], ["NaCl", "TEST", 109, 113], ["30 mM imidazole", "TREATMENT", 115, 130]]], ["Cells were lysed via microfluidization and lysates were cleared by centrifugation and filtration.", [["Cells", "ANATOMY", 0, 5], ["lysates", "ANATOMY", 43, 50], ["Cells", "CELL", 0, 5], ["lysates", "ORGANISM_SUBSTANCE", 43, 50], ["Cells", "TEST", 0, 5], ["microfluidization", "TREATMENT", 21, 38], ["lysates", "TEST", 43, 50], ["filtration", "TEST", 86, 96]]], ["Proteins were purified using Ni-NTA agarose beads and eluted with wash buffer containing 300 mM imidazole.", [["Ni-NTA", "CHEMICAL", 29, 35], ["imidazole", "CHEMICAL", 96, 105], ["Ni-NTA", "CHEMICAL", 29, 35], ["imidazole", "CHEMICAL", 96, 105], ["imidazole", "SIMPLE_CHEMICAL", 96, 105], ["Proteins", "TEST", 0, 8], ["Ni-NTA agarose beads", "TREATMENT", 29, 49], ["wash buffer", "TREATMENT", 66, 77], ["300 mM imidazole", "TREATMENT", 89, 105]]], ["Eluted proteins were further purified by size exclusion chromatography using a Superdex 200 Increase 10/300 column (GE Life Sciences).", [["Eluted proteins", "PROBLEM", 0, 15], ["size exclusion chromatography", "TEST", 41, 70], ["a Superdex", "TREATMENT", 77, 87]]], ["Purified proteins were concentrated by ultrafiltration prior to flash freezing with liquid nitrogen.Extension reactions with RNA-dependent RNA polymerase. ::: MethodsOligonucleotides were purchased from IDT, Inc. The primer and template (sequences shown in Fig. 2) were annealed by heating to 70\u00b0C for 10 min and cooling to room temperature in 1x reaction buffer.", [["nitrogen", "CHEMICAL", 91, 99], ["MethodsOligonucleotides", "SIMPLE_CHEMICAL", 159, 182], ["Purified proteins", "PROTEIN", 0, 17], ["RNA-dependent RNA polymerase", "PROTEIN", 125, 153], ["ultrafiltration", "TREATMENT", 39, 54], ["flash freezing with liquid nitrogen", "TREATMENT", 64, 99], ["Extension reactions", "PROBLEM", 100, 119], ["RNA-dependent RNA polymerase", "PROBLEM", 125, 153], ["MethodsOligonucleotides", "TREATMENT", 159, 182], ["The primer and template (sequences", "TEST", 213, 247], ["dependent", "OBSERVATION_MODIFIER", 129, 138], ["RNA polymerase", "OBSERVATION", 139, 153]]], ["The RNA polymerase mixture consisting of 6 \u03bcM nsp12 and 18 \u03bcM each of cofactors nsp7 and nsp8 was incubated for 15 min at room temperature in a 1:3:3 ratio in 1x reaction buffer.", [["nsp7", "GENE_OR_GENE_PRODUCT", 80, 84], ["nsp8", "GENE_OR_GENE_PRODUCT", 89, 93], ["nsp12", "PROTEIN", 46, 51], ["nsp7", "PROTEIN", 80, 84], ["nsp8", "PROTEIN", 89, 93], ["The RNA polymerase mixture", "TEST", 0, 26], ["nsp12", "TEST", 46, 51], ["cofactors nsp7", "TEST", 70, 84]]], ["Then 5 \u03bcl of the annealed template primer solution containing 2 \u03bcM template and 1.7 \u03bcM primer in 1x reaction buffer was added to 10 \u03bcl of the RNA polymerase mixture and incubated for an additional 10 min at room temperature.", [["the annealed template primer solution", "TREATMENT", 13, 50], ["2 \u03bcM template", "TREATMENT", 62, 75], ["\u03bcM primer", "TREATMENT", 84, 93], ["1x reaction buffer", "TREATMENT", 97, 115], ["the RNA polymerase mixture", "TREATMENT", 138, 164]]], ["Finally 5 \u03bcl of a solution containing either 2 mM 2\u2019-F,Me-UTP (a), 2 mM 3\u2019-F-dTTP (b), 2 mM TFV-DP and 20 \u03bcM UTP (c) or 3\u2019-N3-dTTP (d) in 1x reaction buffer was added, and incubation was carried out for 2 hrs at 30\u00b0C. The final concentrations of reagents in the 20 \u03bcl extension reactions were 3 \u03bcM nsp12, 9 \u03bcM nsp7, 9 \u03bcM nsp8, 425 nM RNA primer, 500 nM RNA template, either 500 \u03bcM 2\u2019-F,Me-UTP (Sierra Bioresearch), 500 \u03bcM 3\u2019-F-dTTP (Amersham Life Sciences), 500 \u03bcM TFV-DP/50 \u03bcM UTP or 500 \u03bcM 3\u2019-N3-dTTP (Amersham Life Sciences), and 1x reaction buffer (10 mM Tris-HCl pH 8, 10 mM KCl, 2 mM MgCl2 and 1 mM \u03b2-mercaptoethanol).", [["UTP", "CHEMICAL", 58, 61], ["3\u2019-F-dTTP", "CHEMICAL", 72, 81], ["TFV-DP", "CHEMICAL", 92, 98], ["UTP", "CHEMICAL", 109, 112], ["UTP", "CHEMICAL", 389, 392], ["3\u2019-F-dTTP", "CHEMICAL", 422, 431], ["UTP", "CHEMICAL", 478, 481], ["Tris-HCl", "CHEMICAL", 559, 567], ["KCl", "CHEMICAL", 580, 583], ["MgCl2", "CHEMICAL", 590, 595], ["\u03b2-mercaptoethanol", "CHEMICAL", 605, 622], ["2\u2019-F", "CHEMICAL", 50, 54], ["UTP", "CHEMICAL", 58, 61], ["3\u2019-F-dTTP", "CHEMICAL", 72, 81], ["TFV-DP", "CHEMICAL", 92, 98], ["UTP", "CHEMICAL", 109, 112], ["3\u2019-N3-dTTP", "CHEMICAL", 120, 130], ["UTP", "CHEMICAL", 389, 392], ["3\u2019-F-dTTP", "CHEMICAL", 422, 431], ["TFV-DP", "CHEMICAL", 465, 471], ["UTP", "CHEMICAL", 478, 481], ["3\u2019-N3-dTTP", "CHEMICAL", 492, 502], ["Tris-HCl", "CHEMICAL", 559, 567], ["KCl", "CHEMICAL", 580, 583], ["MgCl2", "CHEMICAL", 590, 595], ["\u03b2-mercaptoethanol", "CHEMICAL", 605, 622], ["2\u2019-F", "SIMPLE_CHEMICAL", 50, 54], ["Me-UTP", "SIMPLE_CHEMICAL", 55, 61], ["3\u2019-F-dTTP", "SIMPLE_CHEMICAL", 72, 81], ["TFV-DP", "SIMPLE_CHEMICAL", 92, 98], ["UTP (c)", "SIMPLE_CHEMICAL", 109, 116], ["3\u2019-N3-dTTP", "SIMPLE_CHEMICAL", 120, 130], ["Me-UTP", "SIMPLE_CHEMICAL", 386, 392], ["UTP", "SIMPLE_CHEMICAL", 478, 481], ["\u03b2-mercaptoethanol", "SIMPLE_CHEMICAL", 605, 622], ["a solution", "TREATMENT", 16, 26], ["UTP", "TEST", 58, 61], ["dTTP", "TEST", 77, 81], ["TFV", "TEST", 92, 95], ["DP", "TEST", 96, 98], ["UTP", "TEST", 109, 112], ["N3-dTTP (d) in 1x reaction buffer", "TREATMENT", 123, 156], ["nsp12", "TEST", 298, 303], ["nsp8", "TEST", 321, 325], ["RNA primer", "TEST", 334, 344], ["RNA template", "TEST", 353, 365], ["UTP", "TEST", 389, 392], ["TFV", "TEST", 465, 468], ["UTP", "TEST", 478, 481], ["TTP", "PROBLEM", 499, 502], ["Tris", "TEST", 559, 563], ["HCl pH", "TEST", 564, 570], ["10 mM KCl", "TREATMENT", 574, 583], ["2 mM MgCl2", "TREATMENT", 585, 595], ["1 mM \u03b2-mercaptoethanol", "TREATMENT", 600, 622], ["DP", "ANATOMY", 96, 98]]], ["Following desalting using an Oligo Clean & Concentrator (Zymo Research), the samples were subjected to MALDI-TOF-MS (Bruker ultrafleXtreme) analysis.", [["samples", "ANATOMY", 77, 84], ["an Oligo Clean & Concentrator (Zymo Research", "TREATMENT", 26, 70], ["the samples", "TEST", 73, 84], ["MALDI", "TEST", 103, 108], ["MS", "PROBLEM", 113, 115]]]], "be88be39b2b5b24106f788c0d5346833c35aeaac": [["Role of the funding sourceThis study was sponsored by the Bill & Melinda Gates FoundationIntroductionCOVID-19 is a rising infectious disease that poses a great challenge to global public health.", [["infectious disease", "DISEASE", 122, 140], ["This study", "TEST", 26, 36], ["a rising infectious disease", "PROBLEM", 113, 140], ["rising", "OBSERVATION_MODIFIER", 115, 121], ["infectious", "OBSERVATION", 122, 132]]], ["As of 10 July 2020, there were 85,445 confirmed cases in China and 4,648 deaths occurred.", [["deaths", "DISEASE", 73, 79]]], ["Wuhan, the epicenter of the outbreak, have accounted for 58.9% of the total number of cases and 83.2% of the deaths in China.", [["deaths", "DISEASE", 109, 115]]], ["Cui et al. 1 have found that air pollution can affect the case fatality rate (CFR) of severe acute respiratory syndrome (SARS).", [["acute respiratory syndrome", "DISEASE", 93, 119], ["SARS", "DISEASE", 121, 125], ["air pollution", "PROBLEM", 29, 42], ["severe acute respiratory syndrome", "PROBLEM", 86, 119], ["air pollution", "OBSERVATION", 29, 42], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["respiratory syndrome", "OBSERVATION", 99, 119]]], ["The COVID-19 is a respiratory disease with a specific level of likeness to SARS, and there could likewise be a connection between the CFR and air pollution 2 .IntroductionFattorini et al. 3 demonstrated that long-term air-quality data had a significant association with the confirmed number of COVID-19 cases in 71 provinces of Italy, suggesting a favorable context for the spread of the SARS-CoV-2 due to air pollution.IntroductionCoccia et al. 4 came to a similar conclusion that polluted cities in Italy had a very high number of infected people of COVID-19.", [["respiratory", "ANATOMY", 18, 29], ["respiratory disease", "DISEASE", 18, 37], ["SARS", "DISEASE", 75, 79], ["SARS", "DISEASE", 388, 392], ["SARS-CoV-2", "ORGANISM", 388, 398], ["people", "ORGANISM", 542, 548], ["people", "SPECIES", 542, 548], ["COVID-19", "SPECIES", 4, 12], ["SARS-CoV", "SPECIES", 388, 396], ["The COVID", "TEST", 0, 9], ["a respiratory disease", "PROBLEM", 16, 37], ["SARS", "PROBLEM", 75, 79], ["a connection between the CFR and air pollution", "PROBLEM", 109, 155], ["long-term air-quality data", "PROBLEM", 208, 234], ["COVID", "TEST", 294, 299], ["the SARS", "PROBLEM", 384, 392], ["CoV", "TEST", 393, 396], ["air pollution", "PROBLEM", 406, 419], ["COVID", "TEST", 552, 557], ["respiratory disease", "OBSERVATION", 18, 37], ["air pollution", "OBSERVATION", 142, 155], ["air pollution", "OBSERVATION", 406, 419], ["polluted", "OBSERVATION", 482, 490], ["very", "OBSERVATION_MODIFIER", 513, 517], ["high", "OBSERVATION_MODIFIER", 518, 522], ["infected", "OBSERVATION", 533, 541]]], ["Since the association between air pollution and COVID-19 infections has been well described, this study aims to investigate the temporal association between the CFR of COVID-19 and PM concentration (the primary air pollutant in China) in Wuhan.Study areaWe conducted a study to examine the association of PM 2.5 /PM 10 concentrations and the CFR of COVID-19 in Wuhan of China.Data and sourcesThe data of confirmed cases and deaths on COVID-19 were obtained from theData analysis procedureWe conducted a time series analysis to examine the association of PM 2.5 and PM 10 concentrations with the CFR of COVID-19 in Wuhan by using multivariate linear regression, with adjustment for temperature, relative humidity, concentrations of sulfur dioxide (SO 2 ), nitrogen dioxide (NO 2 ), carbon monoxide (CO), and ozone (O 3 ).Data analysis procedureBecause of the lockdown of Wuhan and the short study period, we assumed very little changes on either the total number of the population or its age and gender composition.", [["infections", "DISEASE", 57, 67], ["COVID-19", "CHEMICAL", 168, 176], ["COVID-19", "CHEMICAL", 349, 357], ["deaths", "DISEASE", 424, 430], ["sulfur dioxide", "CHEMICAL", 731, 745], ["SO 2", "CHEMICAL", 747, 751], ["nitrogen dioxide", "CHEMICAL", 755, 771], ["NO", "CHEMICAL", 773, 775], ["carbon monoxide", "CHEMICAL", 781, 796], ["CO", "CHEMICAL", 798, 800], ["ozone", "CHEMICAL", 807, 812], ["sulfur dioxide", "CHEMICAL", 731, 745], ["SO 2", "CHEMICAL", 747, 751], ["nitrogen dioxide", "CHEMICAL", 755, 771], ["NO 2", "CHEMICAL", 773, 777], ["carbon monoxide", "CHEMICAL", 781, 796], ["CO", "CHEMICAL", 798, 800], ["ozone", "CHEMICAL", 807, 812], ["O 3", "CHEMICAL", 814, 817], ["PM", "SIMPLE_CHEMICAL", 181, 183], ["sulfur dioxide", "SIMPLE_CHEMICAL", 731, 745], ["SO 2", "SIMPLE_CHEMICAL", 747, 751], ["nitrogen dioxide", "SIMPLE_CHEMICAL", 755, 771], ["NO 2", "SIMPLE_CHEMICAL", 773, 777], ["carbon monoxide", "SIMPLE_CHEMICAL", 781, 796], ["CO", "SIMPLE_CHEMICAL", 798, 800], ["ozone", "SIMPLE_CHEMICAL", 807, 812], ["air pollution", "TEST", 30, 43], ["COVID-19 infections", "PROBLEM", 48, 67], ["this study", "TEST", 93, 103], ["COVID", "TEST", 168, 173], ["PM concentration", "TREATMENT", 181, 197], ["a study", "TEST", 267, 274], ["the CFR", "TEST", 338, 345], ["COVID", "TEST", 349, 354], ["COVID", "TEST", 434, 439], ["the CFR", "TEST", 591, 598], ["COVID", "TEST", 602, 607], ["temperature", "TREATMENT", 681, 692], ["relative humidity", "TREATMENT", 694, 711], ["sulfur dioxide", "TREATMENT", 731, 745], ["nitrogen dioxide", "TREATMENT", 755, 771], ["carbon monoxide (CO)", "TREATMENT", 781, 801], ["Data analysis", "TEST", 820, 833], ["the short study", "TEST", 880, 895], ["air pollution", "OBSERVATION", 30, 43], ["air pollutant", "OBSERVATION", 211, 224], ["very", "OBSERVATION_MODIFIER", 915, 919], ["little", "OBSERVATION_MODIFIER", 920, 926], ["changes", "OBSERVATION", 927, 934]]], ["We also examined the lag effects and patterns of PM 2.5 and PM 10 on the CFR of COVID -19 by analyzing the association between the CFR and single-day daily average PM concentrations on the current day (lag0) and up to 5 days (lag1-lag5) before the date of infection.ResultsAs illustrated in Fig.1A , there was a delay of approximately 21 days between the peak of newly diagnosed cases and the peak of daily COVID-19 deaths, which was in line with our prior estimation.", [["infection", "DISEASE", 256, 265], ["deaths", "DISEASE", 416, 422], ["the CFR", "TEST", 69, 76], ["COVID", "TEST", 80, 85], ["the CFR", "TEST", 127, 134], ["infection", "PROBLEM", 256, 265], ["infection", "OBSERVATION", 256, 265]]], ["From January 19 to March 15, 2020, the daily CFR \u03bcg/m 3 ); the mean daily temperature and relative humidity were 7.18\u00b0C and 81.37%, respectively (range, 1.8\u00b0C-18.7\u00b0C and 59.0%-93.0%).", [["the mean daily temperature", "TEST", 59, 85], ["relative humidity", "TEST", 90, 107], ["C", "TEST", 118, 119], ["C", "TEST", 157, 158], ["C", "TEST", 164, 165]]], ["As shown in Fig.1B , we found that the daily concentrations of PM 2.5 and PM 10 changed synchronously and were very similar.", [["very", "OBSERVATION_MODIFIER", 111, 115], ["similar", "OBSERVATION_MODIFIER", 116, 123]]], ["We also found that the two air pollutants and the daily CFR exhibited great 8 similarity with respect to their temporal variation curves.", [["the two air pollutants", "PROBLEM", 19, 41], ["the daily CFR", "TEST", 46, 59], ["two", "OBSERVATION_MODIFIER", 23, 26], ["air pollutants", "OBSERVATION", 27, 41]]], ["Further, an obvious time lag existed between daily CFR and daily PM 2.5 and PM 10 concentrations (Fig. 1B) .ResultsAfter adjusting for temperature and relative humidity, SO 2 , NO 2 , CO, and O 3 , we found that the CFR was positively associated with all the lag0-lag5 concentrations of and PM 10 , respectively.", [["NO", "CHEMICAL", 177, 179], ["SO 2", "CHEMICAL", 170, 174], ["NO 2", "CHEMICAL", 177, 181], ["CO", "CHEMICAL", 184, 186], ["O 3", "CHEMICAL", 192, 195], ["NO 2", "SIMPLE_CHEMICAL", 177, 181], ["CO", "SIMPLE_CHEMICAL", 184, 186], ["O 3", "SIMPLE_CHEMICAL", 192, 195], ["temperature", "TEST", 135, 146], ["the CFR", "TEST", 212, 219]]], ["To explore the impact of meteorology on PM, we did a further analysis, and found temperature, relative humidity and rainfall held no significant correlations with PM (r<0.24, p>0.07).DiscussionIn this study, we found that the daily concentrations of PM 2.5 and PM 10 changed synchronously, which might be explained by the fact that PM 10 contained also fine particles (such as PM 2.5 ).", [["a further analysis", "TEST", 51, 69], ["temperature", "TEST", 81, 92], ["this study", "TEST", 196, 206]]], ["In the further time series analysis to examine the association of PM 2.5 and PM 10 concentrations with the CFR of COVID-19 in Wuhan, with adjustment for temperature, relative humidity, concentrations of SO 2 , NO 2 , CO, and O 3 , we found COVID-19 deaths were highly correlated with PM 2.5 and PM 10 concentrations, a trend which was also observed for other respiratory diseases 8 .", [["NO", "CHEMICAL", 210, 212], ["deaths", "DISEASE", 249, 255], ["respiratory diseases", "DISEASE", 359, 379], ["SO 2", "CHEMICAL", 203, 207], ["NO 2", "CHEMICAL", 210, 214], ["CO", "CHEMICAL", 217, 219], ["O 3", "CHEMICAL", 225, 228], ["NO 2", "SIMPLE_CHEMICAL", 210, 214], ["CO", "SIMPLE_CHEMICAL", 217, 219], ["O 3", "SIMPLE_CHEMICAL", 225, 228], ["the CFR", "TEST", 103, 110], ["COVID", "TEST", 114, 119], ["temperature", "TEST", 153, 164], ["CO", "TEST", 217, 219], ["COVID", "TEST", 240, 245], ["other respiratory diseases", "PROBLEM", 353, 379], ["respiratory diseases", "OBSERVATION", 359, 379]]], ["In addition, Bontempi 9 concluded that PM 10 seemed not to affect COVID-19 infections, in accord with our study (r<0.15, p>0.28).DiscussionWorldwide, most COVID-19 deaths have occurred in the elderly especially those with underlying health problems, which potentially make them more vulnerable to air pollution.", [["infections", "DISEASE", 75, 85], ["deaths", "DISEASE", 164, 170], ["COVID", "TEST", 66, 71], ["our study", "TEST", 102, 111], ["underlying health problems", "PROBLEM", 222, 248], ["air pollution", "OBSERVATION", 297, 310]]], ["PM 2.5 , PM 10 , and CFR significantly decreased from January 19 to March 15, 2020, which might be partially attributed to effectively reduce human activities and improved medical support in Wuhan by Perm et al. 10 .", [["human", "ORGANISM", 142, 147], ["human", "SPECIES", 142, 147], ["human", "SPECIES", 142, 147], ["CFR", "TEST", 21, 24]]], ["Patients who died from COVID-19 were likely to be critically ill and most of them had been treated in negative pressure wards 11 .", [["critically ill", "DISEASE", 50, 64], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["COVID", "TEST", 23, 28], ["critically ill", "PROBLEM", 50, 64]]], ["In these wards, air circulation should be limited to avoid potential further COVID-19 transmissions and outdoor PM couldn't affect patients in this stage.", [["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["air circulation", "OBSERVATION", 16, 31]]], ["Therefore, we speculate that the early exposure to PM may play a very important role, rather than in the period after hospitalization.", [["PM", "CHEMICAL", 51, 53]]], ["We theorize that the effect of PM 2.5 and PM 10 on COVID-19 passing primarily influences patients who progress from gentle to serious infection through increasing system inflammation and oxidative stress, which would decrease cardiopulmonary functions 12 .", [["cardiopulmonary", "ANATOMY", 226, 241], ["infection", "DISEASE", 134, 143], ["inflammation", "DISEASE", 170, 182], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["COVID", "TREATMENT", 51, 56], ["serious infection", "PROBLEM", 126, 143], ["increasing system inflammation", "PROBLEM", 152, 182], ["oxidative stress", "PROBLEM", 187, 203], ["serious", "OBSERVATION_MODIFIER", 126, 133], ["infection", "OBSERVATION", 134, 143], ["inflammation", "OBSERVATION", 170, 182], ["oxidative stress", "OBSERVATION", 187, 203]]], ["This process could account for only PM 2.5 and PM 10 during the first several days of infection showing a significant association with the CFR.ConclusionsWe found a positive relationship between PM 2.5 and PM 10", [["infection", "DISEASE", 86, 95], ["infection", "PROBLEM", 86, 95], ["infection", "OBSERVATION", 86, 95], ["significant", "OBSERVATION_MODIFIER", 106, 117], ["positive", "OBSERVATION", 165, 173]]]], "daf9880d3c828fc36a7a8b7e89a120379e0ca81f": [["Comparing to the ATM and POS frauds, CNP fraud is the one which increases most by 2.1% over four years.", [["ATM", "PROTEIN", 17, 20], ["the ATM", "TEST", 13, 20]]], ["Therefore, CNP fraud is a considerably serious problem in the credit card business.IntroductionWhile developing a fraud detection model, numerous problems are encountered such as:Introduction\u2022 generation of training set from hundreds of millions of imbalanced transactions, \u2022 selection of the most appropriate feature combination due to indistinguishable features between fraud and non-fraud instances, \u2022 skewness of the data and cost of the false-positive samples,Introduction\u2022 durability of the model being affected by trend variation called concept drift caused by changes on behaviors of the customers and fraudsters.IntroductionData imbalance is defined as possessing an unequal distribution of classes within a dataset.", [["CNP", "GENE_OR_GENE_PRODUCT", 11, 14], ["numerous problems", "PROBLEM", 137, 154], ["imbalanced transactions", "TREATMENT", 249, 272], ["the data", "TEST", 417, 425], ["the false", "TEST", 438, 447], ["unequal", "OBSERVATION_MODIFIER", 676, 683], ["distribution", "OBSERVATION_MODIFIER", 684, 696]]], ["In this work, we introduce a card-based equalization method on fraud and non-fraud cards to form a training dataset by incorporating all transactions of the sampled cards to provide a solution to the mentioned problems.", [["a training dataset", "TREATMENT", 97, 115], ["a solution", "TREATMENT", 182, 192]]], ["Properties of the fraudulent credit card transactions usually alter over time.", [["fraudulent credit", "OBSERVATION", 18, 35]]], ["The main reason for this is that fraudsters try to bypass fraud detection systems.", [["main", "OBSERVATION_MODIFIER", 4, 8]]], ["In this work, the proposed system is retrained by itself over time to prevent concept drift adaptively.", [["drift", "OBSERVATION", 86, 91]]], ["In this study, we propose a sliding window-based automated training dataset generation technique to solve this issue.IntroductionThe transactions of a credit card can be performed from various sources, named terminals.", [["terminals", "CELLULAR_COMPONENT", 208, 217], ["this study", "TEST", 3, 13], ["a sliding window", "TREATMENT", 26, 42], ["automated training dataset generation technique", "TREATMENT", 49, 96], ["a credit card", "TREATMENT", 149, 162]]], ["For instance, the same merchant name are retrieved differently from the related property of the transaction, like, F ACEBOOK or F ACEBK.", [["F ACEBK", "GENE_OR_GENE_PRODUCT", 128, 135], ["F ACEBOOK", "PROTEIN", 115, 124], ["F ACEBK", "PROTEIN", 128, 135]]], ["In this work, with the purpose of designing a fast and reliable credit card fraud detection system, a Gradient Boosting Tree (GBT) based approach is developed with different types of features.", [["a Gradient Boosting Tree (GBT) based approach", "TREATMENT", 100, 145], ["different types", "OBSERVATION_MODIFIER", 164, 179]]], ["Each transaction includes the typical numeric, hand-crafted numeric, categorical, and textual features.IntroductionThe rest of the paper is organized as follows: In Sect.", [["hand", "ANATOMY", 47, 51], ["hand", "ANATOMY", 47, 51]]], ["The modules of the proposed credit card fraud detection system and the processing modules are described in Sect.", [["the processing modules", "PROBLEM", 67, 89], ["processing modules", "OBSERVATION", 71, 89]]], ["Section 4 is devoted to our results of the experiments to evaluate the importance of feature engineering and automated training set generation approach.", [["automated training set generation approach", "TREATMENT", 109, 151]]], ["5.Related WorkFor the detection of credit card frauds, various feature engineering strategies mostly based on an aggregation of transactions have been proposed in the literature.", [["credit card frauds", "PROBLEM", 35, 53]]], ["Also, Gradient Boosting Tree (GBT) has been investigated and compared with the other state-of-the-art algorithms.Feature Engineering.To improve the performance of credit card fraud detection, Jha et al. [7] proposed a transaction aggregation strategy to derive certain aggregated features such as the total amount or the number of transactions initiated on the same day with the same merchant, currency or country for capturing the buying behaviors of customers.", [["a transaction aggregation strategy", "TREATMENT", 216, 250], ["Gradient", "OBSERVATION_MODIFIER", 6, 14], ["Boosting Tree", "OBSERVATION", 15, 28]]], ["In the study of Whitrow et al. [14] , using a transaction aggregation process resulting in more robust to the problem of population drift, several features are derived at different aggregation periods.", [["the study", "TEST", 3, 12], ["a transaction aggregation process", "TREATMENT", 44, 77], ["population drift", "PROBLEM", 121, 137], ["aggregation periods", "OBSERVATION", 181, 200]]], ["Afterwards, for the detection of credit card frauds, different algorithms are performed on transactional features including the derived ones.", [["credit card frauds", "TEST", 33, 51], ["different algorithms", "TEST", 53, 73]]], ["Also, a novel approach is proposed in this work [12] for the generation of a cardholder's profile by extracting the aggregated daily amounts of the cardholder's transactions.", [["a cardholder's profile", "TREATMENT", 75, 97], ["the cardholder's transactions", "TREATMENT", 144, 173]]], ["Comparison of the decision tree, artificial neural network, and logistic regression approaches for detecting credit card fraud transaction is studied by [13] on the combination of the raw features and eight aggregated features such as the total and average amount, the number of transactions and the failure number of transactions in the same day and the last five days, showing that neural network and logistic regression models over-perform decision tree.", [["neural", "ANATOMY", 44, 50], ["neural network", "ANATOMY", 384, 398], ["neural network", "MULTI-TISSUE_STRUCTURE", 44, 58], ["neural network", "MULTI-TISSUE_STRUCTURE", 384, 398], ["the raw features", "PROBLEM", 180, 196]]], ["Bahnsen et al. [2, 3] presented a transaction strategy for the capturing of the patterns for the periodic behavior of a transaction based on von Mises distribution and spending behavior belonging to a customer by exploiting the previous transactions of the customer.", [["a transaction strategy", "TREATMENT", 32, 54]]], ["Moreover, Lim et al. [10] proposed a novel transaction-level based aggregation strategy using conditional weighted aggregation on the previous transactions.", [["a novel transaction", "TREATMENT", 35, 54], ["conditional weighted aggregation", "PROBLEM", 94, 126]]], ["In this work, two weighting functions using the number of transactions and time are performed to assign more weights to the transactions.Feature Engineering.In addition, the contribution of the aggregation on the detection of credit card frauds is investigated using various time-series based algorithms.", [["aggregation", "DISEASE", 194, 205], ["the aggregation", "PROBLEM", 190, 205], ["credit card frauds", "TEST", 226, 244], ["aggregation", "OBSERVATION", 194, 205]]], ["For each transaction in the sequence, a likelihood value based on the previous transaction is computed, and then, this likelihood values are used as additional features to generate a Random Forest model.Gradient Boosting Trees.", [["a Random Forest model", "TREATMENT", 181, 202]]], ["Fang et al. proposed a Light Gradient BoostingMachine (LightGBM) for detecting credit card frauds [6] .", [["a Light Gradient BoostingMachine (LightGBM)", "TREATMENT", 21, 64]]], ["In the work of [5] , for the detection of credit card frauds, the boosting algorithms, Adaboost, Gradient Boost, and eXtreme Gradient Boosting (XGBoost) were implemented to evaluate the detection performances.", [["[5]", "SIMPLE_CHEMICAL", 15, 18], ["the boosting algorithms", "TREATMENT", 62, 85], ["Gradient Boost", "TREATMENT", 97, 111], ["eXtreme Gradient Boosting (XGBoost)", "TREATMENT", 117, 152], ["the detection performances", "TEST", 182, 208]]], ["It was found out that the XGBoost method outperforms the other algorithms.Proposed Fraud Detection SystemThe proposed system for the detection of credit card frauds is composed of two main modules; offline training and real-time detection as shown in Fig. 1 .", [["credit card frauds", "TEST", 146, 164], ["offline training", "TREATMENT", 198, 214], ["real-time detection", "TEST", 219, 238], ["main", "OBSERVATION_MODIFIER", 184, 188], ["modules", "OBSERVATION", 189, 196]]], ["There is a feature engineering step common in both of the components.", [["step", "OBSERVATION_MODIFIER", 31, 35], ["common", "OBSERVATION_MODIFIER", 36, 42], ["both", "ANATOMY_MODIFIER", 46, 50], ["components", "OBSERVATION_MODIFIER", 58, 68]]], ["The offline training phase covers the automatic generation of the training set to be used in the generation of a model for fraud detection.", [["The offline training phase", "TREATMENT", 0, 26], ["the training", "TREATMENT", 62, 74], ["fraud detection", "TEST", 123, 138]]], ["In the real-time detection phase, the feature vector is extracted from streaming transaction to decide whether it is fraudulent or not.Offline TrainingFeature EngineeringFeature EngineeringA feature engineering process shown in Fig. 2 is required to improve the performance of model under the imbalanced class distributions, the noisy labels and features, skewness of the data, and overlapping transactions existing in both of the classes.", [["the data", "TEST", 368, 376]]], ["Making combination of the different types of features, selection among the distinctive features, and generation of the additional hand-crafted features are used in feature engineering phase on the model generation component of our time-constrained fraud detection system.Feature EngineeringBefore the combination, the encoding of categorical features, generation of aggregated features, and extraction of word representations for the textual data are performed in the offline training and real-time detection stages.", [["hand", "ANATOMY", 130, 134], ["aggregated features", "PROBLEM", 366, 385], ["the textual data", "TEST", 430, 446]]], ["The categorical features are encoded in which a numeric value is set to a distinct categorical value.", [["a numeric value", "TEST", 46, 61]]], ["In addition, the vectors from the word embedding model of merchant names are included to compose the training instance for offline training component and to query the model on real time detection component.Encoding of Categorical AttributesA few algorithms have been proposed to handle the data with categorical features.", [["the vectors", "TREATMENT", 13, 24], ["offline training component", "TREATMENT", 123, 149]]], ["Therefore, an encoding process is required to transform them into numerical features.", [["an encoding process", "TREATMENT", 11, 30]]], ["The values of some categorical attributes belonging to the transactions such as merchant category code, country code, etc. are directly encoded into a set of discrete integer values 0 through k where k is the number of unique categorical values.Extraction of Aggregated FeaturesThe properties of a credit card transaction do not represent the customer's financial behavior.", [["Extraction", "TREATMENT", 245, 255], ["a credit card transaction", "TREATMENT", 296, 321]]], ["In order to capture purchasing patterns to improve the model performance, an aggregation strategy is applied on raw transactional features such as currency, amount, merchant category.", [["an aggregation strategy", "TREATMENT", 74, 97]]], ["Various aggregated features per card, like the total amount of previous transactions, the total number of transactions which have the same merchant category code, total count of the same currency and country, etc., are computed in real-time from the transactions performed in the day before the current day.Training a Word Embedding ModelFor the use of the typical numeric, hand-crafted numeric, categorical, and textual attributes together, a set of a newly composed feature vectors are constructed to train a GBT model.", [["total count", "TEST", 163, 174]]], ["Nevertheless, the attribute corresponding to merchant name is the textual one which have millions of different values including meaningless words and some phrases which have different number of characters.", [["different", "OBSERVATION_MODIFIER", 174, 183], ["number", "OBSERVATION_MODIFIER", 184, 190]]], ["Thus, the same encoding technique used for the categorical attributes may not be useful on merchant names.", [["the same encoding technique", "TREATMENT", 6, 33]]], ["Also, the list of the distinct names is being grown due to names of new merchants and mistyped names of the existing merchants, directly causing the out-of-vocabulary (OOV) problem.Training a Word Embedding ModelIn this study, due to the OOV problem and strict time constraint for fraud detection per transaction, we require a fast solution to convert such information into the numeric form to be used in the corresponding feature vector.", [["this study", "TEST", 215, 225], ["the OOV problem", "PROBLEM", 234, 249], ["a fast solution", "TREATMENT", 325, 340]]], ["Thus, to overcome these problems, fastText library that provides a character-level word embedding approach is exploited for the extraction of embedding vectors from the names.", [["these problems", "PROBLEM", 18, 32], ["a character-level word embedding approach", "TREATMENT", 65, 106], ["the extraction of embedding vectors", "TREATMENT", 124, 159]]], ["Among the last year's transactions, trigram character sequences of all the unique names of the merchants in which at least one transaction and contain only alphabetical characters, are considered to include the model.", [["trigram character sequences", "DNA", 36, 63]]], ["We train an embedding model on a corpus with millions of these filtered unique names.", [["an embedding model", "TREATMENT", 9, 27]]], ["The model provides a 16-D embedding vector generated for each merchant name.", [["a 16-D embedding vector", "TREATMENT", 19, 42]]], ["The vector for the name of an incoming transaction is basically computed by summing all vectors extracted for each trigram sequence in the name, and included into the other features.", [["trigram sequence", "DNA", 115, 131], ["an incoming transaction", "TREATMENT", 27, 50], ["each trigram sequence", "TEST", 110, 131]]], ["Due to the restriction for the prediction time, retraining of the fastText model on the merchant names, including the new ones, is not applicable.Training a Word Embedding ModelIt is required to estimate how the embedding vector should be efficiently utilized.", [["Word Embedding ModelIt", "DNA", 157, 179], ["the embedding vector", "TREATMENT", 208, 228]]], ["To select more distinctive features and also reduce the dimensionality, Principled Component Analysis (PCA) is performed on the vectors of the names in training set like in Fig. 3 .", [["more distinctive", "OBSERVATION_MODIFIER", 10, 26]]], ["Using PCA, the 16-D vectors are projected onto 4-D subspace determined by experiments.", [["16-D vectors", "DNA", 15, 27], ["PCA", "TREATMENT", 6, 9], ["the 16-D vectors", "TREATMENT", 11, 27]]], ["It is observed that the PCA based reduction prevents the dominancy of the vector on the other transactional features, enhances the fraud detection performance, and decreases the prediction time.Training of Credit Card Fraud Detection ModelIn this study, the training set is constructed within several stages to create a data set in which classifiers can have stability against class skewness problems.", [["the PCA based reduction", "TREATMENT", 20, 43], ["the fraud detection performance", "TEST", 127, 158], ["this study", "TEST", 242, 252], ["class skewness problems", "PROBLEM", 377, 400], ["PCA", "OBSERVATION", 24, 27], ["reduction", "OBSERVATION_MODIFIER", 34, 43]]], ["It is desired to equalize fraudulent and legitimate credit card counts and to make sure that the transactions of each credit card covers the equal time range.Training of Credit Card Fraud Detection ModelWe identify credit cards as a fraudulent card if it has at least one fraud transaction in a given time range.", [["credit card counts", "TEST", 52, 70]]], ["Instead of equalizing fraud and nonfraud transaction count, such as undersampling, we take the number of training instances the same for fraud and non-fraud ones.", [["nonfraud transaction count", "TEST", 32, 58]]], ["Although there is still massive class imbalance; however, we consider detecting fraud credit cards instead of the transaction more important.Training of Credit Card Fraud Detection ModelThe training set is constructed in a period of T , with m number of consecutive months.", [["massive class imbalance", "PROBLEM", 24, 47], ["massive", "OBSERVATION_MODIFIER", 24, 31], ["class imbalance", "OBSERVATION", 32, 47]]], ["Following the card selection process, all transactions of the selected cards in t i , are obtained from the range of t i\u2212n , where n is the sliding window parameter.", [["t i\u2212n", "DNA", 117, 122], ["the sliding window parameter", "TREATMENT", 136, 164]]], ["This operation needs reservation of the first n months only to fetch transactions of the t i+n cards.", [["This operation", "TREATMENT", 0, 14], ["reservation", "TREATMENT", 21, 32]]], ["In addition, after a new training set is constructed, a PCA model for the embedding vectors of the merchant names is also updated using the vector representations of the merchant names.", [["a new training set", "TREATMENT", 19, 37], ["a PCA model", "TREATMENT", 54, 65]]], ["However, the same fastText model is utilized since the update of the word-embedding model like the fraud detection model may not enhance the vector representation.Experimental SetupThe experiments were performed using two training sets and test sets incorporating credit card transactions in a private bank.", [["test sets", "TEST", 240, 249]]], ["Also, 30% of each training set has been utilized as a validation set, to be used in the training of the detection model.", [["the detection model", "TEST", 100, 119]]], ["More details about the datasets can be found in Table 1 .Experimental SetupThe proposed system for credit card fraud detection was developed in Python 3.6.8.", [["credit card fraud detection", "TEST", 99, 126]]], ["For the GBT model generation, XGBoost library 0.71 presenting an efficient Gradient Boosted Tree (GBT) implementation is used on these datasets.", [["the GBT model generation", "TREATMENT", 4, 28], ["XGBoost library", "TREATMENT", 30, 45], ["an efficient Gradient Boosted Tree (GBT) implementation", "TREATMENT", 62, 117]]], ["Also, Redis, an in-memory data structure store based on a server-client model with TCP sockets, is utilized for the real-time transaction aggregation.Evaluation MetricsExperiments are evaluated by the following metrics; the False-Positive Rate (FPR), recall, precision, and Area Under Curve (AUC).", [["TCP sockets", "MULTI-TISSUE_STRUCTURE", 83, 94], ["TCP sockets", "TREATMENT", 83, 94], ["Evaluation", "TEST", 150, 160], ["the False", "TEST", 220, 229], ["AUC", "TEST", 292, 295], ["sockets", "OBSERVATION", 87, 94]]], ["We also calculated the Equal Error Rate (EER), which determines the threshold values for its false acceptance rate and its false rejection rate when the rates are equal.", [["the rates", "TEST", 149, 158], ["false rejection", "OBSERVATION", 123, 138], ["equal", "OBSERVATION", 163, 168]]], ["Using the determined threshold values from EER calculation, we evaluated the performance of the credit card fraud detection model.", [["EER calculation", "TEST", 43, 58]]], ["Moreover, we experimentally found that 0.3 is decided as a fixed FPR to obtain the optimum threshold value.Experiments of Feature EngineeringIn the experiments regarding feature engineering process, only encoded features, encoded with aggregated ones, and all of them including word embedding features have been used to train a GBT model.", [["GBT", "CANCER", 328, 331], ["the optimum threshold value", "TEST", 79, 106], ["word embedding features", "PROBLEM", 278, 301]]], ["Figure 6 and Table 4 reveals that, sliding the training set enhances the fraud detection performance in terms of AUC by 0.028%, and in fixed 0.3 FPR, Recall is increased by 0.029%.", [["AUC", "TEST", 113, 116], ["increased", "OBSERVATION_MODIFIER", 160, 169]]], ["Also, we realized that joining recent transactions and decreasing more distant transactions to the training set increases the success of our credit card fraud detection model.ConclusionIn this work, for the real-time detection of credit card fraud, a new approach is proposed for training dataset construction to make usable and valuable of different types of attributes of a transaction by combining numerical, handcrafted numerical, categorical and textual features.", [["training dataset construction", "TREATMENT", 280, 309]]], ["Also, there is a major problem affecting the durability of the model.", [["a major problem", "PROBLEM", 15, 30], ["major", "OBSERVATION_MODIFIER", 17, 22], ["problem", "OBSERVATION", 23, 30], ["durability", "OBSERVATION_MODIFIER", 45, 55]]], ["Therefore, automatic generation of a transaction dataset has been developed to extract feature vectors used as training set to generate a Gradient Boosting Tree (GBT) model for the detection of the fraud transactions.", [["a transaction dataset", "TREATMENT", 35, 56], ["a Gradient Boosting Tree (GBT)", "TREATMENT", 136, 166]]], ["In the future work, new types of aggregated features will be created and an ensemble method will be developed by combining of a number of models trained on the transactions of long-and short-term periods.", [["long-and short-term periods", "TREATMENT", 176, 203]]]], "698aa8b6079c715f0e614c4fe0b6cc52a594e606": [["IntroductionCough associated with acute upper respiratory tract infection (URTI) is a common and troublesome problem and it is surprising that very little is known about the aetiology of this type of cough.", [["upper respiratory tract", "ANATOMY", 40, 63], ["upper respiratory tract infection", "DISEASE", 40, 73], ["URTI", "DISEASE", 75, 79], ["cough", "DISEASE", 200, 205], ["upper respiratory", "ORGANISM_SUBDIVISION", 40, 57], ["tract", "ORGANISM_SUBDIVISION", 58, 63], ["IntroductionCough", "TREATMENT", 0, 17], ["acute upper respiratory tract infection", "PROBLEM", 34, 73], ["a common and troublesome problem", "PROBLEM", 84, 116], ["cough", "PROBLEM", 200, 205], ["acute", "OBSERVATION_MODIFIER", 34, 39], ["upper", "ANATOMY_MODIFIER", 40, 45], ["respiratory tract", "ANATOMY", 46, 63], ["infection", "OBSERVATION", 64, 73], ["cough", "OBSERVATION", 200, 205]]], ["It is assumed that the normal protective reflex of cough is exaggerated in some way during URTI so that cough occurs spontaneously instead of in response to food or fluid coming in contact with the airway epithelium.", [["airway epithelium", "ANATOMY", 198, 215], ["cough", "DISEASE", 51, 56], ["URTI", "DISEASE", 91, 95], ["cough", "DISEASE", 104, 109], ["airway epithelium", "TISSUE", 198, 215], ["cough", "PROBLEM", 51, 56], ["cough", "PROBLEM", 104, 109], ["fluid", "PROBLEM", 165, 170], ["normal", "OBSERVATION_MODIFIER", 23, 29], ["protective", "OBSERVATION_MODIFIER", 30, 40], ["reflex", "OBSERVATION_MODIFIER", 41, 47], ["cough", "OBSERVATION", 51, 56], ["cough", "OBSERVATION", 104, 109], ["fluid", "OBSERVATION", 165, 170], ["airway", "ANATOMY", 198, 204], ["epithelium", "ANATOMY_MODIFIER", 205, 215]]], ["It has been proposed that during URTI there is an increased sensitivity of the sensory nerves in the airway epithelium that mediate cough due to the presence of mediators of inflammation [1, 2] .", [["sensory nerves", "ANATOMY", 79, 93], ["airway epithelium", "ANATOMY", 101, 118], ["URTI", "DISEASE", 33, 37], ["cough", "DISEASE", 132, 137], ["inflammation", "DISEASE", 174, 186], ["sensory nerves", "MULTI-TISSUE_STRUCTURE", 79, 93], ["airway epithelium", "TISSUE", 101, 118], ["an increased sensitivity of the sensory nerves in the airway epithelium", "PROBLEM", 47, 118], ["cough", "PROBLEM", 132, 137], ["inflammation", "PROBLEM", 174, 186], ["increased", "OBSERVATION_MODIFIER", 50, 59], ["sensory nerves", "ANATOMY", 79, 93], ["airway", "ANATOMY", 101, 107], ["cough", "OBSERVATION", 132, 137], ["inflammation", "OBSERVATION", 174, 186]]], ["In a prospective study on healthy volunteers it was shown that cough sensitivity to inhaled capsaicin was increased during periods of URTI [2] .", [["cough", "DISEASE", 63, 68], ["capsaicin", "CHEMICAL", 92, 101], ["URTI", "DISEASE", 134, 138], ["capsaicin", "CHEMICAL", 92, 101], ["volunteers", "ORGANISM", 34, 44], ["capsaicin", "SIMPLE_CHEMICAL", 92, 101], ["a prospective study", "TEST", 3, 22], ["cough sensitivity", "PROBLEM", 63, 80], ["inhaled capsaicin", "TREATMENT", 84, 101], ["URTI", "PROBLEM", 134, 138]]], ["A similar increase in cough sensitivity associated with URTI has been reported when cough was induced with an aerosol of inhaled citric acid [1] or nebulized distilled water [3] .", [["cough", "DISEASE", 22, 27], ["URTI", "DISEASE", 56, 60], ["cough", "DISEASE", 84, 89], ["citric acid", "CHEMICAL", 129, 140], ["citric acid", "CHEMICAL", 129, 140], ["citric acid", "SIMPLE_CHEMICAL", 129, 140], ["A similar increase in cough sensitivity", "PROBLEM", 0, 39], ["URTI", "PROBLEM", 56, 60], ["cough", "PROBLEM", 84, 89], ["an aerosol of inhaled citric acid", "TREATMENT", 107, 140], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["increase", "OBSERVATION_MODIFIER", 10, 18], ["cough", "OBSERVATION", 22, 27]]], ["Empey et al. [1] have proposed that the increase in cough sensitivity during URTI may be due to increased sensitivity of the rapidly adapting airway receptors (RARs).", [["airway", "ANATOMY", 142, 148], ["cough", "DISEASE", 52, 57], ["URTI", "DISEASE", 77, 81], ["airway", "MULTI-TISSUE_STRUCTURE", 142, 148], ["RARs", "GENE_OR_GENE_PRODUCT", 160, 164], ["airway receptors", "PROTEIN", 142, 158], ["RARs", "PROTEIN", 160, 164], ["cough sensitivity", "PROBLEM", 52, 69], ["URTI", "PROBLEM", 77, 81], ["increased sensitivity", "PROBLEM", 96, 117], ["increase", "OBSERVATION_MODIFIER", 40, 48], ["airway", "ANATOMY", 142, 148]]], ["The RARs are particularly sensitive to mechanical stimulation [4, 5] and therefore it should be possible to induce cough with an adequate mechanical stimulus to the airway.", [["airway", "ANATOMY", 165, 171], ["cough", "DISEASE", 115, 120], ["RARs", "GENE_OR_GENE_PRODUCT", 4, 8], ["airway", "MULTI-TISSUE_STRUCTURE", 165, 171], ["RARs", "PROTEIN", 4, 8], ["mechanical stimulation", "TREATMENT", 39, 61], ["cough", "PROBLEM", 115, 120], ["cough", "OBSERVATION", 115, 120], ["mechanical stimulus", "OBSERVATION", 138, 157], ["airway", "ANATOMY", 165, 171]]], ["Mechanical induction of cough has been achieved in anaesthetized animals by intra-tracheal stimulation of the upper airway with bristles or iron slugs [6, 7] and airway vibration has been shown to induce cough in humans [8, 9] .IntroductionStudies on the induction of cough in humans by vibration of the throat or chest have reported that cough can be induced in patients with URTI but that little or no cough occurs in healthy volunteers [8, 9] .", [["intra-tracheal", "ANATOMY", 76, 90], ["upper airway", "ANATOMY", 110, 122], ["bristles", "ANATOMY", 128, 136], ["airway", "ANATOMY", 162, 168], ["throat", "ANATOMY", 304, 310], ["chest", "ANATOMY", 314, 319], ["cough", "DISEASE", 24, 29], ["iron", "CHEMICAL", 140, 144], ["cough", "DISEASE", 204, 209], ["cough", "DISEASE", 268, 273], ["cough", "DISEASE", 339, 344], ["URTI", "DISEASE", 377, 381], ["cough", "DISEASE", 404, 409], ["iron", "CHEMICAL", 140, 144], ["upper airway", "ORGANISM_SUBDIVISION", 110, 122], ["airway", "MULTI-TISSUE_STRUCTURE", 162, 168], ["humans", "ORGANISM", 213, 219], ["humans", "ORGANISM", 277, 283], ["throat", "ORGANISM_SUBDIVISION", 304, 310], ["chest", "ORGANISM_SUBDIVISION", 314, 319], ["patients", "ORGANISM", 363, 371], ["volunteers", "ORGANISM", 428, 438], ["humans", "SPECIES", 213, 219], ["humans", "SPECIES", 277, 283], ["patients", "SPECIES", 363, 371], ["humans", "SPECIES", 213, 219], ["humans", "SPECIES", 277, 283], ["Mechanical induction", "TREATMENT", 0, 20], ["cough", "PROBLEM", 24, 29], ["bristles or iron slugs", "PROBLEM", 128, 150], ["cough", "PROBLEM", 204, 209], ["cough", "PROBLEM", 268, 273], ["cough", "PROBLEM", 339, 344], ["URTI", "PROBLEM", 377, 381], ["cough", "PROBLEM", 404, 409], ["cough", "OBSERVATION", 24, 29], ["upper", "ANATOMY_MODIFIER", 110, 115], ["airway", "ANATOMY", 116, 122], ["iron slugs", "OBSERVATION", 140, 150], ["airway", "ANATOMY", 162, 168], ["cough", "OBSERVATION", 204, 209], ["cough", "OBSERVATION", 268, 273], ["throat", "ANATOMY", 304, 310], ["chest", "ANATOMY", 314, 319], ["cough", "OBSERVATION", 339, 344]]], ["The difference in cough sensitivity between patients with URTI and healthy volunteers as demonstrated by airway vibration supports the hypothesis that cough associated with URTI is caused by hyperreactivity of the cough reflex, perhaps related to an increased sensitivity of airway sensory receptors such as RARs.", [["airway", "ANATOMY", 105, 111], ["airway", "ANATOMY", 275, 281], ["cough", "DISEASE", 18, 23], ["URTI", "DISEASE", 58, 62], ["cough", "DISEASE", 151, 156], ["URTI", "DISEASE", 173, 177], ["cough", "DISEASE", 214, 219], ["patients", "ORGANISM", 44, 52], ["volunteers", "ORGANISM", 75, 85], ["airway", "MULTI-TISSUE_STRUCTURE", 105, 111], ["airway", "MULTI-TISSUE_STRUCTURE", 275, 281], ["RARs", "GENE_OR_GENE_PRODUCT", 308, 312], ["airway sensory receptors", "PROTEIN", 275, 299], ["RARs", "PROTEIN", 308, 312], ["patients", "SPECIES", 44, 52], ["The difference in cough sensitivity", "PROBLEM", 0, 35], ["URTI and healthy volunteers", "PROBLEM", 58, 85], ["cough", "PROBLEM", 151, 156], ["URTI", "PROBLEM", 173, 177], ["hyperreactivity", "PROBLEM", 191, 206], ["the cough reflex", "PROBLEM", 210, 226], ["an increased sensitivity of airway sensory receptors", "PROBLEM", 247, 299], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["cough", "OBSERVATION", 18, 23], ["airway", "ANATOMY", 105, 111], ["cough", "OBSERVATION", 151, 156], ["hyperreactivity", "OBSERVATION", 191, 206], ["increased", "OBSERVATION_MODIFIER", 250, 259], ["airway", "ANATOMY", 275, 281]]], ["The cough model associated with airway vibration may allow measurement of the degree of airway hyperreactivity associated with URTI since cough is not readily induced in healthy volunteers by airway vibration.", [["airway", "ANATOMY", 32, 38], ["airway", "ANATOMY", 88, 94], ["airway", "ANATOMY", 192, 198], ["cough", "DISEASE", 4, 9], ["airway hyperreactivity", "DISEASE", 88, 110], ["URTI", "DISEASE", 127, 131], ["cough", "DISEASE", 138, 143], ["airway", "MULTI-TISSUE_STRUCTURE", 32, 38], ["airway", "MULTI-TISSUE_STRUCTURE", 88, 94], ["volunteers", "ORGANISM", 178, 188], ["airway", "MULTI-TISSUE_STRUCTURE", 192, 198], ["The cough model", "PROBLEM", 0, 15], ["airway vibration", "PROBLEM", 32, 48], ["airway hyperreactivity", "PROBLEM", 88, 110], ["URTI", "PROBLEM", 127, 131], ["cough", "PROBLEM", 138, 143], ["cough", "OBSERVATION", 4, 9], ["airway", "ANATOMY", 32, 38], ["airway", "ANATOMY", 88, 94], ["hyperreactivity", "OBSERVATION", 95, 110], ["airway", "ANATOMY", 192, 198]]], ["The present paper will discuss the mechanism of airway hyperreactivity associated with URTI and the usefulness of the cough model of airway vibration in clinical trials of new treatments for cough associated with URTI.Cough associated with URTI and airway hyperreactivityURTI is associated with viral infection of the upper airways.", [["airway", "ANATOMY", 48, 54], ["airway", "ANATOMY", 133, 139], ["airway", "ANATOMY", 249, 255], ["upper airways", "ANATOMY", 318, 331], ["airway hyperreactivity", "DISEASE", 48, 70], ["URTI", "DISEASE", 87, 91], ["airway vibration", "DISEASE", 133, 149], ["cough", "DISEASE", 191, 196], ["URTI", "DISEASE", 213, 217], ["Cough", "DISEASE", 218, 223], ["URTI", "DISEASE", 240, 244], ["airway hyperreactivityURTI", "DISEASE", 249, 275], ["viral infection of the upper airways", "DISEASE", 295, 331], ["airway", "MULTI-TISSUE_STRUCTURE", 48, 54], ["airway", "MULTI-TISSUE_STRUCTURE", 133, 139], ["airway", "MULTI-TISSUE_STRUCTURE", 249, 255], ["upper airways", "MULTI-TISSUE_STRUCTURE", 318, 331], ["airway hyperreactivity", "PROBLEM", 48, 70], ["URTI", "PROBLEM", 87, 91], ["the cough", "PROBLEM", 114, 123], ["airway vibration", "PROBLEM", 133, 149], ["new treatments", "TREATMENT", 172, 186], ["cough", "PROBLEM", 191, 196], ["URTI", "PROBLEM", 213, 217], ["Cough", "PROBLEM", 218, 223], ["URTI and airway hyperreactivityURTI", "PROBLEM", 240, 275], ["viral infection of the upper airways", "PROBLEM", 295, 331], ["airway", "ANATOMY", 48, 54], ["hyperreactivity", "OBSERVATION", 55, 70], ["airway", "ANATOMY", 133, 139], ["airway", "ANATOMY", 249, 255], ["hyperreactivityURTI", "OBSERVATION", 256, 275], ["associated with", "UNCERTAINTY", 279, 294], ["viral", "OBSERVATION_MODIFIER", 295, 300], ["infection", "OBSERVATION", 301, 310], ["upper", "ANATOMY_MODIFIER", 318, 323], ["airways", "ANATOMY", 324, 331]]], ["The immune response to infection causes the generation of a complex mixture of mediators such as bradykinin, prostaglandins, neuropeptides and cytokines that trigger the process of inflammation [10] .", [["infection", "DISEASE", 23, 32], ["bradykinin", "CHEMICAL", 97, 107], ["prostaglandins", "CHEMICAL", 109, 123], ["inflammation", "DISEASE", 181, 193], ["bradykinin", "CHEMICAL", 97, 107], ["prostaglandins", "CHEMICAL", 109, 123], ["bradykinin", "SIMPLE_CHEMICAL", 97, 107], ["prostaglandins", "SIMPLE_CHEMICAL", 109, 123], ["cytokines", "PROTEIN", 143, 152], ["infection", "PROBLEM", 23, 32], ["a complex mixture of mediators", "TREATMENT", 58, 88], ["bradykinin, prostaglandins", "TREATMENT", 97, 123], ["neuropeptides", "TREATMENT", 125, 138], ["cytokines", "TREATMENT", 143, 152], ["inflammation", "PROBLEM", 181, 193], ["infection", "OBSERVATION", 23, 32], ["inflammation", "OBSERVATION", 181, 193]]], ["The symptoms of URTI such as runny nose, nasal congestion and sore throat are nearly always present but cough is a less common symptom and many cases of URTI do not develop cough to a degree that causes discomfort.Cough and virusesIn an epidemiological study of common cold symptoms in 131 persons over a 1 year period it was found that the group suffered an average of 2.2 colds, with runny nose being the most common symptom (87%) and cough occurring in only 44% of subjects [11] .", [["nasal", "ANATOMY", 41, 46], ["URTI", "DISEASE", 16, 20], ["runny nose", "DISEASE", 29, 39], ["nasal congestion", "DISEASE", 41, 57], ["sore throat", "DISEASE", 62, 73], ["cough", "DISEASE", 104, 109], ["URTI", "DISEASE", 153, 157], ["cough", "DISEASE", 173, 178], ["Cough", "DISEASE", 214, 219], ["colds", "DISEASE", 374, 379], ["cough", "DISEASE", 437, 442], ["nose", "ORGANISM_SUBDIVISION", 35, 39], ["nasal", "ORGANISM_SUBDIVISION", 41, 46], ["throat", "ORGANISM_SUBDIVISION", 67, 73], ["persons", "ORGANISM", 290, 297], ["nose", "ORGANISM_SUBDIVISION", 392, 396], ["persons", "SPECIES", 290, 297], ["The symptoms", "PROBLEM", 0, 12], ["URTI", "PROBLEM", 16, 20], ["runny nose", "PROBLEM", 29, 39], ["nasal congestion", "PROBLEM", 41, 57], ["sore throat", "PROBLEM", 62, 73], ["cough", "PROBLEM", 104, 109], ["a less common symptom", "PROBLEM", 113, 134], ["URTI", "PROBLEM", 153, 157], ["cough", "PROBLEM", 173, 178], ["discomfort", "PROBLEM", 203, 213], ["Cough", "PROBLEM", 214, 219], ["viruses", "PROBLEM", 224, 231], ["an epidemiological study", "TEST", 234, 258], ["common cold symptoms", "PROBLEM", 262, 282], ["runny nose", "PROBLEM", 386, 396], ["cough", "PROBLEM", 437, 442], ["nasal", "ANATOMY", 41, 46], ["congestion", "OBSERVATION", 47, 57], ["sore throat", "ANATOMY", 62, 73], ["cough", "OBSERVATION", 173, 178], ["viruses", "OBSERVATION", 224, 231]]], ["In general, patterns of symptom development are not substantially different with different viruses [12] but there is evidence that some viruses are more likely to cause the symptom of cough.", [["cough", "DISEASE", 184, 189], ["symptom development", "PROBLEM", 24, 43], ["different viruses", "PROBLEM", 81, 98], ["some viruses", "PROBLEM", 131, 143], ["cough", "PROBLEM", 184, 189], ["symptom", "OBSERVATION", 24, 31], ["substantially different", "OBSERVATION_MODIFIER", 52, 75], ["viruses", "OBSERVATION", 91, 98], ["some", "OBSERVATION_MODIFIER", 131, 135], ["viruses", "OBSERVATION", 136, 143], ["cough", "OBSERVATION", 184, 189]]], ["Comparison of the percentages of subjects that experienced various symptoms after viral challenge showed that the incidence of cough varies from 9 to 64% depending on the virus used for challenge [12] .", [["cough", "DISEASE", 127, 132], ["various symptoms", "PROBLEM", 59, 75], ["viral challenge", "TEST", 82, 97], ["cough varies", "PROBLEM", 127, 139], ["the virus", "PROBLEM", 167, 176], ["cough", "OBSERVATION", 127, 132]]], ["This finding indicates that some viruses have the capacity to induce cough whereas others do not.", [["cough", "DISEASE", 69, 74], ["some viruses", "PROBLEM", 28, 40], ["the capacity", "PROBLEM", 46, 58], ["cough", "PROBLEM", 69, 74], ["some", "OBSERVATION_MODIFIER", 28, 32], ["viruses", "OBSERVATION", 33, 40], ["cough", "OBSERVATION", 69, 74]]], ["A simple explanation for this difference may be differences in the novelty of the viruses and previous immune history of the patient.", [["patient", "ORGANISM", 125, 132], ["patient", "SPECIES", 125, 132], ["the viruses", "PROBLEM", 78, 89], ["viruses", "OBSERVATION", 82, 89]]], ["Viruses that are commonly circulating in the community tend to cause mild symptoms and sub-clinical infections because of 'herd' immunity to the virus whereas the introduction of a new virus to a previously unexposed community can cause severe illness.", [["infections", "DISEASE", 100, 110], ["herd", "ORGANISM_SUBDIVISION", 123, 127], ["Viruses", "PROBLEM", 0, 7], ["mild symptoms", "PROBLEM", 69, 82], ["sub-clinical infections", "PROBLEM", 87, 110], ["the virus", "PROBLEM", 141, 150], ["a new virus", "PROBLEM", 179, 190], ["severe illness", "PROBLEM", 237, 251], ["mild", "OBSERVATION_MODIFIER", 69, 73], ["symptoms", "OBSERVATION", 74, 82], ["severe", "OBSERVATION_MODIFIER", 237, 243], ["illness", "OBSERVATION", 244, 251]]], ["Epidemics and pandemics of influenza result because of the novelty of the virus and absence of herd immunity, and severe illness with cough and fever as major symptoms occurs in the population.", [["influenza", "DISEASE", 27, 36], ["illness", "DISEASE", 121, 128], ["cough", "DISEASE", 134, 139], ["fever", "DISEASE", 144, 149], ["Epidemics", "PROBLEM", 0, 9], ["pandemics", "PROBLEM", 14, 23], ["influenza", "PROBLEM", 27, 36], ["the virus", "PROBLEM", 70, 79], ["severe illness", "PROBLEM", 114, 128], ["cough", "PROBLEM", 134, 139], ["fever", "PROBLEM", 144, 149], ["major symptoms", "PROBLEM", 153, 167], ["severe", "OBSERVATION_MODIFIER", 114, 120]]], ["In the recent cases of severe acute respiratory syndrome (SARS) the major self-reported symptoms were fever (99%) and non-productive cough (69%) [13] and the best predictors for the diagnosis of influenza in the community are cough and fever with a positive predictive value of 79% [14] .Trigeminal and vagus nervesMild URTI may not be associated with cough because the infection is restricted to the nose and generates rhinitis with symptoms of runny nose, sneezing and nasal congestion.", [["Trigeminal", "ANATOMY", 288, 298], ["vagus nerves", "ANATOMY", 303, 315], ["nose", "ANATOMY", 401, 405], ["nasal", "ANATOMY", 471, 476], ["acute respiratory syndrome", "DISEASE", 30, 56], ["SARS", "DISEASE", 58, 62], ["fever", "DISEASE", 102, 107], ["cough", "DISEASE", 133, 138], ["influenza", "DISEASE", 195, 204], ["cough", "DISEASE", 226, 231], ["fever", "DISEASE", 236, 241], ["Trigeminal and vagus nerves", "DISEASE", 288, 315], ["URTI", "DISEASE", 320, 324], ["cough", "DISEASE", 352, 357], ["infection", "DISEASE", 370, 379], ["rhinitis", "DISEASE", 420, 428], ["runny nose", "DISEASE", 446, 456], ["sneezing", "DISEASE", 458, 466], ["nasal congestion", "DISEASE", 471, 487], ["vagus nerves", "MULTI-TISSUE_STRUCTURE", 303, 315], ["nose", "ORGAN", 401, 405], ["nose", "ORGANISM_SUBDIVISION", 452, 456], ["nasal", "ORGANISM_SUBDIVISION", 471, 476], ["severe acute respiratory syndrome", "PROBLEM", 23, 56], ["SARS", "PROBLEM", 58, 62], ["symptoms", "PROBLEM", 88, 96], ["fever", "PROBLEM", 102, 107], ["non-productive cough", "PROBLEM", 118, 138], ["influenza", "PROBLEM", 195, 204], ["cough", "PROBLEM", 226, 231], ["fever", "PROBLEM", 236, 241], ["Trigeminal and vagus nerves", "PROBLEM", 288, 315], ["Mild URTI", "PROBLEM", 315, 324], ["cough", "PROBLEM", 352, 357], ["the infection", "PROBLEM", 366, 379], ["rhinitis", "PROBLEM", 420, 428], ["symptoms", "PROBLEM", 434, 442], ["runny nose", "PROBLEM", 446, 456], ["sneezing", "PROBLEM", 458, 466], ["nasal congestion", "PROBLEM", 471, 487], ["severe", "OBSERVATION_MODIFIER", 23, 29], ["acute", "OBSERVATION_MODIFIER", 30, 35], ["respiratory syndrome", "OBSERVATION", 36, 56], ["influenza", "OBSERVATION", 195, 204], ["cough", "OBSERVATION", 226, 231], ["vagus nerves", "ANATOMY", 303, 315], ["URTI", "OBSERVATION", 320, 324], ["may not be associated", "UNCERTAINTY", 325, 346], ["cough", "OBSERVATION", 352, 357], ["infection", "OBSERVATION", 370, 379], ["nose", "ANATOMY", 401, 405], ["rhinitis", "OBSERVATION", 420, 428], ["sneezing", "OBSERVATION", 458, 466], ["nasal", "ANATOMY", 471, 476], ["congestion", "OBSERVATION", 477, 487]]], ["The sensory nerve supply to the nose is from the branches of the trigeminal nerve and stimulation of this pathway results in reflex sneezing and secretion but not cough [15] .", [["sensory nerve", "ANATOMY", 4, 17], ["nose", "ANATOMY", 32, 36], ["trigeminal nerve", "ANATOMY", 65, 81], ["sneezing", "DISEASE", 132, 140], ["cough", "DISEASE", 163, 168], ["sensory nerve", "MULTI-TISSUE_STRUCTURE", 4, 17], ["nose", "ORGAN", 32, 36], ["trigeminal nerve", "MULTI-TISSUE_STRUCTURE", 65, 81], ["this pathway", "TEST", 101, 113], ["reflex sneezing", "PROBLEM", 125, 140], ["secretion", "PROBLEM", 145, 154], ["cough", "PROBLEM", 163, 168], ["sensory nerve", "ANATOMY", 4, 17], ["nose", "ANATOMY", 32, 36], ["branches", "ANATOMY_MODIFIER", 49, 57], ["trigeminal nerve", "ANATOMY", 65, 81], ["reflex sneezing", "OBSERVATION", 125, 140]]], ["Cough is said to be mediated exclusively by the vagus nerves [16] and therefore it is not surprising that a mild common cold is not associated with cough as the infection is restricted to the part of the airway supplied by the trigeminal nerves.", [["vagus nerves", "ANATOMY", 48, 60], ["airway", "ANATOMY", 204, 210], ["trigeminal nerves", "ANATOMY", 227, 244], ["Cough", "DISEASE", 0, 5], ["cough", "DISEASE", 148, 153], ["infection", "DISEASE", 161, 170], ["vagus nerves", "MULTI-TISSUE_STRUCTURE", 48, 60], ["airway", "MULTI-TISSUE_STRUCTURE", 204, 210], ["trigeminal nerves", "MULTI-TISSUE_STRUCTURE", 227, 244], ["Cough", "PROBLEM", 0, 5], ["a mild common cold", "PROBLEM", 106, 124], ["cough", "PROBLEM", 148, 153], ["the infection", "PROBLEM", 157, 170], ["vagus nerves", "ANATOMY", 48, 60], ["mild", "OBSERVATION_MODIFIER", 108, 112], ["common", "OBSERVATION", 113, 119], ["not associated with", "UNCERTAINTY", 128, 147], ["cough", "OBSERVATION", 148, 153], ["infection", "OBSERVATION", 161, 170], ["airway", "ANATOMY", 204, 210], ["trigeminal nerves", "ANATOMY", 227, 244]]], ["With more severe URTI the infection and inflammation may spread down the airway to the larynx, trachea and bronchi, and thus involve parts of the airway supplied by the vagus nerves and therefore trigger cough.", [["airway", "ANATOMY", 73, 79], ["larynx", "ANATOMY", 87, 93], ["trachea", "ANATOMY", 95, 102], ["bronchi", "ANATOMY", 107, 114], ["airway", "ANATOMY", 146, 152], ["vagus nerves", "ANATOMY", 169, 181], ["URTI", "DISEASE", 17, 21], ["infection", "DISEASE", 26, 35], ["inflammation", "DISEASE", 40, 52], ["cough", "DISEASE", 204, 209], ["airway", "MULTI-TISSUE_STRUCTURE", 73, 79], ["larynx", "ORGAN", 87, 93], ["trachea", "MULTI-TISSUE_STRUCTURE", 95, 102], ["bronchi", "MULTI-TISSUE_STRUCTURE", 107, 114], ["airway", "MULTI-TISSUE_STRUCTURE", 146, 152], ["vagus nerves", "MULTI-TISSUE_STRUCTURE", 169, 181], ["more severe URTI the infection", "PROBLEM", 5, 35], ["inflammation", "PROBLEM", 40, 52], ["cough", "PROBLEM", 204, 209], ["more", "OBSERVATION_MODIFIER", 5, 9], ["severe", "OBSERVATION_MODIFIER", 10, 16], ["URTI", "OBSERVATION", 17, 21], ["infection", "OBSERVATION", 26, 35], ["inflammation", "OBSERVATION", 40, 52], ["airway", "ANATOMY", 73, 79], ["larynx", "ANATOMY", 87, 93], ["trachea", "ANATOMY", 95, 102], ["bronchi", "ANATOMY", 107, 114], ["airway", "ANATOMY", 146, 152], ["vagus nerves", "ANATOMY", 169, 181], ["cough", "OBSERVATION", 204, 209]]], ["The restriction of the vagus nerve to the parts of the airway from the larynx downwards may explain why cough is a dominant symptom in severe respiratory infections such as influenza and SARS but not a major symptom with common cold.", [["vagus nerve", "ANATOMY", 23, 34], ["airway", "ANATOMY", 55, 61], ["larynx", "ANATOMY", 71, 77], ["respiratory", "ANATOMY", 142, 153], ["cough", "DISEASE", 104, 109], ["respiratory infections", "DISEASE", 142, 164], ["influenza", "DISEASE", 173, 182], ["SARS", "DISEASE", 187, 191], ["vagus nerve", "MULTI-TISSUE_STRUCTURE", 23, 34], ["airway", "MULTI-TISSUE_STRUCTURE", 55, 61], ["larynx", "ORGAN", 71, 77], ["cough", "PROBLEM", 104, 109], ["a dominant symptom", "PROBLEM", 113, 131], ["severe respiratory infections", "PROBLEM", 135, 164], ["influenza", "PROBLEM", 173, 182], ["SARS", "PROBLEM", 187, 191], ["a major symptom", "PROBLEM", 200, 215], ["common cold", "PROBLEM", 221, 232], ["vagus nerve", "ANATOMY", 23, 34], ["parts", "ANATOMY_MODIFIER", 42, 47], ["airway", "ANATOMY", 55, 61], ["larynx", "ANATOMY", 71, 77], ["cough", "OBSERVATION", 104, 109], ["dominant", "OBSERVATION_MODIFIER", 115, 123], ["severe", "OBSERVATION_MODIFIER", 135, 141], ["respiratory infections", "OBSERVATION", 142, 164]]], ["In the course of URTI cough develops as a late symptom [12] and this may be because the infection starts at the level of the nose and gradually spreads down the airway to the larynx.", [["nose", "ANATOMY", 125, 129], ["airway", "ANATOMY", 161, 167], ["larynx", "ANATOMY", 175, 181], ["URTI cough", "DISEASE", 17, 27], ["infection", "DISEASE", 88, 97], ["nose", "ORGAN", 125, 129], ["airway", "MULTI-TISSUE_STRUCTURE", 161, 167], ["larynx", "ORGAN", 175, 181], ["URTI cough", "PROBLEM", 17, 27], ["a late symptom", "PROBLEM", 40, 54], ["the infection", "PROBLEM", 84, 97], ["infection", "OBSERVATION", 88, 97], ["nose", "ANATOMY", 125, 129], ["airway", "ANATOMY", 161, 167], ["larynx", "ANATOMY", 175, 181]]], ["Only when the inflammation involves the structures of the larynx and below does cough develop as a symptom.Cough thresholdCough is a threshold phenomenon and the generation of cough depends on the intensity of the stimulus.", [["structures", "ANATOMY", 40, 50], ["larynx", "ANATOMY", 58, 64], ["inflammation", "DISEASE", 14, 26], ["cough", "DISEASE", 80, 85], ["Cough", "DISEASE", 122, 127], ["cough", "DISEASE", 176, 181], ["larynx", "ORGAN", 58, 64], ["the inflammation", "PROBLEM", 10, 26], ["cough", "PROBLEM", 80, 85], ["a symptom", "PROBLEM", 97, 106], ["Cough threshold", "PROBLEM", 107, 122], ["Cough", "PROBLEM", 122, 127], ["a threshold phenomenon", "PROBLEM", 131, 153], ["cough", "PROBLEM", 176, 181], ["inflammation", "OBSERVATION", 14, 26], ["larynx", "ANATOMY", 58, 64], ["threshold phenomenon", "OBSERVATION", 133, 153], ["cough", "OBSERVATION", 176, 181]]], ["Studies on cough with nebulized chemical irritants such as citric acid and capsaicin clearly demonstrate the threshold nature of cough.", [["cough", "DISEASE", 11, 16], ["citric acid", "CHEMICAL", 59, 70], ["capsaicin", "CHEMICAL", 75, 84], ["cough", "DISEASE", 129, 134], ["citric acid", "CHEMICAL", 59, 70], ["capsaicin", "CHEMICAL", 75, 84], ["citric acid", "SIMPLE_CHEMICAL", 59, 70], ["capsaicin", "SIMPLE_CHEMICAL", 75, 84], ["Studies", "TEST", 0, 7], ["cough", "PROBLEM", 11, 16], ["nebulized chemical irritants", "TREATMENT", 22, 50], ["citric acid", "TREATMENT", 59, 70], ["capsaicin", "TREATMENT", 75, 84], ["cough", "PROBLEM", 129, 134], ["cough", "OBSERVATION", 129, 134]]], ["Low concentrations of citric acid or capsaicin may not induce cough but as the concentration of the irritant is increased so a cough threshold is reached.", [["citric acid", "CHEMICAL", 22, 33], ["capsaicin", "CHEMICAL", 37, 46], ["cough", "DISEASE", 62, 67], ["cough", "DISEASE", 127, 132], ["citric acid", "CHEMICAL", 22, 33], ["capsaicin", "CHEMICAL", 37, 46], ["citric acid", "SIMPLE_CHEMICAL", 22, 33], ["capsaicin", "SIMPLE_CHEMICAL", 37, 46], ["citric acid", "TREATMENT", 22, 33], ["capsaicin", "TREATMENT", 37, 46], ["cough", "PROBLEM", 62, 67], ["the irritant", "PROBLEM", 96, 108], ["a cough threshold", "PROBLEM", 125, 142], ["cough", "OBSERVATION", 62, 67], ["irritant", "OBSERVATION", 100, 108], ["increased", "OBSERVATION_MODIFIER", 112, 121]]], ["The concentration of citric acid or capsaicin needed to induce cough is lower when subjects are suffering from URTI compared with when they are healthy [1, 2] and this demonstrates the threshold nature of cough.Cough thresholdPatients suffering from URTI may not have cough as a symptom but may have a lowered threshold to stimuli that induce cough.", [["citric acid", "CHEMICAL", 21, 32], ["capsaicin", "CHEMICAL", 36, 45], ["cough", "DISEASE", 63, 68], ["URTI", "DISEASE", 111, 115], ["cough", "DISEASE", 205, 210], ["URTI", "DISEASE", 250, 254], ["cough", "DISEASE", 268, 273], ["cough", "DISEASE", 343, 348], ["citric acid", "CHEMICAL", 21, 32], ["capsaicin", "CHEMICAL", 36, 45], ["citric acid", "SIMPLE_CHEMICAL", 21, 32], ["capsaicin", "SIMPLE_CHEMICAL", 36, 45], ["Patients", "ORGANISM", 226, 234], ["Patients", "SPECIES", 226, 234], ["The concentration of citric acid", "TREATMENT", 0, 32], ["capsaicin", "TREATMENT", 36, 45], ["cough", "PROBLEM", 63, 68], ["URTI", "PROBLEM", 111, 115], ["cough", "PROBLEM", 205, 210], ["Cough threshold", "PROBLEM", 211, 226], ["URTI", "PROBLEM", 250, 254], ["cough", "PROBLEM", 268, 273], ["a symptom", "PROBLEM", 277, 286], ["cough", "PROBLEM", 343, 348], ["cough", "OBSERVATION", 205, 210], ["cough", "OBSERVATION", 268, 273], ["cough", "OBSERVATION", 343, 348]]], ["Cold air is one of the most common coughinducing irritants and many persons suffering from cough complain that cough is induced on contact with cold air [17] .", [["cough", "DISEASE", 91, 96], ["cough", "DISEASE", 111, 116], ["persons", "ORGANISM", 68, 75], ["persons", "SPECIES", 68, 75], ["Cold air", "PROBLEM", 0, 8], ["cough", "PROBLEM", 91, 96], ["cough", "PROBLEM", 111, 116], ["air", "OBSERVATION", 5, 8], ["one of the most common", "OBSERVATION_MODIFIER", 12, 34]]], ["In a population of patients suffering from URTI it is possible to induce cough by a stimulus such as airway vibration even though this group of patients do not have cough as a symptom [8, 9] .", [["airway", "ANATOMY", 101, 107], ["URTI", "DISEASE", 43, 47], ["cough", "DISEASE", 73, 78], ["cough", "DISEASE", 165, 170], ["patients", "ORGANISM", 19, 27], ["airway", "MULTI-TISSUE_STRUCTURE", 101, 107], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 144, 152], ["URTI", "PROBLEM", 43, 47], ["cough", "PROBLEM", 73, 78], ["airway vibration", "PROBLEM", 101, 117], ["cough", "PROBLEM", 165, 170], ["cough", "OBSERVATION", 73, 78], ["cough", "OBSERVATION", 165, 170]]], ["In this case one can speculate that the patients with URTI have a lowered threshold to cough and the stimulus of airway vibration is sufficient to induce cough when suffering from URTI but not in the absence of URTI.Cough induced by airway vibrationMechanical stimulation of the lower airway is a potent stimulus for the induction of cough in man as demonstrated by the inhalation of any foreign body into the lower airway.", [["airway", "ANATOMY", 113, 119], ["airway", "ANATOMY", 233, 239], ["lower airway", "ANATOMY", 279, 291], ["body", "ANATOMY", 396, 400], ["lower airway", "ANATOMY", 410, 422], ["URTI", "DISEASE", 54, 58], ["cough", "DISEASE", 87, 92], ["cough", "DISEASE", 154, 159], ["URTI", "DISEASE", 180, 184], ["URTI", "DISEASE", 211, 215], ["Cough", "DISEASE", 216, 221], ["cough", "DISEASE", 334, 339], ["patients", "ORGANISM", 40, 48], ["airway", "MULTI-TISSUE_STRUCTURE", 113, 119], ["airway", "MULTI-TISSUE_STRUCTURE", 233, 239], ["lower airway", "ORGANISM_SUBDIVISION", 279, 291], ["man", "ORGANISM", 343, 346], ["body", "ORGANISM_SUBDIVISION", 396, 400], ["lower airway", "ORGANISM_SUBDIVISION", 410, 422], ["patients", "SPECIES", 40, 48], ["man", "SPECIES", 343, 346], ["URTI", "PROBLEM", 54, 58], ["a lowered threshold to cough", "PROBLEM", 64, 92], ["airway vibration", "PROBLEM", 113, 129], ["cough", "PROBLEM", 154, 159], ["URTI", "PROBLEM", 180, 184], ["URTI", "PROBLEM", 211, 215], ["Cough", "PROBLEM", 216, 221], ["airway vibration", "TREATMENT", 233, 249], ["Mechanical stimulation", "TREATMENT", 249, 271], ["cough", "PROBLEM", 334, 339], ["cough", "OBSERVATION", 87, 92], ["airway", "ANATOMY", 113, 119], ["airway vibration", "OBSERVATION", 233, 249], ["Mechanical stimulation", "OBSERVATION", 249, 271], ["lower", "ANATOMY_MODIFIER", 279, 284], ["airway", "ANATOMY", 285, 291], ["cough", "OBSERVATION", 334, 339], ["foreign body", "OBSERVATION", 388, 400], ["lower", "ANATOMY_MODIFIER", 410, 415], ["airway", "ANATOMY", 416, 422]]], ["One would therefore expect that vibration of the airway would induce cough, as vibration will cause physical deformation of airway sensory receptors such as RARs that mediate cough.", [["airway", "ANATOMY", 49, 55], ["airway", "ANATOMY", 124, 130], ["cough", "DISEASE", 69, 74], ["cough", "DISEASE", 175, 180], ["airway", "MULTI-TISSUE_STRUCTURE", 49, 55], ["airway", "MULTI-TISSUE_STRUCTURE", 124, 130], ["RARs", "GENE_OR_GENE_PRODUCT", 157, 161], ["airway sensory receptors", "PROTEIN", 124, 148], ["RARs", "PROTEIN", 157, 161], ["vibration of the airway", "PROBLEM", 32, 55], ["cough", "PROBLEM", 69, 74], ["physical deformation of airway sensory receptors", "PROBLEM", 100, 148], ["RARs that mediate cough", "PROBLEM", 157, 180], ["airway", "ANATOMY", 49, 55], ["cough", "OBSERVATION", 69, 74], ["airway", "ANATOMY", 124, 130], ["cough", "OBSERVATION", 175, 180]]], ["Mechanical stimulation of the airway experimentally induces cough in anaesthetized animals [6, 7] but there are no reports in the literature to support the idea that airway vibration will induce cough in man apart from recent publications from this Centre [8, 9] .Vibration of the throatVibration of the throat at the level of the jugular notch with a modified battery-operated shaver induces cough in patients with URTI but little or no cough in healthy subjects.", [["airway", "ANATOMY", 30, 36], ["airway", "ANATOMY", 166, 172], ["throat", "ANATOMY", 281, 287], ["throat", "ANATOMY", 304, 310], ["jugular", "ANATOMY", 331, 338], ["cough", "DISEASE", 60, 65], ["airway vibration", "DISEASE", 166, 182], ["cough", "DISEASE", 195, 200], ["cough", "DISEASE", 393, 398], ["URTI", "DISEASE", 416, 420], ["cough", "DISEASE", 438, 443], ["airway", "MULTI-TISSUE_STRUCTURE", 30, 36], ["airway", "MULTI-TISSUE_STRUCTURE", 166, 172], ["throat", "ORGANISM_SUBDIVISION", 281, 287], ["throat", "ORGANISM_SUBDIVISION", 304, 310], ["jugular notch", "MULTI-TISSUE_STRUCTURE", 331, 344], ["patients", "ORGANISM", 402, 410], ["man", "SPECIES", 204, 207], ["patients", "SPECIES", 402, 410], ["Mechanical stimulation", "TREATMENT", 0, 22], ["cough", "PROBLEM", 60, 65], ["airway vibration", "PROBLEM", 166, 182], ["cough", "PROBLEM", 195, 200], ["a modified battery", "TREATMENT", 350, 368], ["cough", "PROBLEM", 393, 398], ["URTI", "PROBLEM", 416, 420], ["cough in healthy subjects", "PROBLEM", 438, 463], ["airway", "ANATOMY", 30, 36], ["cough", "OBSERVATION", 60, 65], ["airway", "ANATOMY", 166, 172], ["throat", "ANATOMY", 281, 287], ["throat", "ANATOMY", 304, 310], ["jugular notch", "ANATOMY", 331, 344], ["cough", "OBSERVATION", 393, 398], ["no", "UNCERTAINTY", 435, 437], ["cough", "OBSERVATION", 438, 443]]], ["The modified battery shaver is illustrated in Fig. 1 , and its application to the throat in Fig. 2 .", [["throat", "ANATOMY", 82, 88], ["throat", "ORGANISM_SUBDIVISION", 82, 88], ["The modified battery shaver", "TREATMENT", 0, 27], ["throat", "ANATOMY", 82, 88]]], ["Mean cough counts for six consecutive episodes of vibration, in healthy subjects and patients with URTI, are illustrated in Fig. 3 .", [["URTI", "DISEASE", 99, 103], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["Mean cough counts", "TEST", 0, 17], ["vibration", "PROBLEM", 50, 59], ["URTI", "PROBLEM", 99, 103]]], ["The figure shows that there was a progressive increase in the number of coughs over the first three periods of vibration in the patients with URTI.", [["coughs", "DISEASE", 72, 78], ["URTI", "DISEASE", 142, 146], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["a progressive increase", "PROBLEM", 32, 54], ["coughs", "PROBLEM", 72, 78], ["URTI", "PROBLEM", 142, 146], ["progressive", "OBSERVATION_MODIFIER", 34, 45], ["increase", "OBSERVATION_MODIFIER", 46, 54], ["number", "OBSERVATION_MODIFIER", 62, 68], ["coughs", "OBSERVATION", 72, 78]]], ["In total, 7/15 healthy subjects coughed at least once during the periods of airway vibration whereas 28/30 of the patients with URTI coughed.", [["airway", "ANATOMY", 76, 82], ["URTI", "DISEASE", 128, 132], ["airway", "MULTI-TISSUE_STRUCTURE", 76, 82], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["URTI coughed", "PROBLEM", 128, 140], ["airway", "ANATOMY", 76, 82]]], ["There was a significant difference in the mean total cough counts for the six episodes of cough between the healthy subjects (0.73) and the patients with URTI (5.63) (PZ0.001) [9] .", [["cough", "DISEASE", 53, 58], ["cough", "DISEASE", 90, 95], ["URTI", "DISEASE", 154, 158], ["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148], ["the mean total cough counts", "PROBLEM", 38, 65], ["cough", "PROBLEM", 90, 95], ["URTI", "TEST", 154, 158], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["difference", "OBSERVATION_MODIFIER", 24, 34], ["cough", "OBSERVATION", 90, 95]]], ["These results demonstrate that vibration of the upper airway causes cough in patients with URTI but little cough in healthy subjects.Vibration of the chest wallChest percussion is often used to facilitate drainage of respiratory secretions in patients with chronic obstructive pulmonary disease or cystic fibrosis but there are no reports that vibration of the chest wall induces cough.", [["upper airway", "ANATOMY", 48, 60], ["chest wall", "ANATOMY", 150, 160], ["respiratory secretions", "ANATOMY", 217, 239], ["pulmonary", "ANATOMY", 277, 286], ["cystic", "ANATOMY", 298, 304], ["chest wall", "ANATOMY", 361, 371], ["cough", "DISEASE", 68, 73], ["URTI", "DISEASE", 91, 95], ["cough", "DISEASE", 107, 112], ["chronic obstructive pulmonary disease", "DISEASE", 257, 294], ["fibrosis", "DISEASE", 305, 313], ["cough", "DISEASE", 380, 385], ["upper airway", "ORGANISM_SUBDIVISION", 48, 60], ["patients", "ORGANISM", 77, 85], ["chest wall", "MULTI-TISSUE_STRUCTURE", 150, 160], ["patients", "ORGANISM", 243, 251], ["pulmonary", "ORGAN", 277, 286], ["chest wall", "MULTI-TISSUE_STRUCTURE", 361, 371], ["patients", "SPECIES", 77, 85], ["patients", "SPECIES", 243, 251], ["vibration of the upper airway", "PROBLEM", 31, 60], ["cough", "PROBLEM", 68, 73], ["URTI", "PROBLEM", 91, 95], ["little cough in healthy subjects", "PROBLEM", 100, 132], ["Chest percussion", "TEST", 160, 176], ["drainage", "TREATMENT", 205, 213], ["respiratory secretions", "PROBLEM", 217, 239], ["chronic obstructive pulmonary disease", "PROBLEM", 257, 294], ["cystic fibrosis", "PROBLEM", 298, 313], ["cough", "PROBLEM", 380, 385], ["vibration", "OBSERVATION", 31, 40], ["upper", "ANATOMY_MODIFIER", 48, 53], ["airway", "ANATOMY", 54, 60], ["cough", "OBSERVATION", 68, 73], ["little", "OBSERVATION_MODIFIER", 100, 106], ["cough", "OBSERVATION", 107, 112], ["chest", "ANATOMY", 150, 155], ["wall", "ANATOMY_MODIFIER", 156, 160], ["Chest", "ANATOMY", 160, 165], ["percussion", "OBSERVATION", 166, 176], ["respiratory", "ANATOMY", 217, 228], ["secretions", "OBSERVATION", 229, 239], ["chronic", "OBSERVATION_MODIFIER", 257, 264], ["obstructive", "OBSERVATION_MODIFIER", 265, 276], ["pulmonary", "ANATOMY", 277, 286], ["disease", "OBSERVATION", 287, 294], ["cystic", "OBSERVATION_MODIFIER", 298, 304], ["fibrosis", "OBSERVATION", 305, 313], ["chest", "ANATOMY", 361, 366], ["wall", "ANATOMY_MODIFIER", 367, 371], ["cough", "OBSERVATION", 380, 385]]], ["Chest wall vibration in healthy volunteers and patients with asthma has been reported to create a sensation of breathlessness but these studies have not shown any cough [18, 19] .", [["Chest wall", "ANATOMY", 0, 10], ["asthma", "DISEASE", 61, 67], ["breathlessness", "DISEASE", 111, 125], ["cough", "DISEASE", 163, 168], ["Chest wall", "MULTI-TISSUE_STRUCTURE", 0, 10], ["volunteers", "ORGANISM", 32, 42], ["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["Chest wall vibration in healthy volunteers", "PROBLEM", 0, 42], ["asthma", "PROBLEM", 61, 67], ["breathlessness", "PROBLEM", 111, 125], ["these studies", "TEST", 130, 143], ["any cough", "PROBLEM", 159, 168], ["wall", "ANATOMY_MODIFIER", 6, 10], ["vibration", "OBSERVATION", 11, 20], ["healthy volunteers", "OBSERVATION_MODIFIER", 24, 42], ["asthma", "OBSERVATION", 61, 67]]], ["Similarly, studies on chest wall vibration in anaesthetized dogs showed an increased clearance of tracheal mucus but no cough [20, 21] .Vibration of the chest wallVibration of the chest over the manubrium sternum with a chest percussor (model G5 Variko percussor, Physiotherapie Generale, France S.A.) induces cough in patients with URTI but little or no cough in healthy subjects.", [["chest wall", "ANATOMY", 22, 32], ["tracheal mucus", "ANATOMY", 98, 112], ["chest wall", "ANATOMY", 153, 163], ["chest", "ANATOMY", 180, 185], ["manubrium sternum", "ANATOMY", 195, 212], ["chest", "ANATOMY", 220, 225], ["cough", "DISEASE", 120, 125], ["cough", "DISEASE", 310, 315], ["URTI", "DISEASE", 333, 337], ["cough", "DISEASE", 355, 360], ["chest wall", "MULTI-TISSUE_STRUCTURE", 22, 32], ["dogs", "ORGANISM", 60, 64], ["tracheal mucus", "TISSUE", 98, 112], ["chest wall", "MULTI-TISSUE_STRUCTURE", 153, 163], ["chest", "ORGAN", 180, 185], ["sternum", "ORGAN", 205, 212], ["patients", "ORGANISM", 319, 327], ["dogs", "SPECIES", 60, 64], ["patients", "SPECIES", 319, 327], ["chest wall vibration", "TEST", 22, 42], ["anaesthetized dogs", "TEST", 46, 64], ["an increased clearance of tracheal mucus", "PROBLEM", 72, 112], ["cough", "PROBLEM", 120, 125], ["a chest percussor (model G5 Variko percussor", "TREATMENT", 218, 262], ["cough", "PROBLEM", 310, 315], ["URTI", "PROBLEM", 333, 337], ["cough in healthy subjects", "PROBLEM", 355, 380], ["chest", "ANATOMY", 22, 27], ["increased", "OBSERVATION_MODIFIER", 75, 84], ["clearance", "OBSERVATION_MODIFIER", 85, 94], ["tracheal", "ANATOMY", 98, 106], ["mucus", "OBSERVATION", 107, 112], ["no", "UNCERTAINTY", 117, 119], ["cough", "OBSERVATION", 120, 125], ["chest", "ANATOMY", 153, 158], ["wall", "ANATOMY_MODIFIER", 159, 163], ["Vibration", "OBSERVATION", 163, 172], ["chest", "ANATOMY", 180, 185], ["manubrium", "ANATOMY_MODIFIER", 195, 204], ["sternum", "ANATOMY", 205, 212], ["chest", "ANATOMY", 220, 225], ["cough", "OBSERVATION", 310, 315], ["no", "UNCERTAINTY", 352, 354], ["cough", "OBSERVATION", 355, 360]]], ["An illustration of the application of the chest percussor is shown in Fig. 4 .", [["chest", "ANATOMY", 42, 47], ["the chest percussor", "TREATMENT", 38, 57], ["chest", "ANATOMY", 42, 47]]], ["The percussor was applied to the chest and the vibration applied for a maximum of 1 min.", [["chest", "ANATOMY", 33, 38], ["chest", "ORGAN", 33, 38], ["The percussor", "TREATMENT", 0, 13], ["chest", "ANATOMY", 33, 38]]], ["The vibration was switched off when the subject first coughed, and the number of coughs in the 2 min period from the start of the vibration was counted.", [["coughs", "DISEASE", 81, 87], ["The vibration", "TREATMENT", 0, 13], ["coughs", "PROBLEM", 81, 87], ["vibration", "OBSERVATION_MODIFIER", 4, 13], ["coughs", "OBSERVATION", 81, 87]]], ["Mean cough counts for three consecutive episodes of vibration are shown in Fig. 5 .", [["Mean cough counts", "TEST", 0, 17], ["vibration", "PROBLEM", 52, 61]]], ["In total, 2/15 healthy subjects coughed at least once during the periods of airway vibration whereas 25/29 of the patients with URTI coughed.", [["airway", "ANATOMY", 76, 82], ["URTI", "DISEASE", 128, 132], ["airway", "MULTI-TISSUE_STRUCTURE", 76, 82], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["URTI coughed", "PROBLEM", 128, 140], ["airway", "ANATOMY", 76, 82]]], ["There was a significant difference in the mean total cough counts for the three episodes of cough between the healthy subjects (0.47) and the patients with URTI (7.48) (PZ0.01) [8] .", [["cough", "DISEASE", 53, 58], ["cough", "DISEASE", 92, 97], ["URTI", "DISEASE", 156, 160], ["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150], ["the mean total cough counts", "PROBLEM", 38, 65], ["cough", "PROBLEM", 92, 97], ["URTI", "TEST", 156, 160], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["difference", "OBSERVATION_MODIFIER", 24, 34], ["cough", "OBSERVATION", 92, 97]]], ["These results demonstrate that vibration of the chest with a percussor causes cough in patients with URTI but little cough in healthy subjects.Cough recruitmentThe studies on cough induction by airway vibration described above demonstrated that there was a progressive increase in the number of coughs with each period of airway vibration.", [["chest", "ANATOMY", 48, 53], ["airway", "ANATOMY", 194, 200], ["airway", "ANATOMY", 322, 328], ["cough", "DISEASE", 78, 83], ["URTI", "DISEASE", 101, 105], ["cough", "DISEASE", 117, 122], ["Cough", "DISEASE", 143, 148], ["cough", "DISEASE", 175, 180], ["coughs", "DISEASE", 295, 301], ["chest", "ORGAN", 48, 53], ["patients", "ORGANISM", 87, 95], ["airway", "MULTI-TISSUE_STRUCTURE", 194, 200], ["airway", "MULTI-TISSUE_STRUCTURE", 322, 328], ["patients", "SPECIES", 87, 95], ["vibration of the chest", "PROBLEM", 31, 53], ["a percussor", "TREATMENT", 59, 70], ["cough", "PROBLEM", 78, 83], ["URTI", "PROBLEM", 101, 105], ["little cough in healthy subjects", "PROBLEM", 110, 142], ["Cough recruitment", "PROBLEM", 143, 160], ["The studies", "TEST", 160, 171], ["cough induction", "TREATMENT", 175, 190], ["airway vibration", "TEST", 194, 210], ["a progressive increase", "PROBLEM", 255, 277], ["coughs", "PROBLEM", 295, 301], ["airway vibration", "PROBLEM", 322, 338], ["vibration", "OBSERVATION", 31, 40], ["chest", "ANATOMY", 48, 53], ["cough", "OBSERVATION", 78, 83], ["little", "OBSERVATION_MODIFIER", 110, 116], ["cough", "OBSERVATION", 117, 122], ["recruitment", "OBSERVATION_MODIFIER", 149, 160], ["airway", "ANATOMY", 194, 200], ["progressive", "OBSERVATION_MODIFIER", 257, 268], ["increase", "OBSERVATION_MODIFIER", 269, 277], ["number", "OBSERVATION_MODIFIER", 285, 291], ["coughs", "OBSERVATION", 295, 301], ["airway vibration", "OBSERVATION", 322, 338]]], ["This recruitment of cough is clear in Fig. 3 . where the number of coughs reached a maximum after three periods of throat vibration, and is also apparent in Fig. 5 where the number of coughs is greatest after three periods of chest percussion.", [["throat", "ANATOMY", 115, 121], ["chest", "ANATOMY", 226, 231], ["cough", "DISEASE", 20, 25], ["coughs", "DISEASE", 67, 73], ["coughs", "DISEASE", 184, 190], ["throat", "ORGANISM_SUBDIVISION", 115, 121], ["chest", "ORGANISM_SUBDIVISION", 226, 231], ["cough", "PROBLEM", 20, 25], ["coughs", "PROBLEM", 67, 73], ["throat vibration", "PROBLEM", 115, 131], ["coughs", "PROBLEM", 184, 190], ["chest percussion", "TEST", 226, 242], ["cough", "OBSERVATION", 20, 25], ["clear", "OBSERVATION", 29, 34], ["coughs", "OBSERVATION", 67, 73], ["coughs", "OBSERVATION", 184, 190], ["greatest", "OBSERVATION_MODIFIER", 194, 202], ["chest", "ANATOMY", 226, 231]]], ["These results indicate that there is some recruitment or facilitation of cough with repeated airway vibration.", [["airway", "ANATOMY", 93, 99], ["cough", "DISEASE", 73, 78], ["airway", "MULTI-TISSUE_STRUCTURE", 93, 99], ["cough", "PROBLEM", 73, 78], ["repeated airway vibration", "PROBLEM", 84, 109], ["some", "OBSERVATION_MODIFIER", 37, 41], ["recruitment", "OBSERVATION", 42, 53], ["cough", "OBSERVATION", 73, 78], ["airway", "ANATOMY", 93, 99]]], ["The cough recruitment could be due to cough itself traumatizing the airway and causing the release of inflammatory mediators, or it could be due to a central rather than a peripheral mechanism.", [["airway", "ANATOMY", 68, 74], ["cough", "DISEASE", 4, 9], ["cough", "DISEASE", 38, 43], ["airway", "MULTI-TISSUE_STRUCTURE", 68, 74], ["inflammatory mediators", "PROTEIN", 102, 124], ["The cough recruitment", "PROBLEM", 0, 21], ["cough", "PROBLEM", 38, 43], ["inflammatory mediators", "PROBLEM", 102, 124], ["a peripheral mechanism", "PROBLEM", 170, 192], ["cough", "OBSERVATION", 4, 9], ["could be due to", "UNCERTAINTY", 22, 37], ["cough", "OBSERVATION", 38, 43], ["airway", "ANATOMY", 68, 74], ["inflammatory", "OBSERVATION_MODIFIER", 102, 114], ["central", "OBSERVATION_MODIFIER", 150, 157], ["peripheral mechanism", "OBSERVATION", 172, 192]]], ["Brainstem mechanisms such as cough exhibit plasticity and short-and long-term memories that affect the response [22] and it is possible that this type of memory would lead to an enhancement of the cough reflex.Airway vibration as a cough modelIn a recent review on the development of new cough medicines O'Connell [23] stated that:Airway vibration as a cough modelPreliminary studies in healthy human volunteers may continue to be useful but ultimately these studies should also be carried out in patients with cough who show enhanced cough sensitivity to inhaled tussigens.", [["Airway", "ANATOMY", 210, 216], ["Airway", "ANATOMY", 331, 337], ["cough", "DISEASE", 29, 34], ["cough", "DISEASE", 197, 202], ["cough", "DISEASE", 232, 237], ["cough", "DISEASE", 288, 293], ["cough", "DISEASE", 353, 358], ["cough", "DISEASE", 511, 516], ["cough", "DISEASE", 535, 540], ["Airway", "MULTI-TISSUE_STRUCTURE", 210, 216], ["Airway", "MULTI-TISSUE_STRUCTURE", 331, 337], ["human", "ORGANISM", 395, 400], ["volunteers", "ORGANISM", 401, 411], ["patients", "ORGANISM", 497, 505], ["human", "SPECIES", 395, 400], ["patients", "SPECIES", 497, 505], ["human", "SPECIES", 395, 400], ["Brainstem mechanisms", "PROBLEM", 0, 20], ["cough", "PROBLEM", 29, 34], ["short-and long-term memories", "PROBLEM", 58, 86], ["the cough reflex", "PROBLEM", 193, 209], ["Airway vibration", "PROBLEM", 210, 226], ["a cough model", "PROBLEM", 230, 243], ["new cough medicines", "PROBLEM", 284, 303], ["Airway vibration", "PROBLEM", 331, 347], ["a cough model", "TREATMENT", 351, 364], ["Preliminary studies", "TEST", 364, 383], ["these studies", "TEST", 453, 466], ["cough", "PROBLEM", 511, 516], ["enhanced cough sensitivity", "PROBLEM", 526, 552], ["inhaled tussigens", "TREATMENT", 556, 573], ["cough", "OBSERVATION", 197, 202], ["Airway", "ANATOMY", 331, 337]]], ["Based on current knowledge, the challenge is to find an antitussive agent which can return the abnormal sensitivity of the cough reflex to normal.Airway vibration as a cough modelA case can be made that airway vibration as described above may prove to be a useful model for future clinical trials on cough medicines that can return the sensitivity of the cough reflex towards normal, and that airway vibration may have some advantages for inducing cough when compared with methods using inhaled tussigens.Ease of use of airway vibrationCompared with methods using inhaled tussigens airway vibration offers a much easier means of inducing cough.", [["Airway", "ANATOMY", 146, 152], ["airway", "ANATOMY", 203, 209], ["airway", "ANATOMY", 393, 399], ["airway", "ANATOMY", 520, 526], ["airway", "ANATOMY", 582, 588], ["cough", "DISEASE", 123, 128], ["cough", "DISEASE", 168, 173], ["cough", "DISEASE", 300, 305], ["cough", "DISEASE", 355, 360], ["cough", "DISEASE", 448, 453], ["cough", "DISEASE", 638, 643], ["Airway", "MULTI-TISSUE_STRUCTURE", 146, 152], ["airway", "MULTI-TISSUE_STRUCTURE", 203, 209], ["airway", "MULTI-TISSUE_STRUCTURE", 393, 399], ["airway", "MULTI-TISSUE_STRUCTURE", 520, 526], ["airway", "MULTI-TISSUE_STRUCTURE", 582, 588], ["an antitussive agent", "TREATMENT", 53, 73], ["the cough reflex", "TEST", 119, 135], ["Airway vibration", "PROBLEM", 146, 162], ["a cough model", "PROBLEM", 166, 179], ["airway vibration", "PROBLEM", 203, 219], ["cough medicines", "TREATMENT", 300, 315], ["the cough reflex", "TEST", 351, 367], ["airway vibration", "TREATMENT", 393, 409], ["inducing cough", "PROBLEM", 439, 453], ["inhaled tussigens", "TREATMENT", 487, 504], ["airway vibration", "TREATMENT", 520, 536], ["inhaled tussigens airway vibration", "TREATMENT", 564, 598], ["inducing cough", "PROBLEM", 629, 643], ["airway", "ANATOMY", 203, 209], ["airway", "ANATOMY", 393, 399], ["cough", "OBSERVATION", 448, 453], ["airway", "ANATOMY", 520, 526], ["cough", "OBSERVATION", 638, 643]]], ["The Variko G5 percussor is a standard clinical instrument that is marketed world wide for the mobilisation of secretions in patients with chronic respiratory disease.", [["secretions", "ANATOMY", 110, 120], ["respiratory", "ANATOMY", 146, 157], ["chronic respiratory disease", "DISEASE", 138, 165], ["secretions", "ORGANISM_SUBSTANCE", 110, 120], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["The Variko G5 percussor", "TREATMENT", 0, 23], ["a standard clinical instrument", "TREATMENT", 27, 57], ["secretions", "PROBLEM", 110, 120], ["chronic respiratory disease", "PROBLEM", 138, 165], ["secretions", "OBSERVATION", 110, 120], ["chronic", "OBSERVATION_MODIFIER", 138, 145], ["respiratory disease", "OBSERVATION", 146, 165]]], ["In comparison with methods using inhaled tussigens the use of the percussor offers a much simpler method of inducing cough as minimal cooperation is required from the patient, there is no need to make up and store tussigenic solutions, and the duration and intensity of the stimulus is easily controlled.SafetyAirway vibration is a non-invasive and safe method of inducing cough, and chest percussion is widely used in children as a means of mobilizing airway secretions in conditions such as cystic fibrosis [24] .", [["chest", "ANATOMY", 384, 389], ["airway", "ANATOMY", 453, 459], ["cystic", "ANATOMY", 493, 499], ["cough", "DISEASE", 117, 122], ["cough", "DISEASE", 373, 378], ["chest percussion", "DISEASE", 384, 400], ["cystic fibrosis", "DISEASE", 493, 508], ["patient", "ORGANISM", 167, 174], ["chest", "ORGANISM_SUBDIVISION", 384, 389], ["children", "ORGANISM", 419, 427], ["airway secretions", "MULTI-TISSUE_STRUCTURE", 453, 470], ["patient", "SPECIES", 167, 174], ["children", "SPECIES", 419, 427], ["the percussor", "TREATMENT", 62, 75], ["inducing cough", "PROBLEM", 108, 122], ["inducing cough", "PROBLEM", 364, 378], ["chest percussion", "TEST", 384, 400], ["mobilizing airway secretions in conditions", "PROBLEM", 442, 484], ["cystic fibrosis", "PROBLEM", 493, 508], ["chest", "ANATOMY", 384, 389], ["airway", "ANATOMY", 453, 459], ["secretions", "OBSERVATION", 460, 470], ["cystic", "OBSERVATION_MODIFIER", 493, 499], ["fibrosis", "OBSERVATION", 500, 508]]], ["Although there are no reported safety issues with inhaled tussigens such as citric acid and capsaicin the fact that they are administered directly into the airway and that they may induce bronchoconstriction means that they need to be used with care in patients with respiratory disease.StandardisationInhaled tussigens have been used for decades and there is a large literature on this method of inducing cough.", [["airway", "ANATOMY", 156, 162], ["respiratory", "ANATOMY", 267, 278], ["citric acid", "CHEMICAL", 76, 87], ["capsaicin", "CHEMICAL", 92, 101], ["respiratory disease", "DISEASE", 267, 286], ["tussigens", "CHEMICAL", 310, 319], ["cough", "DISEASE", 406, 411], ["citric acid", "CHEMICAL", 76, 87], ["capsaicin", "CHEMICAL", 92, 101], ["tussigens", "SIMPLE_CHEMICAL", 58, 67], ["citric acid", "SIMPLE_CHEMICAL", 76, 87], ["capsaicin", "SIMPLE_CHEMICAL", 92, 101], ["airway", "MULTI-TISSUE_STRUCTURE", 156, 162], ["patients", "ORGANISM", 253, 261], ["patients", "SPECIES", 253, 261], ["inhaled tussigens", "TREATMENT", 50, 67], ["citric acid", "TREATMENT", 76, 87], ["capsaicin", "TREATMENT", 92, 101], ["bronchoconstriction", "PROBLEM", 188, 207], ["respiratory disease", "PROBLEM", 267, 286], ["StandardisationInhaled tussigens", "TREATMENT", 287, 319], ["inducing cough", "PROBLEM", 397, 411], ["no", "UNCERTAINTY", 19, 21], ["airway", "ANATOMY", 156, 162], ["respiratory disease", "OBSERVATION", 267, 286], ["large", "OBSERVATION_MODIFIER", 362, 367], ["cough", "OBSERVATION", 406, 411]]], ["However, there is no standardization of methods for induction of cough with inhaled tussigens and Morice et al. [25] state that results from different centres are difficult to compare or reproduce as a wide range of different methods are used, and absence of standardization is a major problem.", [["cough", "DISEASE", 65, 70], ["cough", "PROBLEM", 65, 70], ["inhaled tussigens", "TREATMENT", 76, 93], ["a major problem", "PROBLEM", 278, 293], ["no", "UNCERTAINTY", 18, 20]]], ["Airway vibration is a new method of inducing cough but it has the potential for easy standardization as standard medical equipment such as the Variko G5 percussor is available for use.Discrimination between healthy and hyperreactive subjectsIt is important that any method of inducing cough should be able to discriminate between healthy and hyperreactive subjects as future research on cough medicines will be directed towards returning the sensitivity of the cough reflex back towards normal as described above [23] .Discrimination between healthy and hyperreactive subjectsIt is possible to demonstrate airway hyperreactivity with inhaled tussigens but airway vibration may be a more sensitive method.", [["Airway", "ANATOMY", 0, 6], ["airway", "ANATOMY", 606, 612], ["airway", "ANATOMY", 656, 662], ["cough", "DISEASE", 45, 50], ["cough", "DISEASE", 285, 290], ["cough", "DISEASE", 387, 392], ["cough", "DISEASE", 461, 466], ["Airway", "MULTI-TISSUE_STRUCTURE", 0, 6], ["airway", "MULTI-TISSUE_STRUCTURE", 606, 612], ["airway", "MULTI-TISSUE_STRUCTURE", 656, 662], ["Airway vibration", "PROBLEM", 0, 16], ["inducing cough", "PROBLEM", 36, 50], ["standard medical equipment", "TREATMENT", 104, 130], ["the Variko G5 percussor", "TREATMENT", 139, 162], ["hyperreactive subjects", "PROBLEM", 219, 241], ["inducing cough", "PROBLEM", 276, 290], ["hyperreactive subjects", "PROBLEM", 342, 364], ["cough medicines", "TREATMENT", 387, 402], ["the cough reflex", "TEST", 457, 473], ["hyperreactive subjects", "PROBLEM", 554, 576], ["airway hyperreactivity", "PROBLEM", 606, 628], ["inhaled tussigens", "TREATMENT", 634, 651], ["airway vibration", "PROBLEM", 656, 672], ["vibration", "OBSERVATION", 7, 16], ["new", "OBSERVATION_MODIFIER", 22, 25], ["hyperreactive", "OBSERVATION", 219, 232], ["hyperreactive", "OBSERVATION", 554, 567], ["possible to demonstrate", "UNCERTAINTY", 582, 605], ["airway", "ANATOMY", 606, 612], ["hyperreactivity", "OBSERVATION", 613, 628], ["airway", "ANATOMY", 656, 662]]], ["In a study on citric acid-induced cough the threshold concentration that caused cough in patients with URTI was 2% whereas the threshold concentration in healthy subjects was 3.75% [1] .", [["citric", "CHEMICAL", 14, 20], ["cough", "DISEASE", 34, 39], ["cough", "DISEASE", 80, 85], ["URTI", "DISEASE", 103, 107], ["citric acid-induced", "CHEMICAL", 14, 33], ["citric", "SIMPLE_CHEMICAL", 14, 20], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["a study", "TEST", 3, 10], ["citric acid-induced cough", "TREATMENT", 14, 39], ["the threshold concentration", "TREATMENT", 40, 67], ["cough", "PROBLEM", 80, 85], ["URTI", "PROBLEM", 103, 107], ["cough", "OBSERVATION", 80, 85]]], ["In a study on capsaicin-induced cough the log concentration of capsaicin (micromoles) needed to induce two coughs (C2) in patients with URTI was 0.27 whereas in healthy subjects the C2 was 0.89 [2] .", [["capsaicin", "CHEMICAL", 14, 23], ["cough", "DISEASE", 32, 37], ["capsaicin", "CHEMICAL", 63, 72], ["micromoles", "CHEMICAL", 74, 84], ["coughs", "DISEASE", 107, 113], ["URTI", "DISEASE", 136, 140], ["capsaicin", "CHEMICAL", 14, 23], ["capsaicin", "CHEMICAL", 63, 72], ["micromoles", "CHEMICAL", 74, 84], ["capsaicin", "SIMPLE_CHEMICAL", 14, 23], ["capsaicin", "SIMPLE_CHEMICAL", 63, 72], ["micromoles", "SIMPLE_CHEMICAL", 74, 84], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["a study", "TEST", 3, 10], ["capsaicin", "TREATMENT", 14, 23], ["cough", "PROBLEM", 32, 37], ["capsaicin (micromoles)", "TREATMENT", 63, 85], ["two coughs (C2)", "PROBLEM", 103, 118], ["URTI", "TEST", 136, 140], ["C2", "ANATOMY", 182, 184]]], ["These studies on inhaled tussigens indicate that patients with URTI need only 30-50% of the concentration of tussigen in order to induce cough compared with healthy subjects.", [["URTI", "DISEASE", 63, 67], ["tussigen", "CHEMICAL", 109, 117], ["cough", "DISEASE", 137, 142], ["tussigen", "CHEMICAL", 109, 117], ["patients", "ORGANISM", 49, 57], ["tussigen", "SIMPLE_CHEMICAL", 109, 117], ["patients", "SPECIES", 49, 57], ["These studies", "TEST", 0, 13], ["inhaled tussigens", "TEST", 17, 34], ["URTI", "PROBLEM", 63, 67], ["the concentration of tussigen", "TREATMENT", 88, 117], ["cough", "PROBLEM", 137, 142], ["cough", "OBSERVATION", 137, 142]]], ["The studies on airway vibration described above, indicate that this method may be better able to discriminate between healthy and hyperreactive patients than methods using inhaled tussigens.", [["airway", "ANATOMY", 15, 21], ["hyperreactive", "DISEASE", 130, 143], ["airway", "MULTI-TISSUE_STRUCTURE", 15, 21], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152], ["The studies on airway vibration", "TEST", 0, 31], ["inhaled tussigens", "TREATMENT", 172, 189], ["airway", "ANATOMY", 15, 21], ["hyperreactive", "OBSERVATION_MODIFIER", 130, 143]]], ["A great advantage is that airway vibration induces very little cough in healthy subjects and therefore there is a great difference in the total number of coughs induced in healthy and URTI patients as described above.", [["airway", "ANATOMY", 26, 32], ["cough", "DISEASE", 63, 68], ["coughs", "DISEASE", 154, 160], ["URTI", "DISEASE", 184, 188], ["airway", "MULTI-TISSUE_STRUCTURE", 26, 32], ["patients", "ORGANISM", 189, 197], ["patients", "SPECIES", 189, 197], ["airway vibration", "PROBLEM", 26, 42], ["very little cough in healthy subjects", "PROBLEM", 51, 88], ["coughs", "PROBLEM", 154, 160], ["airway", "ANATOMY", 26, 32], ["very", "OBSERVATION_MODIFIER", 51, 55], ["little", "OBSERVATION_MODIFIER", 56, 62], ["cough", "OBSERVATION", 63, 68], ["great", "OBSERVATION_MODIFIER", 114, 119], ["difference", "OBSERVATION_MODIFIER", 120, 130], ["coughs", "OBSERVATION", 154, 160]]], ["The large difference in cough sensitivity between healthy and URTI patients demonstrated with airway vibration means that this method could be useful in studying cough medicines that may return the sensitivity of the cough reflex back towards normal, as normal in this case would be the absence of cough or a very long latency to cough.ConclusionsAirway vibration is a safe, non-invasive method of inducing cough in patients with URTI.", [["airway", "ANATOMY", 94, 100], ["Airway", "ANATOMY", 347, 353], ["cough", "DISEASE", 24, 29], ["URTI", "DISEASE", 62, 66], ["cough", "DISEASE", 162, 167], ["cough", "DISEASE", 217, 222], ["cough", "DISEASE", 298, 303], ["cough", "DISEASE", 330, 335], ["cough", "DISEASE", 407, 412], ["URTI", "DISEASE", 430, 434], ["patients", "ORGANISM", 67, 75], ["airway", "MULTI-TISSUE_STRUCTURE", 94, 100], ["Airway", "MULTI-TISSUE_STRUCTURE", 347, 353], ["patients", "ORGANISM", 416, 424], ["patients", "SPECIES", 67, 75], ["patients", "SPECIES", 416, 424], ["The large difference in cough sensitivity", "PROBLEM", 0, 41], ["airway vibration", "TREATMENT", 94, 110], ["cough medicines", "TREATMENT", 162, 177], ["the cough reflex", "TEST", 213, 229], ["cough", "PROBLEM", 298, 303], ["a very long latency to cough", "PROBLEM", 307, 335], ["inducing cough", "PROBLEM", 398, 412], ["URTI", "PROBLEM", 430, 434], ["large", "OBSERVATION_MODIFIER", 4, 9], ["difference", "OBSERVATION_MODIFIER", 10, 20], ["cough", "OBSERVATION", 24, 29], ["airway", "ANATOMY", 94, 100], ["cough", "OBSERVATION", 298, 303], ["Airway", "ANATOMY", 347, 353], ["cough", "OBSERVATION", 407, 412]]], ["The relatively low level of cough induced by airway vibration in healthy subjects indicates that this method may be useful for studies on airway hyperreactivity as the method readily discriminates between health and disease.", [["airway", "ANATOMY", 45, 51], ["airway", "ANATOMY", 138, 144], ["cough", "DISEASE", 28, 33], ["airway", "MULTI-TISSUE_STRUCTURE", 45, 51], ["airway", "MULTI-TISSUE_STRUCTURE", 138, 144], ["cough", "PROBLEM", 28, 33], ["airway vibration in healthy subjects", "PROBLEM", 45, 81], ["airway hyperreactivity", "PROBLEM", 138, 160], ["disease", "PROBLEM", 216, 223], ["relatively", "OBSERVATION_MODIFIER", 4, 14], ["low", "OBSERVATION_MODIFIER", 15, 18], ["cough", "OBSERVATION", 28, 33], ["airway", "ANATOMY", 45, 51], ["airway", "ANATOMY", 138, 144], ["hyperreactivity", "OBSERVATION", 145, 160]]]], "aad05ced5d7417fb57a6a64a14858663e5601fa8": [["Additionally, individual genetic variation in the three major histocompatibility complex (MHC) class 1 genes have been reported to affect the severity of SARS-CoV-2 infection, 14 which could also explain the manifestation of Kawasaki disease in some infected children observed in Europe and the USA who might share a different MHC class 1 gene from that of Asian children.", [["SARS-CoV-2 infection", "DISEASE", 154, 174], ["Kawasaki disease", "DISEASE", 225, 241], ["major histocompatibility complex (MHC) class 1", "GENE_OR_GENE_PRODUCT", 56, 102], ["SARS-CoV-2", "ORGANISM", 154, 164], ["children", "ORGANISM", 259, 267], ["MHC class 1", "GENE_OR_GENE_PRODUCT", 327, 338], ["children", "ORGANISM", 363, 371], ["major histocompatibility complex (MHC) class 1 genes", "DNA", 56, 108], ["MHC class 1 gene", "DNA", 327, 343], ["children", "SPECIES", 259, 267], ["children", "SPECIES", 363, 371], ["SARS-CoV-2", "SPECIES", 154, 164], ["individual genetic variation", "PROBLEM", 14, 42], ["SARS", "PROBLEM", 154, 158], ["CoV-2 infection", "PROBLEM", 159, 174], ["Kawasaki disease", "PROBLEM", 225, 241], ["genetic variation", "OBSERVATION", 25, 42], ["SARS", "OBSERVATION", 154, 158], ["Kawasaki disease", "OBSERVATION", 225, 241]]], ["Genetic studies in SARS-CoV-2-infected children worldwide can provide more information regarding the association of certain MHC class 1 genes with Kawasaki disease, MIS-C, or PIMS-TS.", [["SARS-CoV-2-infected", "DISEASE", 19, 38], ["Kawasaki disease", "DISEASE", 147, 163], ["SARS-CoV-2", "ORGANISM", 19, 29], ["children", "ORGANISM", 39, 47], ["MHC class 1", "GENE_OR_GENE_PRODUCT", 124, 135], ["MIS-C", "GENE_OR_GENE_PRODUCT", 165, 170], ["MHC class 1 genes", "DNA", 124, 141], ["CoV-2", "SPECIES", 24, 29], ["children", "SPECIES", 39, 47], ["SARS-CoV-2", "SPECIES", 19, 29], ["Genetic studies", "TEST", 0, 15], ["SARS", "TEST", 19, 23], ["CoV", "TEST", 24, 27], ["Kawasaki disease", "PROBLEM", 147, 163], ["PIMS", "PROBLEM", 175, 179]]]], "dc91750f913c083da70bb7dd1816c0418eaf346d": [["In the early years of emergency care, EDs received a limited number of patients, most of whom had experienced some form of injury.", [["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["injury", "PROBLEM", 123, 129], ["injury", "OBSERVATION", 123, 129]]], ["With demographic changes in society, increasing life expectancy and greater personal and clinical expectations, EDs now deal with a greater proportion of patients with medical illnesses rather than traumatic injury, and attendance rates have soared [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] .IntroductionOvercrowding in EDs is well recognised to contribute to poor outcomes, increased mortality, and poor staff morale.", [["traumatic injury", "DISEASE", 198, 214], ["Overcrowding", "DISEASE", 318, 330], ["[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11]", "CHEMICAL", 249, 294], ["patients", "ORGANISM", 154, 162], ["[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13]", "SIMPLE_CHEMICAL", 249, 304], ["patients", "SPECIES", 154, 162], ["medical illnesses", "PROBLEM", 168, 185], ["traumatic injury", "PROBLEM", 198, 214], ["attendance rates", "TEST", 220, 236], ["increased mortality", "PROBLEM", 389, 408]]], ["Access block is commonly encountered in the ED, and is a function of hospital-wide issues with poor discharge planning and lack of beds being common causes.", [["Access block", "TREATMENT", 0, 12]]], ["Increased expectations from patients, emergency physicians, and other clinicians has led to increasing demands on ED services, and higher expectations of definitive diagnosis has led to more testing and radiological investigations being performed in the ED setting.IntroductionPoint of care testing has extended this further and means that some patients who previously would have been admitted to hospital to exclude a particular condition are now treated solely in the ED.", [["patients", "ORGANISM", 28, 36], ["patients", "ORGANISM", 345, 353], ["patients", "SPECIES", 28, 36], ["patients", "SPECIES", 345, 353], ["more testing", "TEST", 186, 198], ["radiological investigations", "TEST", 203, 230], ["care testing", "TEST", 286, 298], ["a particular condition", "PROBLEM", 417, 439]]], ["These 'rule-out' strategies are clearly favoured by patients as they do not demand hospital admission, but they increase the demands on the ED considerably.", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60]]], ["Consequently, EDs have a major role as gatekeepers of the hospital, ensuring that patients are appropriately admitted or discharged, and that hospital beds are well utilised.IntroductionThree major factors have affected health care in Hong Kong in the new millennium-the Harvard report [14] , the adverse global economic climate [15] [16] [17] [18] , and the outbreak of Severe Acute Respiratory Syndrome (SARS) [19] [20] [21] .", [["Acute Respiratory Syndrome", "DISEASE", 378, 404], ["SARS", "DISEASE", 406, 410], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["Severe Acute Respiratory Syndrome (SARS)", "SPECIES", 371, 411], ["the adverse global economic climate", "PROBLEM", 293, 328], ["Severe Acute Respiratory Syndrome", "PROBLEM", 371, 404], ["Severe", "OBSERVATION_MODIFIER", 371, 377], ["Acute", "OBSERVATION_MODIFIER", 378, 383], ["Respiratory Syndrome", "OBSERVATION", 384, 404]]], ["The Harvard report and economic pressures led to the introduction of a HK$ 100 (~US$13) charge for patients attending EDs, effective from November 2002.", [["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["economic pressures", "TEST", 23, 41]]], ["The charge was introduced partly in an attempt to reduce the number of patients attending EDs who probably do not have emergency illnesses or injury, and partly to raise revenue to support the Hospital Authority's financial deficit.", [["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["emergency illnesses", "PROBLEM", 119, 138], ["injury", "PROBLEM", 142, 148], ["financial deficit", "PROBLEM", 214, 231]]], ["The introduction of charges was rapidly followed by the SARS outbreak in February 2003.IntroductionThe objective of this study is to investigate changes in emergency department (ED) presentations, hospital admissions, and ED staffing over 5 years, and to investigate the relationship between patient demand, ED staff resources, and waiting times and processing times, in a mixed adult/ paediatric emergency department in a Hong Kong university teaching hospital.MethodsThis observational study was a retrospective analysis of data collected prospectively for an ED administrative database.", [["SARS", "DISEASE", 56, 60], ["patient", "ORGANISM", 292, 299], ["patient", "SPECIES", 292, 299], ["this study", "TEST", 116, 126], ["This observational study", "TEST", 469, 493], ["a retrospective analysis", "TEST", 498, 522], ["an ED administrative database", "TEST", 559, 588]]], ["The study was undertaken in Prince of Wales Hospital (PWH), a university teaching hospital and tertiary referral facility with 1,400 beds.", [["The study", "TEST", 0, 9]]], ["The ED at PWH is situated near the centre of a highly developed new town and provides a 24-h, specialistled emergency medicine service for both adults and children, serving a population of 630,000 people in Shatin district.", [["children", "ORGANISM", 155, 163], ["people", "ORGANISM", 197, 203], ["children", "SPECIES", 155, 163], ["people", "SPECIES", 197, 203]]], ["It serves as the trauma centre for the New Territories of Hong Kong, covering the Shatin, Tai Po, and North District areas with a total population of about 1.31 million people [22] [23] [24] .MethodsAll clinical services are available on-site.", [["trauma", "DISEASE", 17, 23], ["people", "SPECIES", 169, 175], ["the Shatin", "TREATMENT", 78, 88], ["Tai Po", "TREATMENT", 90, 96], ["a total population", "TREATMENT", 128, 146]]], ["A second computed tomography (CT) scanner was installed in the ED in December 2004, in addition to the main hospital CT scanner, which the ED had previously been able to access for urgent scans.", [["A second computed tomography (CT) scanner", "TEST", 0, 41], ["urgent scans", "TEST", 181, 193]]], ["ED point-of-care testing includes troponin T, glucose, and haemoglobin testing, along with arterial blood gas analysis.", [["arterial blood", "ANATOMY", 91, 105], ["glucose", "CHEMICAL", 46, 53], ["glucose", "CHEMICAL", 46, 53], ["troponin T", "GENE_OR_GENE_PRODUCT", 34, 44], ["glucose", "SIMPLE_CHEMICAL", 46, 53], ["haemoglobin", "SIMPLE_CHEMICAL", 59, 70], ["arterial", "MULTI-TISSUE_STRUCTURE", 91, 99], ["blood", "ORGANISM_SUBSTANCE", 100, 105], ["care testing", "TEST", 12, 24], ["troponin T", "TEST", 34, 44], ["glucose", "TEST", 46, 53], ["haemoglobin testing", "TEST", 59, 78], ["arterial blood gas analysis", "TEST", 91, 118]]], ["Analyses from the main chemical pathology and haematology laboratories are usually available within 2 h, 24 h a day, for ED samples.", [["haematology laboratories", "TEST", 46, 70], ["ED samples", "TEST", 121, 131]]], ["A 6-h troponin T-and ECG-based chest pain protocol is used to reduce hospital admissions due to low risk chest pain.MethodsHong Kong does have private general practitioners, some of whom have formal training in family medicine, but they tend to be used mainly by those with health-care insurance or those who can afford their fees.", [["chest", "ANATOMY", 31, 36], ["chest", "ANATOMY", 105, 110], ["chest pain", "DISEASE", 31, 41], ["chest pain", "DISEASE", 105, 115], ["troponin T", "GENE_OR_GENE_PRODUCT", 6, 16], ["chest", "ORGANISM_SUBDIVISION", 105, 110], ["troponin T", "TEST", 6, 16], ["ECG", "TEST", 21, 24], ["chest pain protocol", "TREATMENT", 31, 50], ["low risk chest pain", "PROBLEM", 96, 115], ["chest", "ANATOMY", 31, 36], ["chest", "ANATOMY", 105, 110], ["pain", "OBSERVATION", 111, 115]]], ["Patients who cannot personally afford the costs, or who lack insurance, typically come to the ED for many of their health-care needs.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["The emergency ambulance service is accessed by dialing '999' from any telephone in Hong Kong, and it is free to all users.MethodsIn the study, monthly data for PWH ED between January 1999 and April 2005 were retrieved and analysed in order to determine quantitative changes in the ED caseload using the Accident and Emergency Information System (AEIS), a Hong Kong-wide ED data capture and management system.MethodsThe following data were retrieved: monthly attendance, numbers of trauma and non-trauma cases, number of ambulance attendances and admissions, rate of unplanned re-attendance within 48 h, number of admissions, number of cases in triage categories 1 to 5, average waiting time, average processing time, and the number of emergency medical and nursing staff.MethodsEvery patient who attends the ED goes through a triage process and is assigned one of five categories.", [["trauma", "DISEASE", 481, 487], ["non-trauma", "DISEASE", 492, 502], ["patient", "ORGANISM", 784, 791], ["patient", "SPECIES", 784, 791], ["the study", "TEST", 132, 141], ["management system", "TREATMENT", 390, 407], ["trauma", "PROBLEM", 481, 487]]], ["A typical ED in Hong Kong is divided into resuscitation rooms that manage category 1 and 2 cases, cubicles for trolley patients, and ambulatory areas where category 3-5 patients are managed.MethodsIn PWH ED, patients in categories 1 and 2 are seen immediately.", [["patients", "ORGANISM", 119, 127], ["patients", "ORGANISM", 169, 177], ["patients", "ORGANISM", 208, 216], ["patients", "SPECIES", 119, 127], ["patients", "SPECIES", 169, 177], ["patients", "SPECIES", 208, 216]]], ["There is a specific stream for category 3 patients between 0800 h and 2359 h daily, and category 4 trolley patients are also seen in a specific stream between 0800 h and 2200 h daily.", [["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 107, 115]]], ["Outside of these times, and for all category 4 and 5 cases who are ambulatory, there is no streaming, and patients are seen in the order in which they arrive.MethodsMedical and nursing staffing was determined by reference to ED staffing records.", [["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["streaming", "PROBLEM", 91, 100], ["no", "UNCERTAINTY", 88, 90]]], ["Changes in overall staffing were determined by senior hospital managers outside of the ED.Statistical analysisData were exported to Microsoft Excel (Microsoft Corporation, Redmond, WA) and StatView software (SAS Institute Inc, Cary, NC), which were used to generate graphical results.", [["Cary, NC)", "TREATMENT", 227, 236]]], ["Categorical data were analysed using the chi-square test.", [["Categorical data", "TEST", 0, 16], ["the chi-square test", "TEST", 37, 56]]], ["Correlations between staffing levels and process and waiting times (average summary measures for each 12-month period) were performed using SPSS v13.0 (SPSS Inc, Chicago, IL).", [["staffing levels", "TEST", 21, 36], ["SPSS v", "TEST", 140, 146]]], ["Statistical significance was set at p<0.05.AttendanceBetween January 1999 and April 2005, there were 1,115,592 new patient visits to the ED at PWH.", [["patient", "ORGANISM", 115, 122], ["patient", "SPECIES", 115, 122]]], ["The overall monthly attendance and breakdown by triage category are shown in Fig. 1 .", [["triage category", "TEST", 48, 63]]], ["Over the study period, there was a 29.5% reduction in overall mean monthly patient attendance from 17,371 in January 1999 to 12,254 in April 2005.", [["patient", "ORGANISM", 75, 82], ["patient", "SPECIES", 75, 82]]], ["Between 1999 and 2002 there were some winter peaks in category 3 cases, but otherwise there were no major seasonal variations.AttendanceAn obvious and dramatic dip was seen early in 2003, which reflected patient behaviour during the global SARS outbreak.", [["SARS", "DISEASE", 240, 244], ["patient", "ORGANISM", 204, 211], ["patient", "SPECIES", 204, 211], ["major seasonal variations", "PROBLEM", 100, 125], ["dramatic dip", "PROBLEM", 151, 163], ["the global SARS outbreak", "PROBLEM", 229, 253], ["no major", "UNCERTAINTY", 97, 105], ["seasonal variations", "OBSERVATION", 106, 125], ["dramatic", "OBSERVATION_MODIFIER", 151, 159]]], ["This decrease in attendance did recover, but not to pre-SARS levels.", [["decrease", "OBSERVATION_MODIFIER", 5, 13]]], ["Category 1 (critical) remained unchanged, but there was a small absolute increase in category 2 patients.", [["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["unchanged", "OBSERVATION_MODIFIER", 31, 40], ["small", "OBSERVATION_MODIFIER", 58, 63], ["absolute", "OBSERVATION_MODIFIER", 64, 72], ["increase", "OBSERVATION_MODIFIER", 73, 81]]], ["Categories 3 and 4 also reduced in absolute numbers, while category 5 patients showed an increasing trend.Hospital admissionThere was a gradual increase in the overall admission rate from 17% in 1999 to 27% in 2005.", [["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["an increasing trend", "PROBLEM", 86, 105], ["a gradual increase", "PROBLEM", 134, 152], ["the overall admission rate", "TEST", 156, 182], ["increasing", "OBSERVATION_MODIFIER", 89, 99], ["trend", "OBSERVATION_MODIFIER", 100, 105], ["gradual", "OBSERVATION_MODIFIER", 136, 143], ["increase", "OBSERVATION_MODIFIER", 144, 152], ["overall", "OBSERVATION_MODIFIER", 160, 167]]], ["An increasing number of these admitted cases were brought to hospital by ambulance.", [["increasing", "OBSERVATION_MODIFIER", 3, 13], ["number", "OBSERVATION_MODIFIER", 14, 20]]], ["The number of patients who were brought to the ED by ambulance increased markedly in both absolute and relative terms; in 1999, there were only 2,129 (12.8%) cases per month, and the figure almost reached 3,000 (21.5%) monthly in 2004.Hospital admissionMore than half of all admitted patients were admitted to medical specialties, such as general medicine and paediatrics.", [["patients", "ORGANISM", 14, 22], ["patients", "ORGANISM", 284, 292], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 284, 292]]], ["Decreases in patient attendance were evident for general surgery, orthopaedics, paediatrics, and gynaecology.", [["patient", "ORGANISM", 13, 20], ["patient", "SPECIES", 13, 20], ["general surgery", "TREATMENT", 49, 64]]], ["General medicine admissions increased, but obstetric admissions were steady.Hospital admissionThere was also a reduction in trauma patients in both absolute and relative terms (Fig. 2) .", [["trauma", "DISEASE", 124, 130], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["a reduction in trauma patients", "PROBLEM", 109, 139], ["reduction", "OBSERVATION_MODIFIER", 111, 120], ["trauma", "OBSERVATION", 124, 130]]], ["In 1999, there were 35,148 patient visits, accounting for 19% of total attendances at that time.", [["patient", "ORGANISM", 27, 34], ["patient", "SPECIES", 27, 34]]], ["In 2005, trauma attendances had decreased to 25,923 (16.4%).", [["trauma", "DISEASE", 9, 15]]], ["However, the reduction in non-trauma cases was even more pronounced than that seen in trauma (Fig. 2) .", [["non-trauma", "DISEASE", 26, 36], ["trauma", "DISEASE", 86, 92], ["the reduction in non-trauma cases", "PROBLEM", 9, 42], ["reduction", "OBSERVATION_MODIFIER", 13, 22], ["more pronounced", "OBSERVATION_MODIFIER", 52, 67]]], ["There were three acute hospitals in the New Territories East cluster; PWH, North District Hospital, and Alice Ho Nethersole Hospital.", [["three", "OBSERVATION_MODIFIER", 11, 16], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["hospitals", "OBSERVATION_MODIFIER", 23, 32]]], ["Prior to 2003, each hospital in the cluster only admitted its own cases, but in 2003, due to the SARS crisis and the subsequent pressures on the hospital system, the decision was made to utilise all beds in the cluster for patients needing emergency admission.Hospital admissionThere was a gradual increase in waiting times, which is defined here as the time between ED registration and first assessment by an ED doctor (Fig. 4) .", [["SARS", "DISEASE", 97, 101], ["patients", "ORGANISM", 223, 231], ["patients", "SPECIES", 223, 231], ["the SARS crisis", "PROBLEM", 93, 108], ["ED registration", "TEST", 367, 382], ["first assessment", "TEST", 387, 403], ["gradual", "OBSERVATION_MODIFIER", 290, 297], ["increase", "OBSERVATION_MODIFIER", 298, 306]]], ["The overall waiting time closely correlated with the waiting times for category 4 and 5 patients.", [["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96]]], ["Unplanned reattendance reduced gradually.", [["reduced", "OBSERVATION_MODIFIER", 23, 30], ["gradually", "OBSERVATION_MODIFIER", 31, 40]]], ["In 1999, 6,490 patients (3.5% of total attendance)ED staffingActual ED manpower over the study period also changed significantly (DiscussionThis study shows that during the first 5 years of the 21st century, new patient attendances at PWH ED have decreased substantially.", [["patients", "ORGANISM", 15, 23], ["patient", "ORGANISM", 212, 219], ["patients", "SPECIES", 15, 23], ["patient", "SPECIES", 212, 219], ["This study", "TEST", 140, 150], ["decreased", "OBSERVATION_MODIFIER", 247, 256]]], ["This reduction is not only in trauma, but also in non-trauma patients, and is most evident in category 3 and 4 triage cases.", [["trauma", "DISEASE", 30, 36], ["non-trauma", "DISEASE", 50, 60], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["trauma", "PROBLEM", 30, 36], ["not only", "UNCERTAINTY", 18, 26]]], ["One distinct but transitory Despite the overall reduction in new patient attendances, there has been an increase in ambulance patients in the ED and a marked increase in the medical admission rate.", [["patient", "ORGANISM", 65, 72], ["patients", "ORGANISM", 126, 134], ["patient", "SPECIES", 65, 72], ["patients", "SPECIES", 126, 134], ["distinct", "OBSERVATION_MODIFIER", 4, 12], ["transitory", "OBSERVATION_MODIFIER", 17, 27], ["reduction", "OBSERVATION_MODIFIER", 48, 57], ["new", "OBSERVATION_MODIFIER", 61, 64], ["increase", "OBSERVATION_MODIFIER", 104, 112], ["marked", "OBSERVATION_MODIFIER", 151, 157], ["increase", "OBSERVATION_MODIFIER", 158, 166]]], ["The decrease in overall attendance rates has been accompanied by an overall decrease in staff numbers reflecting the hospital's policy of resourcing the ED according to the number of attendances rather than case mix and work load.", [["decrease", "OBSERVATION_MODIFIER", 4, 12], ["overall", "OBSERVATION_MODIFIER", 68, 75], ["decrease", "OBSERVATION_MODIFIER", 76, 84]]], ["Increases in waiting times have accompanied the 25% decrease in medical and nursing staff.DiscussionA sudden but transient decrease in total attendance followed the introduction of ED charges and the SARS outbreak.", [["SARS", "DISEASE", 200, 204], ["the SARS outbreak", "PROBLEM", 196, 213], ["transient", "OBSERVATION_MODIFIER", 113, 122], ["decrease", "OBSERVATION_MODIFIER", 123, 131]]], ["The failure of ED patient attendances to return to pre-SARS levels may be a result of changing public perceptions of the safety of hospitals, a realisation for some that the ED is intended for genuine emergencies rather than primary health-care needs, or a result of increasing ED charges.DiscussionHong Kong began charging emergency room fees at public hospitals on 29 November 2002, ending a century-old tradition of free emergency treatment, with the immediate aim of reducing abuse of the emergency care system and as a step in the reform of health-care financing.", [["patient", "ORGANISM", 18, 25], ["patient", "SPECIES", 18, 25], ["increasing ED charges", "PROBLEM", 267, 288], ["free emergency treatment", "TREATMENT", 419, 443], ["failure", "OBSERVATION", 4, 11]]], ["Patients are now charged for ED services on arrival at the ED, but critically ill patients and patients who are unable to pay at the time of presentation are billed when they register.", [["critically ill", "DISEASE", 67, 81], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 82, 90], ["patients", "ORGANISM", 95, 103], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 82, 90], ["patients", "SPECIES", 95, 103]]], ["Current charges are still well below those charged by private general practitioners and do not reflect the true cost of providing emergency medical care.", [["emergency medical care", "TREATMENT", 130, 152]]], ["Thus, it is difficult to say whether the decrease in attendance is a result of SARS or of the introduction of fees.DiscussionThe Hospital Authority (HA) revealed that the total ED attendance across Hong Kong climbed to its maximum in 2001, 75% of whom were classified as category 4 ('semiurgent') or category 5 ('non-urgent') cases.", [["SARS", "DISEASE", 79, 83], ["SARS", "PROBLEM", 79, 83], ["the introduction of fees", "TREATMENT", 90, 114]]], ["The unnecessary use of ED resources by patients with primary health-care problems [27] distracts medical and nursing staff from managing genuine emergencies.DiscussionChanges in triage categories may reflect changes in the presentations of patients, or they may reflect changes in triage assignment.", [["patients", "ORGANISM", 39, 47], ["patients", "ORGANISM", 240, 248], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 240, 248]]], ["Although clear triage protocols are in place, and local audit suggests that nurses follow these protocols closely, nevertheless there are still grey areas where patients may be upgraded or downgraded according to an individual nurse's judgement.", [["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 161, 169], ["these protocols", "TEST", 90, 105]]], ["The slight increase in the use of category 5 may not reflect increasing attendance of minor cases, but rather re-categorisation of some patients in light of increasing and changing demands.DiscussionThe elderly population (\u226565 years) grew rapidly in our study period, with an annual growth rate of 12%, compared with a 3% annual growth rate for the general population.", [["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144], ["an annual growth rate", "TEST", 273, 294], ["the general population", "PROBLEM", 345, 367], ["slight", "OBSERVATION_MODIFIER", 4, 10], ["increase", "OBSERVATION_MODIFIER", 11, 19], ["increasing", "OBSERVATION_MODIFIER", 61, 71], ["increasing", "OBSERVATION_MODIFIER", 157, 167]]], ["Since the introduction in 2003 of a Community Geriatric Service with old age home medical support, there has been a 30% reduction in the transfer of institutionalised patients to EDs [26] .", [["patients", "ORGANISM", 167, 175], ["patients", "SPECIES", 167, 175], ["old age home medical support", "TREATMENT", 69, 97], ["a 30% reduction", "TREATMENT", 114, 129]]], ["The increase in both category 3 patients and ambulance cases may reflect the increasingly ageing population.", [["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["increase", "OBSERVATION_MODIFIER", 4, 12]]], ["These patients have more complex conditions due to more comorbidities which in turn may account for the increase in admission rates.DiscussionThe decrease in admission to paediatric and surgical specialties may be partly explained by the decreasing birth rate, resulting in the reduction in the paediatric population in Hong Kong.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["more complex conditions", "PROBLEM", 20, 43], ["more comorbidities", "PROBLEM", 51, 69], ["admission rates", "TEST", 116, 131], ["may account for", "UNCERTAINTY", 84, 99], ["increase", "OBSERVATION_MODIFIER", 104, 112], ["decrease", "OBSERVATION_MODIFIER", 146, 154], ["reduction", "OBSERVATION_MODIFIER", 278, 287]]], ["Paediatricians are becoming more communitybased, and strong community paediatric support facilitates early discharge of young patients.", [["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134]]], ["It is also possible that surgical patients are using more private medical care to access earlier treatment.", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["earlier treatment", "TREATMENT", 89, 106], ["also possible", "UNCERTAINTY", 6, 19]]], ["The reduction in trauma cases is well recognised throughout the developed world [28] , due to reductions in road traffic accidents and elderly falls, and these factors may have contributed to the observed reduction in admissions.DiscussionLee and colleagues [29] [30] suggest that there are high levels of inappropriate ED utilisation, particularly in the evening and early morning.", [["trauma", "DISEASE", 17, 23], ["accidents", "DISEASE", 121, 130], ["falls", "DISEASE", 143, 148], ["The reduction in trauma cases", "PROBLEM", 0, 29], ["elderly falls", "PROBLEM", 135, 148], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["trauma", "OBSERVATION", 17, 23]]], ["Increasing ED attendance has been previously explained as a consequence of free service and treatment.", [["treatment", "TREATMENT", 92, 101]]], ["Reductions in medical and nursing staff may seem appropriate given the reduction in overall patient attendance, but increasing waiting and process times suggest that despite the decrease in numbers, workload has increased with a progressively complex, ageing population.", [["patient", "ORGANISM", 92, 99], ["patient", "SPECIES", 92, 99], ["the decrease in numbers", "PROBLEM", 174, 197], ["decrease", "OBSERVATION_MODIFIER", 178, 186], ["increased", "OBSERVATION_MODIFIER", 212, 221]]], ["The strong correlations between increased process time and increased waiting times may not be surprising, but there was an even stronger correlation between the reduction in medical staff numbers and the increase in process time.", [["increased", "OBSERVATION_MODIFIER", 32, 41], ["reduction", "OBSERVATION_MODIFIER", 161, 170], ["increase", "OBSERVATION_MODIFIER", 204, 212]]], ["This suggests that reductions in staff adversely impact waiting and process times for all patients despite the decrease in overall patient numbers, which lends support to increasing staff numbers back to their original levels at least.ConclusionThere have been major changes in the patterns of ED attendances and ED waiting times over the study period in PWH.", [["PWH", "DISEASE", 355, 358], ["patients", "ORGANISM", 90, 98], ["patient", "ORGANISM", 131, 138], ["patients", "SPECIES", 90, 98], ["patient", "SPECIES", 131, 138], ["the study", "TEST", 335, 344], ["reductions", "OBSERVATION_MODIFIER", 19, 29], ["decrease", "OBSERVATION_MODIFIER", 111, 119], ["major", "OBSERVATION_MODIFIER", 261, 266], ["changes", "OBSERVATION", 267, 274]]], ["Decreasing overall ED numbers are offset by an increasingly aged population and a more complex case mix that demands more detailed assessment and seem to prolong ED waiting times.", [["detailed assessment", "TEST", 122, 141], ["overall", "OBSERVATION_MODIFIER", 11, 18]]], ["Reducing medical and nursing staff appears to reduce the capacity of EDs to provide timely assessments and care and to function as gatekeepers of the hospital.", [["timely assessments", "TEST", 84, 102]]]]}